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Antimicrobial resistance (AMR) is one of the biggest health threats that human kind is facing nowadays and 
that will have to face in the next decades1. An increasing number of drug-resistant bacterial strains are reported 
every year and the phenomenon is expected to further grow, leading to alarming healthcare and economic 
consequences. AMR is foreseen to cause 1 million deaths/year by 2050 and to generate an economic burden 
of 100 trillion US dollars1. On this basis, US as well as Europe are committed in implementing the number of 
social and economic plans and assets dedicated to face this threat. Europe is founding an increasing number of 
projects proposing innovative solutions to tackle this global crisis. 
This PhD research is an example of such European commitment as it has been carried on in the frame of the 
European Project ITN “Cyclon Hit”, which aims at developing nanocarriers for the delivery of antimicrobial 
agents as a strategy to fight resistance mechanisms. In particular, this research project was dedicated to an 
especially challenging and important goal, the treatment of intracellular infections. Intracellular bacteria 
possess the ability to “hide” inside the cells of the host immune system, transforming them in their preferred 
habitat and thus escaping from the action of many antibiotics2,3. 
This project proposes the use of nanocarriers as a promising tool to efficiently entrap antibiotics, protecting 
them from degradation, overcoming their limitations such as low solubility, inability to cross cell membrane 
and unfavourable biodistribution, possibly reducing their toxic side effects and hence increasing patient’s 
compliance. 
This PhD work focused more specifically on the development, optimisation and advanced characterisation of 
biodegradable and biocompatible polyester-based and cyclodextrin (CD)-based nanoparticles (NPs) for 
antimicrobial drugs encapsulation. The main polyesters used in this study were poly(lactic acid) (PLA), 
poly(lactic-co-glycolic) (PLGA) and poly(ε-caprolactone) (PCL) which are all approved by FDA for 
pharmaceutical applications4–6. Both polyesters and CDs are among the most employed materials for the 
preparation of drug delivery systems with tailorable properties. The success of these two carrier systems lies 
in their ability to improve the physico-chemical characteristics and biodistribution of antibiotics and to 
disassemble in non-toxic units, which are easily cleared from the body. 
A first part (Introduction) will give a literature overview on the background of this research and its related 
challenges. It is thus focused on intracellular bacteria and AMR and gives a summary on the structure, safety 
profile and applications of the two biodegradable NPs systems listed above and on the main techniques used 
for their characterisation as well as for their intracellular in vitro localisation. 
Afterwards, the first two chapters are centered on the main results obtained in the development, optimisation 
and characterisation of such polymeric NPs encapsulating challenging antimicrobial drugs.  
• Firstly, PLA NPs and crosslinked CD (pCD) NPs were employed for the co-encapsulation of ethionamide 
(ETH), a second-line anti-TB drug, and a molecule improving its activity, named Booster. This potent 
recently discovered drug combination7,8 opened tremendous opportunities in tuberculosis (TB) treatment 
by increasing the therapeutic activity of ETH. However, this drug pair presented some limitations, mainly 
related to the difficulty to find a common solvent, much less a biological-compatible one, to their 
completely different biodistribution profiles and to the strong tendency of ETH to crystallise. These 
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limitations greatly hampered the possibility to co-administer this drug pair in an effective way. The main 
pharmacological purpose and challenge of this study consisted in the co-encapsulation of these drugs to 
allow their administration directly in the infection site, overcoming the technological barriers of the free 
molecules. Once the co-encapsulation was achieved, an in-depth characterization of PLA NPs systems was 
conducted by using complementary advanced techniques (Chapter I – Section A). The main advantage 
provided by pCD NPs was the encapsulation of both drugs at a molecular level, thus totally avoiding ETH 
crystallization. To complement this study, a combination of spectroscopic techniques was employed to 
unravel the type and strength of interactions occurring between the ETH and pCD NPs (Chapter I – 
Section B).  
Both drug-loaded PLA and pCD NPs were tested in vitro on extracellular and intracellular bacteria by 
means of an automated high-content screening platform. Then their compatibility with the Microsprayer®, 
the device for in vivo endotracheal administration, was assessed. One of the main achievements in this 
work consisted in the evaluation of pCD NPs safety profile after repeated administration of high doses of 
such carrier. Then the antibacterial activity of loaded pCD NPs was estimated (Chapter I – Section A). 
• A second study was performed to address the challenges related to the incorporation of a first-generation 
quinolone, pipemidic acid (PIP), in PLA/PLGA and pCD NPs with the aim of “recycling” this old 
antibiotic by optimising its intracellular delivery for the treatment of infections such as salmonellosis9,10. 
The loading capabilities of polyester NPs, formulated by either nanoemulsion or nanoprecipitation 
methods, were compared and the role of PIP acid in NPs formation as well as its localisation and affinity 
for each components of the NPs were explored. In order to overcome the technological barriers related to 
the physical encapsulation approaches and to obtain NPs with a high PIP loading, a new self-assembling 
prodrug was developed. A prodrug was successfully obtained by conjugating PIP with PCL through an 
original catalyst-free drug-initiated polymerisation. The PCL-PIP NPs were in depth characterised by 
combining four advanced techniques and their degradation was studied. The NPs contained around 27 wt% 
PIP, highlighting the interest of developing drug conjugated by a straightforward method (Chapter II).  
These formulation studies highlighted the importance of an in-depth characterisation of the complex NP 
structures containing one or more antibiotics susceptible to crystallize and/or to locate near the NP top layers. 
Drug location deeply impact upon the release patterns and NPs stability in biological media. To the best of our 
knowledge, there is no experimental method yet to unravel the structure of each individual NP and to assess 
the homogeneity of a preparation. Thus, it was our aim to go beyond the state of art in the nanomedicine field, 
and we proposed in the second part of the work an original nanospectroscopic technique adapted both to 
unravel the structure of core-shell NPs and to localise them inside cells without the need of any labelling 
(Chapter III and IV). This recently developed technique combines the nanoscale spatial resolution offered 
by atomic force microscopy (AFM) with the chemical characterisation offered by infrared spectroscopy (IR) 
and it is therefore referred to as AFM-IR11. A general overview (Chapter III – Section A) is given at the 
beginning of this second part to introduce the AFM-IR technique and to explain its potential through the 
already developed applications12. Then, our studies present the intriguing information that this technique can 
provide when applied to NPs characterisation and detection.  
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• The first great opportunity offered by AFM-IR was the possibility to obtain precise chemical information 
on the distribution of the components of each individual PLGA NP. A wavenumber, characteristic of the 
specific IR absorption of each NP component, was selected as fingerprint and for the first time a chemical 
mapping of single NPs could be obtained, allowing unravelling their structure. The major breakthrough of 
this study is the first application of AFM-IR in tapping mode. Indeed, all previously published results were 
obtained by using the technique in contact mode, thus hampering the possibility of analysing soft or 
loosely-adhesive samples. The advantage of the new tapping mode was clearly shown here in the case of 
PLGA NPs which were crushed and/or displaced in contact mode, whereas they were very well-described 
thanks to tapping mode. The technique allowed to undoubtedly demonstrate for the first time the existence 
of PLGA NPs core-corona structure which was up to now only hypothesized. Moreover, when analysing 
PIP-loaded PLGA NPs, tapping AFM-IR allowed precisely localising PIP distribution and confirming the 
hypothesis made in our previous studies presented in Chapter II (Chapter III – Section B). Noticeably, 
this technique allowed visualising nano-objects as small as 10 nm mainly composed of PIP and surfactant. 
Finally, tapping AFM-IR enabled obtaining the chemical mapping also in the case of PCL-PIP NPs as well 
as a first quantification of PIP/PCL ratio on a particle by particle basis. IR cartographies of PCL-PIP NPs 
displayed a well-distributed PIP loading and their analysis provided quantitative information about NPs 
loading in addition to the already appealing qualitative ones (Chapter III – Section C). 
• AFM-IR further proved its attractivity in the label-free detection and unambiguous chemical identification 
of polyester NPs internalised in cells. Indeed, these NPs, totally composed of organic materials, usually 
require the addition of labels to be detected by the most common imaging techniques (such as confocal 
fluorescence microscopy and transmission electron microscopy). Thus, the NPs are indirectly detected by 
observing their label. Here we could apply AFM-IR to directly localise NPs by using the polymer IR 
specific response as a fingerprint. 
Finally, the main results of this research are discussed, the main conclusions are gathered and the numerous 
perspectives of this work are presented. 
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La résistance aux antimicrobiens constitue aujourd’hui l’une des plus graves menaces pesant sur la santé 
publique et ainsi l’un des plus grands défis que l’humanité devra relever dans les prochaines décennies. Un 
nombre sans cesse croissant de bactéries résistantes à l’action de plusieurs antibiotiques est détecté chaque 
année et ce phénomène devrait s’amplifier, entrainant de graves conséquences sanitaires ainsi qu'économiques 
à l'échelle mondiale1. En effet, l’impact de cette résistance a été estimé à 1 million de morts par an d’ici 2050, 
s’accompagnant d’un poids économique énorme (environ 100 trillions de dollars américains2).   
C'est pour cela que les Etats Unis et l’Europe se sont engagés à mettre en œuvre de nombreux plans au niveau 
économique comme social pour faire face à cette menace. Ainsi, l'Europe est en train de financer un nombre 
croissant de projets proposant des solutions innovantes pour affronter cette crise mondiale. 
Ce travail de thèse représente un exemple de cet engagement européen du fait qu’il s’inscrit dans le cadre du 
Projet Européen ITN « Cyclon Hit », visant à développer des nanovecteurs pour administrer de manière 
optimisée les agents antimicrobiens et empêcher les mécanismes de résistance. Plus précisément, ce projet 
s’est consacré à un défi particulièrement ambitieux et complexe comme le traitement des infections 
intracellulaires. Les bactéries intracellulaires ont la capacité de « se cacher » à l’intérieur des cellules de l’hôte, 
en particulier celles du système immunitaire, en les transformant en leur habitat préféré et en échappant ainsi 
à l'action de nombreux antibiotiques3,4. 
Ce projet propose donc l’utilisation de nanovecteurs pour encapsuler efficacement les antibiotiques, les 
protéger de la dégradation, surmonter leurs limitations telles que leur faible solubilité, leur incapacité à franchir 
les membranes cellulaires et leur biodistribution défavorable, en réduisant par là même leurs effets secondaires 
toxiques et en améliorant l’observance des patients aux traitements. 
Ainsi, au sein de ce projet, mon travail de thèse est axé sur le développement, l’optimisation et la caractérisation 
avancée de nanoparticules (NPs) biodégradables et biocompatibles, composés de polyesters ou de 
cyclodextrines (CD), et chargées en antibiotiques. Les polyesters principaux employés dans cette étude sont 
l’acide polylactique (PLA), l’acide poly(lactique-co-glycolique) (PLGA) et le polycaprolactone (PCL) qui sont 
tous approuvés pour les utilisations pharmaceutiques par la FDA, l’agence américaine des produits 
alimentaires et médicamenteux5–7. De plus, ces polyesters aussi bien que les CDs sont parmi les matériaux les 
plus employés pour la préparation de systèmes d’administration des médicaments à propriétés modulables. La 
clef du succès de ces matériaux dépend surtout de leur capacité d’améliorer les caractéristiques physico-
chimiques et la biodistribution des antibiotiques ainsi que du fait qu’ils se désassemblent en unités non-
toxiques, facilement éliminées par l’organisme. 
Une première partie introductive (Introduction) consiste en une revue de la littérature touchant les domaines 
scientifiques à la base de cette étude et les défis majeurs qui lui sont associés. 
Les bactéries intracellulaires et la résistance aux antibiotiques seront plus particulièrement abordées. La 
structure, le profil d’innocuité et les applications des polyesters ainsi que des CDs utilisés dans notre étude 
pour la formulation des NPs seront détaillés. En outre, les principales techniques utilisées pour la 
caractérisation de ces NPs et pour leur localisation intracellulaire in vitro seront également décrites. 
Par la suite, les deux premiers chapitres seront consacrés aux principaux résultats obtenus dans le 
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développement, l’optimisation et la caractérisation de NPs polymériques chargées de molécules antibiotiques 
difficiles à administrer. 
 
• Tout d’abord, ces NPs, fabriqués en PLA ou en CD réticulées (pCDs), ont été utilisées pour la co-
encapsulation de l’éthionamide (ETH), un antibiotique de deuxième ligne pour le traitement de la 
tuberculose (TB), et du Booster, une molécule capable d’améliorer l’activité de l’ETH. L’association très 
puissante de ces deux molécules, découverte récemment8,9 a ouvert des opportunités formidables dans le 
traitement de la TB grâce à sa capacité d’augmenter notablement l’efficacité thérapeutique de l’ETH. 
Toutefois, cette association présente quelques limites, essentiellement liés à la difficulté de trouver un 
solvant commun, (qui plus est, compatible avec le milieu biologique), aux profils de biodistribution 
complètement différents des deux molécules et à la forte tendance de l’ETH à cristalliser. Ces contraintes 
ont freiné considérablement la possibilité de coadministrer cette association de façon efficace. Donc, 
l’objectif ainsi que le défi pharmacologique principal de cette étude consistait à co-encapsuler ces 
médicaments dans les NPs pour permettre de les administrer directement au site d’infection et « de lever 
les verrous technologiques » (contourner les propriétés physiques) des molécules libres. Une fois cette co-
encapsulation obtenue, une caractérisation approfondie des NPs en PLA a été réalisée à l’aide de 
techniques complémentaires et avancées (Chapter I – Section A). Le principal avantage offert par les NPs 
en pCDs résidait dans leur capacité d’incorporer les deux médicaments au niveau moléculaire et d’éviter 
ainsi totalement la cristallisation de l’ETH. En complément à cette étude, une combinaison de techniques 
spectroscopiques a été employée pour analyser le type et la force des interactions qui existent entre l’ETH 
et les NP en pCDs (Chapter I – Section B).  
L’efficacité in vitro des NPs en PLA et en pCDs chargées en antibiotiques a été évaluée sur les bactéries 
extra ou intracellulaires grâce à l’aide d’une plateforme automatisée de criblage à haut rendement. Ensuite, 
la compatibilité des NPs avec le dispositif pour l’administration in vivo par voie endotrachéale, le 
Microsprayer®, a été étudiée. L’un des principaux résultats de ce travail a été l’évaluation du profil 
d’innocuité des NPs en pCDs après administration pulmonaire répétée de fortes doses de ce vecteur. De 
plus, l’activité antibactérienne des NPs en pCDs chargées avec l’association des deux molécules actives a 
été déterminée in vivo en montrant une diminution de 3-log de la charge bactérienne pulmonaire des 
animaux infectés après seulement 6 administrations (Chapter I – Section A). 
• Le deuxième chapitre de cette thèse est consacré à la résolution des défis liés à l'incorporation d'une autre 
molécule active, une quinolone de première génération, l'acide pipémidique (PIP). Le but, était de recycler 
un ancien antibiotique en optimisant sa distribution intracellulaire dans des infections telles que la 
salmonellose10,11.  
La capacité à encapsuler le PIP des NPs en polyester, obtenus par les techniques de nanoemulsion ou de 
nanoprecipitation, a été étudiée. Le rôle de cet antibiotique dans la formation des NPs ainsi que sa 
localisation dans la structure du vecteur et son affinité pour les différentes molécules composantes les NPs 
ont été examinés. L’encapsulation du PIP a été confrontée à des défis liés à la cristallisation du principe 
actif et à sa libération incontrôlée. Afin de s’affranchir de ces « barrières technologiques »et d’obtenir des 
NPs avec une charge de PIP importante, une approche alternative a été développée basée sur la synthèse 
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d’un promédicament capable de s’auto-assembler sous forme de NPs. Cette prodrogue a été obtenue en 
couplant le PIP avec du PCL via une réaction de polymérisation sans catalyseur initiée par le médicament. 
Les NPs en PCL-PIP ont été caractérisées précisément en combinant quatre techniques de pointe et leur 
dégradation a été également étudiée. Les NPs contenaient environ 27 % (en poids) de PIP. Ce résultat a 
mis en évidence l’intérêt de développer un conjugué du médicament par une méthode simple pour en 
obtenir une encapsulation efficace (Chapter II). 
Ces études de formulation ont mis l’accent sur l’importance d’une caractérisation approfondie de la structure 
complexe des NPs qui peuvent contenir à la fois plusieurs antibiotiques susceptibles de cristalliser ou de se 
localiser près de la surface des NPs. La localisation du médicament a une influence très importante sur son 
profil de libération et sur la stabilité des NPs dans les milieux biologiques. Au début de notre étude n’existait 
aucune méthode expérimentale permettant d’analyser la composition de chaque NPs individuellement et de 
déterminer l’homogénéité d’une formulation. C’était ainsi notre objectif d’aller au-delà de l’état de l’art dans 
le domaine de la nanomédicine et de proposer dans la deuxième partie de ce travail de thèse une technique 
nanospectroscopique innovante adaptée pour définir de manière approfondie la structure et la composition du 
noyau et de la couronne des nanostructures, mais aussi pour les détecter après internalisation dans les cellules 
sans avoir recours à leur marquage (Chapter III and IV). Cette technique récemment développée est capable 
de combiner la  résolution spatiale à l’échelle nanoscopique offerte par la microscopie de force atomique 
(AFM) avec la caractérisation chimique apportée par la spectroscopie infrarouge (IR). Elle a donc été nommée 
AFM-IR12.   
Au début de cette deuxième partie du travail, une revue générale (Chapter III – Section A) est donnée pour 
introduire l’AFM-IR et pour mettre en évidence son potentiel à travers la présentation des applications déjà 
développées13. Ensuite, les résultats extraordinaires de caractérisation et de détection des NPs obtenus par cette 
technique seront présentés (Chapter III – Section B, C). 
• Le premier avantage considérable offert par l’AFM-IR a été de pouvoir acquérir des informations très 
précises sur la distribution des composants de chaque NP en PLGA individuellement. Une longueur 
d’onde, spécifique de l’absorption IR de chaque élément constituant les NPs, a été sélectionné comme leur 
« signature » et une cartographie chimique des NPs prise individuellement a été réalisée en permettant de 
décoder leur structure à l’échelle nanométrique. L’avancée majeure de cette étude a été l’application pour 
la première fois de l’AFM-IR en mode tapping. En effet, tous les résultats précédemment publiés ont été 
obtenus en utilisant cette technique en mode contact, mode qui n’offre pas la possibilité d’étudier les 
échantillons souples ou adhérant faiblement à la surface du support. L’avantage de ce nouveau mode a été 
clairement démontré dans le cas des NPs en PLGA qui étaient écrasées et/ou déplacées avec le mode 
contact alors qu’elles ont pu être décrites très précisément grâce au mode tapping. Cette technique a permis 
de prouver définitivement l’existence d’une structure cœur-couronne des NPs en PLGA, ce qui était 
jusqu’à présent seulement une hypothèse. En outre, lors de l’exploration des NPs en PLGA chargées en 
PIP, l’AFM-IR en mode tapping a rendu possible de localiser précisément la distribution du PIP à 
l’intérieur de NPs et ainsi de confirmer les hypothèses qu’on avait formulé lors de nos études précédentes 
présentées dans le chapitre II (Chapter III – Section B). L’AFM-IR a permis la visualisation de nano-
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objets de seulement 10 nm, principalement composés de PIP et de surfactant. Enfin, l’AFM-IR en mode 
tapping a permis d’obtenir également la cartographie chimique des NPs en PCL-PIP aussi bien qu’une 
première estimation quantitative du ratio PIP/PCL de ces NPs une par une. Les cartographies IR des NPs 
en PCL-PIP ont permis de quantifier la charge en PIP et de démontrer une répartition de cette charge assez 
homogène (Chapter III – Section C). 
• Un autre avantage très attrayant de l’AFM-IR est, comme démontré dans le dernier chapitre de ce 
manuscrit, qu’il peut détecter sans marquage et identifier chimiquement sans ambiguïté les NPs en 
polyesters internalisées par les cellules. En effet, ces NPs, en étant constituées exclusivement de 
matériaux organiques, exigent généralement le rajout d’un marqueur pour pouvoir être détectées par 
les techniques les plus courantes d’imagerie (telles que la microscopie confocale à fluorescence et la 
microscopie électronique en transmission). Les NPs sont ainsi identifiées indirectement en visualisant 
leur marqueur. Dans cette étude, nous avons pu montrer que l’AFM-IR peut être employé avec succès 
pour repérer les NPs à l’intérieur des cellules en utilisant la réponse IR du polymère comme signature 
spécifique.  
Pour finir, l’ensemble des résultats démontrés au cours de cette thèse seront discutés, les principales 
conclusions et les nombreuses perspectives ouvertes par ces études seront présentées.  
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1. Intracellular bacteria and antimicrobial resistance 
 
1.1. Intracellular bacteria 
 
Bacteria are among the most numerous forms of life on earth and they are consistently present in the human 
body, both inside (especially in the gastrointestinal tract) and on its surface (skin). A considerable number of 
bacteria are able to live in symbiosis with humans and are innocuous, sometimes beneficial or even necessary. 
However, some of them, namely pathogenic bacteria, are able to colonise, invade and harm their host thus 
causing diseases1,2. Indeed, pathogens can cause infections either in specific localised niches in the host or they 
can invade the entire organism, even becoming life-threatening. Some examples of such dangerous infection 
are tuberculosis (TB), endocarditis, pneumonia, osteomyelitis and septicaemia. 
Intracellular pathogens are causative agents of some of the infections listed above which are recurrent, 
persistent and particularly difficult to defeat. Therefore, they represent an important public health concern. 
The peculiarity of intracellular bacteria lies in their ability to thrive within the organism by hiding inside the 
cells of the host and surviving in active or latent form over a long period of time, despite the presence of a 
well-functioning immune system. Indeed, they have found a way not only to circumvent the host immune 
system but also to colonise and replicate in the cells belonging to it, such as the ones of the reticuloendothelial 
system (RES)1. The RES consists of phagocytic cells such as macrophages and monocytes which main role is 
to uptake and destroy foreign bodies trough phagocytosis and to activate the adaptive component of the 
immune system through presentation of bacterial antigens. Once the bacteria are engulfed by phagocytes they 
are enclosed in vesicles, called phagosomes, which further fuse with cells lysosomes resulting in 
phagolysosome formation3. In the phagolysosome, bacteria are usually destroyed thanks to the contribution of 
different factors; low pH, production of oxygen reactive species, nitric oxides, proteases etc4,5. 
Despite the efficiency of host immune system, intracellular bacteria have hence developed a number of 
ingenious mechanisms to hijack the phagocytic pathway at different stages and exploit the protection offered 
by the cell to multiply6. For example, bacteria can escape from the phagosome and survive in the cytosol, or 
block the system at the early endosome stage such as Mycobacterium Tuberculosis (Mtb), or at the late 
endosome stage like Salmonella and transform these vacuoles in their preferred habitat7. In such way, these 
bacteria give rise to chronic infections difficult to defeat. 
For instance, TB, a respiratory disease caused by Mtb, is ranked above HIV/AIDS as one of the leading causes 
of death from an infectious disease (1.8 million deaths in 2015)8 and its treatment requires at least 6 months 
daily administration of an association of first-line antibiotics (isoniazid, rifampicin, pyrazinamide, ethambutol 
and streptomycin) or two years therapy of second-line drugs (ethionamide, aminoglycosides, fluoroquinolones, 
etc) in case of resistant TB9–11. Another interesting example is Salmonellosis which is caused by an 
opportunistic intracellular pathogen, Salmonella Typhimurium, and consists in an uncomplicated 
gastroenteritis in immunocompetent patients whereas can be life-threatening in immunocompromised ones. 
Salmonellosis is related to a high risk of mortality and morbidity with economic losses of billions of dollars 
and in Sub-Saharan Africa is associated with a case of fatality of 20-25% (often relates to AIDS patients). 
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Multidrug resistant strains of S. Typhimurium have recently been identified and labelled as emerging diseases 
in Africa12. 
Other particularly challenging facultative intracellular bacteria include Staphylococcus aureus, Listeria 
monocytogenes and Burkholderia pseudomallei. These pathogens, together with Mtb, stand out for their 
capacity of using circulating macrophages as “Trojan horses”, hence spreading within the host and establishing 
secondary infectious foci1. 
 
1.2. Antibiotics 
 
Antibiotics are antibacterial drugs able to cause bacterial death (bactericidal drugs) or to inhibit their replication 
(bacteriostatic drugs). The same antibiotic molecule can be bacteriostatic at low dose and bactericidal at high 
dose13. The choice of the most suitable antibiotic and its dosage is based upon the gravity of the infection and 
on the specific sensitivity of the strain. Antibiotics can be classified according to different methods, mainly on 
the basis of their mode of action13: 
• Inhibitors of cell wall synthesis (Beta-lactams such as penicillins, cephalosporins, monobactams and 
carbapenems; Glycopeptides; Fosfomycins) 
• Inhibitors of protein synthesis (Aminoglycosides; Macrolides; Tetracyclines, Glycylcyclines; 
Phenocols; Oxazolidinones; Ansamycins) 
• Inhibitors of membrane function (Lipopeptides; Polymyxins) 
• Inhibitors of nucleic acid synthesis (Quinolones; Trimethoprim-sulfamethoxazole; Ryfamycins). 
Despite their undeniable usefulness, antibiotic efficacy is often hampered by low bioavailability, side-effects, 
the inability of some of them to cross tissular and cellular barriers, the onset of resistance and the ability of 
bacteria to organise in biofilms. 
Antibiotics, in order to be effective, need to reach the infection site at a therapeutic concentration that has to 
be maintained stable for a sufficient amount of time. Therefore, antibiotic doses have to be high enough and 
administered frequently enough to make up for all the losses/degradations taking place on the way from the 
administration site to the target. Indeed, just as all other drugs systemically administered, antibiotics undergo 
a uniform distribution in the body meaning that only a small fraction of the dose actually reaches the target. 
Moreover, the need to cross biological barriers and in some cases a mucus layer (lungs, gastrointestinal tract, 
etc) makes even harder for the antibiotic to reach the targeted bacteria. In addition, in the case of intracellular 
pathogens, antibiotics also have to cross the cell membrane and reach the bacteria in their subcellular hideouts. 
Inability of crossing the cell membranes (polar drugs such as β-lactams and aminoglycosides), efflux 
phenomena (macrolides and fluoroquinolones) and inactivation due to intracellular pH or enzymes can also 
result in subtherapeutic concentrations and lead to inefficacy1. It is evident that antibiotics do not have an easy 
task. 
 
1.3. Emergency of antimicrobial resistance 
 
As outlined in the previous paragraphs, intracellular bacteria are a pharmaceutical challenge per-se and thus 
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antibiotics are not always effective enough to defeat them. In addition to the already described difficulties, the 
scientific community has witnessed a progressive increase in the onset of antimicrobial resistance phenomena 
in a growing number of bacteria in the last 50 years. 
Antimicrobial resistance (AMR) can be defined as the ability of an organism to resist the action of an 
antimicrobial agent to which it was previously susceptible2.  
Bacteria can exhibit intrinsic resistance to antimicrobials due to their inherent structural (G+/G-) or functional 
characteristics. Indeed, all the bacteria are not sensitive to all the antibiotics. Moreover, they can acquire AMR 
as a result of spontaneous chromosomal genes mutations or by horizontal gene transfer (plasmids, 
transposons)14. The acquisition of resistance can be mediated by three main classes of mechanisms: i) the 
transport of the antibiotics through the bacterial cell wall and membrane (reduced permeability due to down-
regulation of porins or increased efflux phenomena), ii) the synthesis of enzymes or modification of cellular 
environment to inactivate the antibiotics and iii) the structural modification of the antibiotic target by genetic 
mutation or post-translational modification14,15. 
When a bacterium survives to a drug, thanks to one of these mechanisms of AMR, the strain capable of 
surviving grows and spreads due to the lack of competition with other strains (resistant pathogen selection)16. 
Multiple resistance arise when a bacterium already containing a drug resistance gene acquires another type of 
drug resistance genes17. This phenomena have led to the emergence of “superbugs” such as Methicillin-
resistant Staphylococcus aureus (MRSA) and extremely drug resistant (XDR) tuberculosis11 which are very 
difficult or even impossible to treat with the existing antibiotics18. Moreover, we are down to using “last line” 
antibiotic for the treatment of drug-resistant gonorrhoea and to reintroducing antibiotics that were not used 
anymore because of their serious side effects. For instance, colistin, an antibiotic causing kidney failure, has 
been reintroduced in clinic as last-resort treatment for particular hard-to-treat gram negative bacterial 
infections, but colistin-resistance already emerged at the end of 201516. 
Although AMR is a natural adaptive response of bacteria observed since the discovery of antibiotics, it has 
become a serious problem in recent times due to the increased rate of resistance development and diffusion. 
Indeed, in the past, AMR prevailed in the healthcare environment where the antibiotic selective pressure is 
intensive. However, over the past decade resistant infections have arisen also in the rest of the community16. 
The worldwide spread of resistant bacteria can be viewed as an ecological consequence of the systematic use 
and sometimes misuse of antibiotics. Furthermore, there is a continuous exposure to low doses of antibiotics 
contained in food (animal-derived products and agriculture)1. 
Recent assessments have estimated that, without aggressive policies to stop the worrying spread of AMR, 10 
million people will die every year from bacterial infections by 2050 overcoming the number of deaths due to 
cancer16. Indeed, AMR is considered as one of the biggest threats that humankind will have to face in the next 
decades.  
Taking into account that very few new antibiotics are in the development pipeline18, new strategies are required 
to administrate already existing antimicrobial agents in an optimized manner to help fighting against this treat. 
Nanomedicine is considered as one of the most promising strategies in this perspective17 (Figure 1). 
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2. Nanomedicine 
 
Nanomedicine is a branch of medicine that applies the knowledge and tools of nanotechnology to the 
prevention and treatment of disease. It involves the use of nanoscale materials, such as biocompatible 
nanoparticles and nanorobots, for diagnosis, delivery, sensing or actuation purposes in a living organism19. 
During the last decades, this field gained ever-growing interest as a promising tool to overcome the drawbacks 
of traditional therapeutic agents (Figure 1). Indeed, drug-loaded nanoparticles are able to: i) improve 
physicochemical properties of drugs (low solubility, tendency to form crystals); ii) protect them towards 
degradation; iii) increase their bioavailability and improve their pharmacokinetic; iv) target them to the disease; 
v) reduce toxic side effects; vi) increase patient compliance and vii) reduce treatment duration and related 
costs20. 
 
Figure 1 – Schematic representation of an infected cell treated with free antibiotic or with antibiotic-loaded 
nanoparticles (NPs). Free drugs often poorly penetrate inside cells due to several factors such as their chemical structure 
(polar drugs such as β-lactams and aminoglycosides), their decreased uptake caused by resistance mechanisms (down 
regulation of membrane carriers), intracellular degradation and the onset of efflux phenomena. Such circumstances 
individually or simultaneously contribute to the inefficacy of free antibiotics. On the contrary, nanocarriers are able to 
protect the drugs, improve their physico-chemical properties and target them inside cells. Indeed, drug-loaded NPs are 
taken up inside endosomes where they degrade (hydrolytic enzymes and acidic pH) and release their payload. Then, drugs 
able to diffuse can escape endosomes and reach the bacteria in their preferential locations (cytosol or vacuolar niches). 
Interestingly, non-diffusible drugs still have the opportunity to reach the bacteria thanks to the ability of some NPs to 
escape endosomes or to the capacity of NPs-containing endosomes to fuse with the bacterial vacuoles1. 
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2.1. Nanoparticles as intriguing strategy to overcome drugs physicochemical limitations and 
tackle intracellular bacteria 
 
Liposomes were the first nanosized delivery system introduced in 1960 and since then a broad variety of 
nanocarriers such as nanoparticles (NPs), nanogels, dendrimer and micelles have been prepared by using a 
wide variety of organic (polymers and lipids) and inorganic materials (silica and metals). Ideal NPs have to be 
non-toxic, biocompatible and possibly biodegradable and to have tailored well-defined size, shape and surface 
properties and release their payload in a controlled manner. 
Drugs may be incorporated into NPs by three different methods. They can be loaded during or after the NPs 
formulation, absorbed to NPs surface or alternatively chemically bound to the NPs21. 
Poor aqueous solubility and rate of dissolution are the two critical factors that heavily impact on formulation 
and development of drugs, limiting their therapeutic application22. Indeed, recent statistical analyses have 
reported that around 40% of currently marketed drugs and about 90% of drugs in their developmental phase 
encounter solubility-related problems23. Failures in the development of a drug are thus tightly connected to 
poor biopharmaceutical properties such as solubility and permeability. Actually, on the basis of these two 
parameters, drugs have been divided in four main biopharmaceutical classes which are shown in Figure 2. 
 
 
Figure 2 - Biopharmacutical Classification System (BCS) of drugs established by FDA. The classification is based 
on drugs solubility (with a soluble drug defined as one in which highest dose intended for human use dissolves in 250 mL 
of water) and permeability (with a permeable drug defined as one with ≥ 90% oral bioavailability or ≥ 90% absorption)24. 
 
Class II and class IV drugs represent the biggest pharmaceutical challenges when it comes to their in vivo 
administration25. Remarkably, most of the cytotoxic anticancer drugs belong to the IV class having both low 
aqueous solubility and permeability26,27. Indeed, drug discovery has evolved over the years towards high-
throughput screenings putting evolutionary pressure on drug candidates. This has led to a systematic increase 
in drugs molecular weight, lipophilicity and decrease in their water solubility24,27. Challenging type II 
compounds (see Figure 2) are increasingly selected and their inclusion in NPs can represent an efficient 
strategy to make them behave as type I compounds which results in an increase of bioavailability24. 
Furthermore, NPs can also be extremely beneficial in improving drug stability during storage, avoiding drug 
crystallisation or degradation, and during in vivo administration, protecting it from chemical and enzymatical 
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degradation. Moreover, NPs not only can protect the drug from the organism, but they have also proved to be 
able to protect the host from drug toxicity due to non-specific interaction of the active molecule with other 
organs than target (i.e. Doxil, doxorubicin-loaded liposomes which reduce cardiac toxicity)28.  
 
As previously pointed out, to efficiently eradicate intracellular bacteria, NPs have to be capable of carrying 
their drug cargo inside cells. Indeed, NPs have been shown to penetrate RES cells by different mechanisms 
depending on their composition, size and physicochemical properties. For instance, the modification of their 
surface with hydrophilic polymers such as poly(ethylene glycol) (PEG) decrease their recognition and uptake 
by the immune system leading to extended vascular circulation. This approach has proved its usefulness 
especially in cancer therapy, where NPs uptake by RES cells is not desired, and allowed NPs passive targeting 
to cancer cells thanks to the enhanced permeability and retention effect29–32. Therefore, in antimicrobial 
applications, PEG coating is normally avoided or considerably reduced in order to allow NPs internalisation 
by RES cells and hence targeting intracellular bacteria. 
NPs colloidal properties are of paramount importance in establishing which endocytic pathway NPs will 
undergo and consequently which will be their intracellular location. Largest particles are generally taken up 
by phagocytosis (characteristic endocytic pathway of professional phagocytes) whereas smaller one by 
pinocytosis (possible in every type of cells). Pinocytosis can be further divided in clathrin-mediated, caveolae-
mediated as well as clathrin- and caveolae-independent endocytosis and micropinocytosis1,33. The mechanism 
of NPs internalisation determines, trough very complex trafficking processes, their intracellular fate. For 
instance, clathrin-mediated and caveolae-mediated internalisation determine a lysosomal or a cytoplasmic 
localisation, respectively33. Interestingly, some NPs have shown the ability to escape their 
endosomal/endolysosomal compartments and release their cargo in the cytoplasm34,35. Indeed, the subcellular 
location of the NPs can determine the success or the failure of the developed delivery system. As a matter of 
facts, in some cases NPs have shown an improved intracellular accumulation but any improvement in the 
antibacterial effect could be detected. This situation is most likely due to NPs being localised in a different 
cellular compartment than bacteria and to the inability of the released drug molecules to reach their target1. 
Another factor which may contribute to the scene is the dormant state that some bacteria, such as Salmonella 
and Mtb, can assume during the infection making them insensitive to antibiotics36,37.  
The physicochemical properties of the NPs have also a very high impact in determining the release profile of 
the antibiotic. Ideally, the drug should be released only once the NPs have been internalised and possibly in 
the vicinity of the bacteria to insure the highest probability of success. As intracellular controlled release is 
challenging, stimuli-responsive NPs have been designed to trigger the release at a specific moment and under 
a specific stimulation34,38–41. Despite the decoration of NPs surface is certainly appealing and advantageous, 
one must keep in mind that building complex drug delivery systems normally requires multiple synthetic steps 
and will raise questions on their biocompatibility, long-term toxicity and genotoxicity. Thus, the number of 
tests, money and time necessary to market the final product will significantly increase. Therefore, a balance 
should be kept between nanocarrier complexity and feasibility and the necessity of surface decoration must be 
thoroughly assessed. 
The choice of the appropriate administration route is another important parameter impacting on the efficacy of 
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NPs against bacteria. Intravenous administration is the most adapted way to treat intracellular infections 
particularly when liver and spleen are involved42,43. Oral administration is intuitively the route of choice in the 
treatment of infections localised in the intestinal tract (Salmonella)44,45. Pulmonary administration is instead 
the most employed and efficient way to treat respiratory infections such as TB1,43,46. 
A broad variety of NPs have proved their capability in reaching therapeutic drug concentration inside different 
cell lines thus improving antibiotic efficacy47–49. Liposomes have been the first type of carrier successfully 
applied in the field39,50–53 but they presented some drawbacks in comparison to NPs such as higher instability 
(drug leaking), lower capacity of encapsulate drugs and a difficulty to be sterilised1,54. Indeed, different types 
of NPs were also employed including poly(D,L-lactic-co-glycolic acid) (PLGA) NPs and polymeric NPs, 
mesoporous silica NPs, polymer micelles, solid lipid NPs, niosomes and dendrimers1. Moreover, a plethora of 
NPs endowed with intrinsic antibacterial activity were developed by using organic or inorganic materials 
(metals and metal oxides) and were used alone or in association with antibiotics17,55,56. Their action is generally 
based on the production of free radicals inducing oxidative stress and the generation of reactive oxygen species 
which irreversibly damage bacterial DNA. 
 
 
3. Biocompatible and biodegradable nanocarriers 
 
The idea of a nanocarrier, able to break-down in harmless products and be cleared from the body after 
delivering its drug cargo in an optimised fashion, has captured scientists’ attention since the conception of 
Erlich’s “magic bullet” at the beginning of 1900s. 
To produce such NPs, a vast array of biodegradable materials, natural, synthetic and hybrid, have been studied 
and developed over the years57,58. Herein, we will focus firstly on the most employed ones, poly(lactic acid) 
(PLA),PLGA and poly(ε-caprolactone) (PCL) based NPs and subsequently on cyclodextrins (CDs), CDs 
derivatives and CD-based polymeric NPs. 
 
3.1. PLA/PLGA and PCL nanoparticles 
 
3.1.1. PLA and PLGA copolymers history, properties and degradation 
 
Poly(glycolic acid) (PGA), PLA and their copolymer PLGA are a family of highly versatile biocompatible and 
biodegradable polyesters which are widely applied in the medical field. 
PGA is the first polymer of this family used for biomedical applications. Indeed, it was firstly employed in 
1960s in the development of biodegradable sutures marketed in 1970s under the commercial name of Dexon57. 
However, the tension of the sutures decreased too fast due to PGA relatively fast degradation. Therefore, a 
PLGA copolymer was developed to lengthen the degradation time. This 10:90 PLGA was marketed under the 
name of Vicryl and Polyglactin59. From this first application, which demonstrated the good mechanical 
properties, the biocompatibility and the tuneable degradation rate of the material, the use of PLGA copolymers 
was expanded to tissue engineering and drug delivery systems21,29. 
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PLGA copolymers have therefore received the approval of the Food and Drug Administration (FDA) and 
several products have been marketed ranging from sutures and bone fixatives, to artificial skin and blood 
vessels, to drug delivery57,59. Lupron-Depot (leuprolide acetate) was the first parenteral (intramuscular or 
subcutaneous) sustained-release formulation utilising PLA polymers and it was approved in 1989. 
Since then, PLGA-based NPs have been used over the years to efficiently carry active agents for the treatment 
of a wide range of diseases1,21,60,61. 
Because PLGA is a copolymer, it can be employed in a broad range of formulations by varying both the 
lactic:glycolic ratio and the molecular weight. The different compositions of PLGA can be used to manipulate 
the crystallinity, hydrophobicity, the glass transition temperature (between 40 and 60°C) and the degradation 
rate of the copolymers62. Typically, a higher ratio of lactic acid results in a more hydrophobic copolymer 
whereas an increase in the amount of glycolic acid produces a more hydrophilic polymer matrix. Indeed, PLA 
present a methyl side group and it has an asymmetric carbon. Consequently, PLA exists in 2 enantiomers which 
display crystalline character57. Therefore, the use of PLA racemic mixtures is preferred over the pure 
enantiomer to form PLGA copolymers. In this way, disordered polymer chains can be obtained and the 
copolymer exhibits more amorphous features which can improve homogeneous dispersion of the drug in the 
polymer matrix29. Conversely, glycolic acid is devoid of this methyl side group and displays a highly crystalline 
structure (Figure 3)31,62. 
 
 
Figure 3 – Chemical structure of PGA, PLA and PLGA 
 
The glass transition temperature (Tg) of PLGA copolymers is above 37°C and hence they are glassy in nature 
and exhibit a fairly rigid chain structure. This confers them a significant mechanical strength which decreases 
with the decrease of the lactic content and the decrease in their molecular weight29,31. 
The degradation of PLGA occurs by simple hydrolysis of the ester bonds which connects the lactic and glycolic 
units, leading first to oligomers and finally to monomers. These degradation products are both non-toxic and 
they are either excreted unchanged in the kidneys (only in the case of glycolic acid) or metabolised by the body 
and eliminated as carbon dioxide and water29,31,62. PLGA degradation is a bulk process which takes place by 
random scission wherever water is able to penetrate into the polymer structure57. The degradation rate depends 
mostly on PLA/PGA ratio, polymer molecular weight, crystallinity, size of the device and on environmental 
factors such as pH and presence of enzymes, among others29. Several studies demonstrated that the ratio of the 
two monomers is the parameter which affects the most PLGA degradation. However, the prediction of PLGA 
degradation is not trivial because of the influence of all the other parameters listed above. In general, the higher 
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the glycolic acid percentage the faster is PLGA degradation apart from PLGA 50:50 which exhibits the fastest 
degradation31. Indeed, as already highlighted, lactic acid is more hydrophobic than glycolic acid, hence lactide-
rich PLGA absorb less water and hydrolyse more slowly29. 
 
3.1.2. PCL polymer history, properties and degradation 
 
PCL (Figure 4) was one of the first polyester polymers synthesised in the early 1930s and its biodegradable 
property was firstly identified in 197332.  
 
 
Figure 4 – PCL chemical structure 
 
It is a hydrophobic, semi-crystalline polymer, whose crystallinity increases with the decrease of its molecular 
weight. PCL has a much lower Tg  (-60 °C) in comparison to PGA, PLA and PLGA and this characteristic 
endows it with flexible mechanical properties suitable for paramedical application, wound dressing, 
contraceptive and dentistry63. The other main difference in comparison to PLA, PGA and PLGA is the much 
lower degradation rate. Therefore, PCL was originally used in drug delivery devices active for over 1 year and 
in slowly degrading suture materials (Maxon)64. Thanks to the development of these first devices, PCL 
received FDA approval. However, PCL mechanical flexibility and slow degradation rate were initially seen as 
a disadvantage. The polymer was too soft and flexible to be able to replace metal devices such as plates and 
screws and its slow degradation was perceived as a factor leading to higher toxicity risks. Consequently, PLGA 
copolymers were preferred over PCL for over two decades. PCL potentialities, such as superior rheological 
and viscoelastic properties in comparison with other resorbable-polymers, were reassessed thanks to the 
development of tissue engineering in 1990s and 2000s. Therefore, PCL was employed to produce a wide range 
of biocompatible resorbable scaffolds64.  
Moreover, the possibility of blending PCL with a broad range of other polymers to improve its mechanical 
resistance and increase the degradation rate opened the way for its use in drug delivery for the development of 
micro and nanoparticles. Similarly to PLGA, PCL degradation occurs by random hydrolytic chain scission of 
the ester linkages. High molecular weight polymers take longer time to be degraded because of the necessity 
to cleave a higher number of ester bonds. PCL hydrolytic product, the 6-hydroxyl caproic acid, has been proved 
to be nontoxic and it  associate to acetycl coenzyme A (Ac-CoA), enters in the citric acid cycle and is easily 
eliminated from the body32,64. 
 
3.1.3. Nanoparticles preparation methods 
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The selection of the appropriate methodology for NPs preparation is of crucial importance to achieve specific 
needs and the physico-chemical characteristics of both polymer and drug must be taken into account65. 
The preparation techniques of NPs can be mainly divided into two synthetic approaches; the self-assembly of 
preformed polymers and the polymerisation of monomers66. Generally, the methods using the first approach 
are preferred to avoid the presence of toxic residues which can be an unwanted consequence of methods based 
on monomer polymerisation. 
Among methods starting from preformed polymers, herein we will focus on the five most common; 
nanoprecipitation, salting-out, emulsification diffusion, emulsification evaporation and double emulsion 
solvent evaporation65. 
Nanoprecipitation is also known as solvent diffusion or displacement and was firstly developed in 1989. The 
polymer and the drug are dissolved in an organic solvent, miscible with water (i.e. acetone, ethanol). This 
organic phase is added drop-wise under magnetic stirring to an aqueous solution which ideally has to be a non-
solvent for both the polymer and the drug. Nanoprecipitation occurs by rapid desolvation of the polymer when 
the two phases are mixed. Nanoparticles formation is governed by interfacial turbulences between the solvent 
and the non-solvent67,68. Local fluctuation in the polymer concentration leads to the formation of nucleation 
sites which further grow to form monodispersed NPs, if all operating conditions are correctly set.  Ideally, the 
process is characterised by a high nucleation rate,  strongly dependent on the supersaturation, and low growth 
rate65,67. Then the organic solvent is evaporated under stirring at room temperature or at reduced pressure. NPs 
with this method can be obtained with or without the need of a surfactant, such as poly(vinyl alcohol) 
(PVA)68,69. In this method, the NPs size is strongly affected by operating parameters such as polymer 
concentration and molecular weight, the choice of organic solvent, solvent/non-solvent ratio, stirring speed 
and the presence of surfactants. Nanoprecipitation method is simple, reproducible, scalable and does not 
require the use of organic solvents considered as highly toxic. However, it leads to a lower polymer 
concentration in the final solution in comparison to other techniques and it is not advantageous for hydrophilic 
drugs65. 
Salting-out technique consists in forming an emulsion between an organic solvent totally miscible with water 
(i.e. acetone, methanol, ethanol and acetonitrile) and an aqueous solution thanks to the salting-out effect66. The 
organic solvent contains the polymer and the drug and the aqueous phase contains a colloidal stabiliser and the 
salting-out agent. The salting-out agent is normally an electrolyte (i.e. magnesium chloride, calcium chloride, 
magnesium acetate or sucrose) which hinders the mixing of the two solvents. 
The obtained emulsion is then diluted with a high volume of pure water which allow the diffusion of the 
organic phase in the aqueous one thanks to the lowering of salting-out agent concentration below a threshold. 
Similarly to nanoprecipitation, interfacial turbulences, generated because of the sudden miscibility of the two 
solvents, lead to NPs formation. This technique is versatile, scalable and reproducible but it requires extensive 
NPs washing to eliminate the salting-out agent and leads to poor encapsulation of hydrophilic drugs. Moreover, 
the high concentration of salts needed to prepare the NPs can be incompatible with the drug stability65. 
Emulsification diffusion method is very similar to salting-out but avoids the high salt concentration. The 
technique requires a first step of mutual saturation between the organic solvent (partially miscible with water, 
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such as ethyl acetate or methyl ethyl ketone) and water. Polymer and drug are solubilised in the organic solvent 
whereas the stabiliser is added in water. The two solvents are than mixed together (usually, 1:2 o/w ratio) 
forming an emulsion which is broken by adding water as for salting-out. The water can contain an additional 
amount of stabiliser (PVA or poloxamer 188). Most common disadvantages are poor encapsulation efficiency 
of hydrophilic drugs and the necessity to concentrate the final NPs suspension. Finally this method requires 
longer processing times compared with nanoprecipitation65. 
Emulsion evaporation technique is the first method proposed for polymeric NPs preparation in 197965 and is 
one of the most frequently used together with nanoprecipitation. This time a water-immiscible and volatile 
organic solvent such as dichloromethane (DCM) or ethyl acetate is required. The organic phase containing 
drug and polymer is emulsified with an aqueous solution containing a surfactant (oil in water –o/w- emulsion). 
Then the emulsion is broken to even smaller drops by applying an external high sheer-stress such as sonication 
or homogenisation. The solvent is then evaporated under magnetic stirring or reduced pressure leading to 
polymer precipitation and thus to NPs formation. NPs size is affected by the force and type of sheer-stress 
applied, by the polymer concentration, by drug/polymer ratio by organic solvent/water ratio and by the 
surfactant used. This method is generally highly efficient for hydrophobic drugs encapsulation but it is not 
suitable for hydrophilic molecules65. 
Double emulsion evaporation technique has been developed starting from emulsion evaporation for the need 
to encapsulate hydrophilic molecules. Interestingly, this method allows the encapsulation of both hydrophobic 
and hydrophilic molecules separately or simultaneously. The procedure is equivalent to that of emulsion 
evaporation, but an additional step is added at its beginning, leading to the formation of a w/o/w emulsion. 
Indeed, this first additional step consists in the solubilisation of the hydrophilic drug in a first aqueous solution 
that will represent the inner phase of the double emulsion. This water phase is emulsified with the organic 
solvent containing the polymer (and/or a lipophilic drug) and a lipophilic emulsifier. This first w/o emulsion 
is used as “organic phase” for the standard emulsion evaporation process. This method has been successfully 
used to encapsulate nucleic acid and proteins. It is worth noticing that this technique can be used also to obtain 
o/w/o emulsions. The principal issues of the technique lie in the difficult stabilisation of the double emulsion, 
in the high sheer-forces used, which can damage biomolecules, and in the frequent formation of some large 
non-uniform NPs65. 
 
3.1.4. Polymeric NPs biological degradation, controlled release and safety profile 
 
Although the mechanism of degradation of polymeric devices is influenced by many variables and may 
therefore be complex, a generalisation of the process can be given. Initially, the water penetrates from the 
surface into the centre of the device triggering the hydrolysis of the polymer. As the degradation proceeds, 
oligomers and monomers are cleaved from the polymer matrix and begin to erode away from the device31. The 
degradation occurs first in the amorphous domains and in a second moment in the crystalline regions. As a 
consequence, the overall crystallinity of the device increases during time thanks to the increased mobility of 
the partially degraded polymer and the realignment of polymer chains21. At this point, heterogeneous 
degradation occurs in large-sized devices21,57. The core begins to degrade faster than the surface because the 
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monomers in the interior are not able to diffuse away, begin to accumulate and their carboxylic end groups 
lower the pH catalysing further hydrolysis in the inside of the device. In the case of implants, when the outer 
section of the device becomes thin enough, it breaks down and releases the degradation products57. Such 
mechanism has been shown to occur both in vitro and in vivo70,71. This bimodal degradation mechanism takes 
place also in the case of microparticles where the osmotic pressure increases until the “capsule” made of the 
remaining non-degraded polymer burst57,72. Oppositely, in small microparticles and in nanoparticles the 
degradation occurs homogeneously with an equal degradation rate in the core and at the surface probably 
thanks to a faster clearance of degradation products from small particles21,57,73. Therefore, NPs seems 
advantageous over microparticles because no low-pH inner pockets are formed, thus decreasing the risk of 
sensitive payload damages.  A difference in the NPs degradation rate is usually observed between in vitro and 
in vivo conditions, with the in vivo one being faster31. This is likely due to the fact that enzymatic degradation 
contribute to the hydrolytic one after in vivo administration31,74,75. Interestingly, the intervention of the 
phagocytic cells of the immune system was found to play a major role in the degradation of NPs, thus allowing 
the selective targeting of such cells to fight against intracellular infections or to use them as “trojan horses” to 
guide NPs towards a specific target40,76,77. The trojan horse idea has been derived by scientists from the ability 
of some intracellular bacteria to behave the same (see Introduction Section 1.1). Furthermore, phagocytic 
cells have been shown to intervene also in the last steps of polymeric microparticles and implants degradation, 
when their residues reach a size small enough to be phagocytated21,32,64. 
Since the degradation process of the polymeric NPs is already influenced by a wide variety of parameters, the 
prediction of drug release rate is even more difficult and often impossible. However, two drug release steps 
can usually be observed; an initial burst release of drug associated to NPs surface and a second phase of 
progressive release due to drug diffusion following particle erosion31. The relative relevance of the two phases 
is due to drug characteristics, drug concentration and polymer hydrophobicity which are typical of each system. 
Therefore, the evaluation of drug release process must be assessed on a case by case basis and the 
characteristics of the polymeric nanoparticles can be tuned to reach the desired properties and, if necessary, a 
controlled release31,58,62. Interestingly, different biodegradable polymers, such as PLGA and PCL, can be 
combined with each other to obtain new copolymers with optimised characteristics59,62. Moreover, different 
kind of “sensors” can be coupled to the polymeric NPs to achieve controlled drug release as response to an 
external stimulus (increase of blood sugars, change in pH, magnetic signal, etc.)58. Another intriguing strategy, 
which can provide controlled release, is the direct conjugation of the drug molecule to the polymer through a 
stimulus sensitive linkage which allow the drug release in a time or location-dependent manner (i.e. colon 
targeting where the cleavage of the bond is ensured by bacteria)58,78. 
One of the main advantages of polymeric NPs lies in their high biocompatibility. PLGA has shown minimal 
systemic toxicity and excellent biocompatibility in vitro and in vivo. An important amount of data is available 
thanks to the success of these materials in drug delivery over the past decades. However, this is an active area 
of research as the safety of newly developed systems have to be systematically proven. 
NPs administration has been performed by exploiting all the possible administration ways. Herein, some 
examples of safe NPs delivery will be reported. Orally administered polymeric NPs have been described to be 
able to release their drug cargo in the gastrointestinal lumen or to cross the intestinal barrier (generally if their 
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size is lower than 500 nm) through Payer’s patches, delivering the drug to the systemic circulation. Moreover, 
they were demonstrated to be safe both after in vitro and in vivo evaluations29,79. For example, no signs of 
toxicity or inflammation could be detected in liver, spleen and intestine after oral administration of estradiol-
loaded PLGA NPs to rats80,81. Moreover, polymeric NPs have been reported to be non-cytotoxic on a wide 
range of cells such as different types of epithelial cells (Caco-2, HeLa, Hepg-2)82, bronchial cells83 and alveolar 
cells84. PLGA NPs resulted safe also after pulmonary administration in mice no matter their surface charge 
(neutral, positive or negative)85. 
Furthermore, PLGA NPs did not present any in vitro cito- or genotoxicity on different cell types86. 
Concerning the intravenous administration, unmodified polymeric NPs are usually taken up few minutes after 
injection by the mononuclear phagocytic system, mainly in Kupffer cells of the liver, and by the spleen 
macrophages. Indeed, to increase their blood circulation time and decrease their recognition by the host 
immune system, di-block copolymers, principally with PEG, were synthesised enabling reaching their target62.  
 
3.1.5. Polymeric NPs applications 
 
The unique properties, including versatile degradation kinetics, established safety, and biocompatibility, make 
these polymers ideal for a wide variety of applications in medical field. Some of the applications PLGA and 
PCL devices have been marketed for, are sutures, bone fixatives and regeneration, dental materials, artificial 
skin and blood vessels, as well as proteins, nucleic acids and small molecules delivery32,57,59,64,87,88. 
In drug delivery domain, polymeric NPs can successfully carry drugs for a broad range of diseases such as 
cancer, neurodegenerative disorders, cardiovascular disease, microbial or viral infections, diabetes and 
osteoporosis32,66,87. Polymeric NPs could provide solubilisation and stabilisation of insoluble or instable drugs 
or improve their pharmacodynamic and pharmacokinetic properties. Furthermore they could grant a better 
penetration of therapeutics inside cells concealing eventual drugs toxicity and helping in the fight against 
multidrug resistant cancer cells or bacteria60,89,90. PEG-copolymers could endow NPs with long circulation 
abilities thus allowing their intravenous administration and passive targeting58,60. 
Importantly, active targeting of such NPs could also be achieved, by modifying their surface with moieties 
able to direct them to a specific body district or target. However, the feasibility and scale up possibilities of 
such decorated NPs must be taken into account. The more complex the NP system is, the longer will be the 
process of its approval, the higher the amount of toxicity tests required to allow commercialisation and the 
higher will be the cost of the marketed product. 
 
3.2. Cyclodextrins (CDs) and CD-based nanoparticles 
 
3.2.1. Cyclodextrins: structure and host-guest interactions 
 
Cyclodextrins (CDs) were firstly described by Antoine Villiers in 1891 as by-products of enzymatic starch 
degradation and they were initially named by him “cellulosines”91,92. The elucidation of their chemical 
structure took several years and the contribution of numerous scientists. Finally in the middle of the 1900s, 
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CDs were demonstrated to be a family of cyclic oligosaccharides composed of glucopyranose units bounded 
together by α-1,4 linkages92. The most common natural (native) CDs are α-CD, β-CD, and γ-CD, which consist 
of six, seven, and eight glucopyranose units, respectively (Figure 5). 
In view of the “chair” conformation of their units, CDs display the peculiar shape of a truncated cone (or 
toroidal shape) with the secondary hydroxyl groups extending from the wider edge and the primary ones from 
the narrower, in both cases oriented towards the cone exterior. This characteristic endows the CDs molecules 
with a hydrophilic outer surface and with an hydrophobic central cavity93 (Figure 5). The lipophilicity of such 
inner surface has been estimated to be comparable with an aqueous ethanolic solution93,94. This unique structure 
renders them capable of forming inclusion complexes (host-guest) with a wide variety of hydrophobic guests, 
thus acting like molecular cages. 
 
 
Figure 5 - Structure, configuration and main characteristics of native CDs. 
 
The interaction between the CD (the host) and included molecule (its guest) is maintained thanks to a set of 
intermolecular interactions such as hydrogen bonds, hydrophobic interactions, steric interactions and van der 
Waals forces95. Such interactions are dependent upon the characteristics of the guest (hydrophobicity, 
hydrosolubility, ionization state and steric hindrance), those of the host (native or modified CDs) and those of 
the solution (solvent, pH, ionic strength, temperature, presence of a cosolvent, etc.)96 and they lead to a state 
that is more thermodynamically stable overall. 
Whereas there is a general consensus about these stabilising forces, some controversy surrounds the nature of 
the “driving force” which lead to the host-guest complex formation and especially the role of water molecules. 
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According to Szejtli97, the main driving force is given by the displacement of the high enthalpy water molecule, 
which form polar-apolar unfavourable interactions with the cavity, by the entering of the guest which is a more 
hydrophobic molecule and therefore leading to more favourable apolar-apolar bonding. Otherwise Liu and 
Guo questioned this theory by stating that the water in CDs cavity do not intervene to any extent in the 
complexation phenomena92,98. 
Beside the role of water molecules in the inclusion process, studies generally agree that is the most hydrophobic 
part of the host molecule which is preferentially included in the cavity of the CDs and the encapsulated 
molecules are oriented in such a way as to maximize the contact between their hydrophobic parts and the 
apolar CD cavity92. The strength of the complexation phenomena and therefore their stability are key factors 
for CDs applications99. Indeed, as no covalent bonds are involved in the process of complex formation, the 
guest-CDs complexes, upon dilution, establish rapidly an equilibrium between dissociated and associated 
species so that an equilibrium with free guest molecules exists at any time. 
The guest-CD complex stability is determined by a thermodynamic equilibrium association constant (Ka) or 
dissociation constant (Kd) which are an index of changes in physico-chemical properties of a compound upon 
inclusion. The majority of methods for determining K values are based on titrating changes in the physico-
chemical properties of the guest molecules within the CDs and then analysing the concentration 
dependencies93,94. Properties that can be titrated in this way include: aqueous solubility100–103, phase solubility 
measurements104–106, chemical reactivity and photochemical stability106–108, molar absorptivity and other 
optical properties (such as circular dichroism)109–112, NMR chemical shift113,114, pH-metric and calorimetric 
titration115,116 and liquid chromatography retention times. Most commonly the order of magnitude of drugs-
CDs binding constant is between 10 M-1 and 2 x 103 M-1 (occasionally 104 and very rarely higher than 105)93,117 
and the molar ratios of drug-CDs complexes are tipically 1:1, 1:2 or 2:1, host-guest respectively. Besides host-
guest complexes, CDs are also well known to form non-inclusion complexes and self-assembling aggregates 
capable of dissolving molecules through micelle-like structures92,93,118. 
 
3.2.2. CDs derivatives 
Although native CDs and their complexes are hydrophilic, their water solubility, especially in case of β-CDs 
(around 18 mg/mL), can be rather limited. This is attributed to the crystal state of natural CDs and to their 
relatively high crystal lattice energy. The random substitution of hydroxyl groups even with hydrophobic 
moieties such as methoxy functions dramatically improve CDs solubility. The main reason of the 
aforementioned CDs derivatives solubility enhancement (generally to more than 500 mg/mL) lies in the fact 
that chemical modification often transforms crystalline CDs into amorphous mixtures of isomeric derivatives93. 
More generally, the aim of CDs derivatisation consist in: i) the improvement of the solubility of CDs and their 
complexes, ii) the improvement of the fitting and association between the CD and its guest, iii) the attachment 
of specific moieties to confer some catalytic, biological or therapeutic activity to CDs and iv) the 
immobilisation of CDs onto polymers (for example for chromatographic purposes) and v) the reduction of 
toxicity119. 
The possible number of CDs derivatives is virtually unlimited as α-, β- and γ- CDs bear 18, 21 and 24 
Introduction 
 
44 
substitutable hydroxyl groups, respectively92. In reality, the majority of these derivatives will never find 
application especially because of their too high production costs and for the impossibility of scaling-up 
complicated multi-steps reactions119. Considerable efforts have been thus made over the years to optimise the 
synthesis in order to decrease the amount of reaction steps and to develop selective reactions to limit the post-
synthetic steps (e.g. purification) to the essential120. 
The main derivatives of pharmaceutical interest, which are industrially produced, include the hydroxypropyl 
derivatives (HP-β-CD and HP-γ-CD), randomly methylated βCD (RM-β-CD or RAMEB), sulfobutylether 
βCD sodium salt (SBE-β-CD) and the so-called branched CDs, such as maltosyl-βCD (M-β-CD)93. 
These synthetized derivatives, both hydrophilic (e.g. HP-β-CD) and lipophilic (e.g. RM-β-CD)121 could find 
successful applications in a wide variety of fields, such as analytical chemistry, pharmaceutical, cosmetic and 
food industry. 
 
3.2.3. CD-based crosslinked polymers and nanoassemblies for drug delivery 
 
CDs have been successfully employed to create novel nanomaterials122 such as nanoparticles, nanosponges, 
nanomicelles, nanovesicles and hydrogels founding applications especially in drug delivery field23,123. 
CD-based crosslinked polymers as well as CD-based nano-objects have emerged as an innovative approach to 
overcome the disadvantages related with native CDs while keeping or even improving their advantages. 
Three main strategies can be identified in the preparation of cross-linked network: i) direct cross-linking of 
CDs (condensation with a cross-linker); ii) copolymerization of CDs with vinyl- or acrylic- comonomers, and 
iii) grafting of CDs to preformed polymer (i.e. PLGA, PLA, PCL, PEG etc..)124,125. 
When taking into consideration the first strategy, cross-linked CD polymers can be prepared by using different 
cross-linking agents, such as aldehydes, isocyanates or epoxides124. Epichlorohydrin (EPI) is the first and 
probably the most investigated between them. It possesses two reactive functional groups which, under alkaline 
conditions, can react with the hydroxyl groups of CDs forming polymeric CDs (pCDs). This pCDs are 
normally obtained in the form of microgels. However, hydrosoluble pCDs can be obtained when stopping the 
reaction in the vicinity of the gelation. Interestingly, TEM investigations showed that they were under the form 
of 10-15 nm NPs in water126,127 (Figure 6). pβCDs NPs synthetized by this way draw particular attention thanks 
to their higher water solubility in comparison to native βCDs and thanks to their ability to greatly enhance the 
apparent solubility of several guests128. 
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Figure 6 – Polymerisation of βCD with epichlorohydrin leading to the formation of cross-linked polymeric CDs 
(pCDs) which in water assemble under the form of NPs. 
 
This type of pCDs has also been widely employed to construct nanospheres and nanogels via host-guest 
interaction mediated self-assembly using hydrophobically modified hydrophilic polymers or hydrophobic 
polymers as guests125. For example, nanogels of 100-200 nm have been prepared by spontaneous self-
association of pβCDs with dodecyl-modified dextran in aqueous solution and has been used to encapsulate 
hydrophilic molecules129–131. 
Another intriguing CDs network is represented by polypseudorotaxanes, inclusion complexes in which CDs 
are threaded onto a polymer chain125,129. 
Interestingly, CDs could also be used to decorate nano or micro particles prepared with other materials, such 
as mesoporous silica NPs or metal organic frameworks (MOFs)132,133, and to prepare hybrid organic-inorganic 
NPs, such as CD-MOFs using the CDs as organic ligands134.  
  
3.2.4. Cyclodextrins biological degradation and safety profile 
 
In solid state CDs can be stored for several years at room temperature without any detectable degradation. In 
aqueous solution instead, they can undergo to both non-enzymatic and enzymatic degradation. The non-
enzymatic one requires quite strong acidic conditions (t1/2 15h at pH1.1 and 70°C) and it consists in the acid-
catalysed hydrolysis of the α-acetal linkage, whilst they are chemically stable in basic and neutral aqueous 
solution. Regarding the enzymatic hydrolysis, CDs are resistant to β-amylases whereas they are slowly 
degraded by α-amylases, which are present mainly in pancreatic juice and saliva. The γ-CDs are more sensitive 
to such enzymes and therefore, after oral administration, they are almost completely digested in the 
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gastrointestinal tract whereas α- and β-CDs are digested mostly by colon bacteria. Free CDs are generally 
digested faster than CDs complex93. 
Most of the pharmaceutically interesting CDs are hydrophilic and have high molecular weights. Consequently, 
they are poorly absorbed by the gastrointestinal tract (bioavailability below 4%) and therefore practically non-
toxic after oral administration, with the only exception of RM- β-CDs. These methylated CDs derivatives 
display a higher lipophilicity (as compared with other derivatives and native CDs) and a higher oral 
bioavailability which leads often to some toxicity, probably due to their interactions with cell lipids93,117. The 
parenteral administration of CDs is also possible but more restricted. CDs are cleared rapidly from the 
bloodstream and are renally excreted intact. However, both native α- and β-CDs, as well as  RM- β-CDs, show 
renal toxicity probably due to the formation of cholesterol-CDs insoluble complexes which aggregate and 
crystallise in the kidneys117,135. Moreover, an haemolytic effect on human erythrocytes is observed from some 
derivatives93. Fewer studies have also been performed on nasal, pulmonar, rectal, dermal and ocular 
administration136–138. The HP-β-CDs and SBE-β-CDs resulted the more versatile and therefore used for all the 
administration ways. The α-CDs are applied especially for parenteral route (excipient in prostaglandin 
infusion), γ-CDs for oral and dermal formulations and RM- β-CDs for nasal formulation24,139. 
The availability of information regarding the toxicity of CDs supramolecular complexes, especially on 
humans, is limited due to their recent development. Nonetheless, it is worth mentioning that polymeric β-CDs 
NPs have reached clinical trials for the administration of siRNA for cancer treatment showing promising results 
and no toxicity to this day140,141. 
 
3.2.5. Application fields of CDs and their derivatives 
 
As already mentioned, CDs and their derivatives have a very broad variety of applications in almost every 
scientific field including chemistry, catalysis, pharmacy, medicine, foods, cosmetics, biotechnology and textile 
industry142. Herein some examples of such applications are provided. 
In chemical and catalysis field CDs are used to increase molecule stability (i.e. to light or oxygen) and 
solubility, to produce HPLC columns allowing chiral enantiomers separation and to catalyse selective organic 
reactions143,144. In the food industry CDs are useful to prepare cholesterol-free products, stabilise volatile or 
unstable compounds and reduce unwanted tastes and odours144,145. These features are also useful for cosmetic 
industry applications146. Moreover, they demonstrated their ability in facilitating the handling and storage of 
toxic substances (pesticides) and in the extraction of pollutants from the environment144. 
The most attractive applications in our case consist in the ones within pharmaceutical and biomedical fields 
where they are mainly employed to form inclusion complexes with drug molecules24,125. CDs can increase drug 
solubility and stability147, which are the main technological limitations of free drugs. Interestingly, CDs cross-
linked polymeric NPs allowed increasing the apparent solubility of challenging crystalline drugs thus solving 
formulation issues128,131. Moreover, CDs are used to enhance drugs absorption148, mask their unpleasant smell 
or taste149, control drug release profiles150, decrease their toxicity24 and improve their permeability across 
biological barrier151. Another interesting application lies in the ability of sugammadex, a γ-CDs derivative, to 
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act as antidote against steroids curare-like agents (rocuronium, vecuronium) by forming an inactive complex 
with these molecules which are used as muscle relaxants in modern anesthesia92. 
 
 
4. Nanoparticles characterisation techniques 
 
The development of a drug delivery system faces several challenges in order to ideally obtain the release of 
the drug in a time controlled manner, in the vicinity of the target and limiting the possible drug adverse effects. 
These objectives have to be achieved together with maintaining nanocarrier biocompatibility and stability until 
its purpose is fulfilled. Before reaching its target, the nanocarrier distributes inside the body possibly having 
to cross epithelial barriers. Once the target is reached, the NP still need to execute its effect and subsequently 
have to be degraded and/or cleared by the organism152. 
Size, shape and surface properties are the main key factors, beside the NPs composition itself, that strongly 
influence NPs stability and their interactions with living systems. 
The size is the first crucial factor normally assessed. Frequently, sizing techniques determine the hydrodynamic 
diameter of the particle rather than its dry one. The hydrodynamic diameter is basically the size of the 
hydrated particle and it is defined as the size of a hypothetical hard sphere that diffuses in the same fashion as 
that of the particle being measured153. A particle, dispersed in a solution, is surrounded by a dipole double 
hydration layer which is tightly connected to it and moves with the particle in its Brownian motion. The 
thickness of this layer depends on various factors, such as the electrical conductivity of the liquid (the higher 
the ionic strength, the thinner the dipole layer). As a consequence, if the particles surface is decorated by 
moieties forming a hydrated corona (PEGylated layer, surfactant, lipid layer), this corona will be accounted 
for as a part of the particles. This will lead to a higher diameter in comparison to that determined by the 
techniques which measure the dry one.  
Surface properties are assessed in a first instance by measuring the surface charge of the NPs. Indeed, surface 
charge has a potential influence on receptor binding and physiological barrier crossing. Moreover, it governs 
the dispersion stability, agglomeration and aggregation154. 
Aggregation more than agglomeration have a high impact on NPs exploitability. Indeed, whereas agglomerates 
are due to the association of NPs through week interactions and are thus easily redispersed to single NPs after 
vortexing or sonicating, aggregates are formed by tight NPs association, or even fusion, and are therefore non 
redispersible. Aggregation have to be cautiously avoided and its occurrence can be foreseen by estimating NPs 
Zeta potential. The zeta potential is the value of the potential at a distance from the surface known as the 
slipping plane. This is the distance within which the electrical double layer around the NP (the same that 
compose NPs hydrodynamic diameter) move as part of it, and from the charge point of view defines the 
particle. Indeed, it is important to highlight that NPs interact according to the magnitude of the zeta potential 
not their surface charge. Stability dividing line is generally considered to be ± 30mV for aqueous systems and 
correspond to the point where repulsive forces between particles dominate over attractive ones155–157. Zeta 
potential can be affected by changes in pH, conductivity (concentration and/or type of salt) and changes in the 
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concentration of a formulation component (e.g. polymer, surfactant).  
In addition, the shape of NPs plays and important role affecting cellular uptake, retention in tissue and 
degradation. NPs shape is normally visualised thanks to electron microscopies154. 
 
A wide range of techniques are currently available to characterise all these aspects of NPs suspensions. 
However, as none of them is perfect, NPs characterisation with at least two techniques, possibly based on 
different technical principles, is of key importance to insure a correct assessment of NPs size, shape and surface 
properties. The association of multiple technique allows combining their strong point and limiting the impact 
of possible instrumental error, ambiguities and results misinterpretation152,158. 
Herein, we will focus on the basic principles, features and drawbacks of dynamic light scattering (DLS), as 
bulk technique, and on nanoparticle tracking analysis (NTA), tuneable resistive pulse sensing (TRPS), 
scanning electron microscopy (SEM) and transmission electron microscopy (TEM), as particle by particle 
techniques. All the described characterisation methods typically require NPs dilution to meet each instrument 
specifications. 
 
4.1. DLS 
 
DLS, also known as photon correlation spectroscopy, is a well-established technique to assess rapidly the mean 
hydrodynamic diameter, size distribution, polydispersity index (PdI) and zeta potential (ZP) of a NPs 
suspension. This method is the best suited for routine measurements of NPs between around 50 nm and 1 µm 
(although these limits are sample dependent)152 and has been widely used thanks to its applicability to a broad 
spectrum of particles and dispersion media. 
DLS determines the hydrodynamic diameter of NPs by measuring the changes in the speckle pattern 
produced by particles scattering light as they undergo to Brownian motions in solution159. 
During DLS measurements all the NPs in solution that are hit by the laser of the instrument diffract the light 
in all directions (Figure 7). The diffracted light coming from different particles can interfere constructively of 
destructively giving a speckle pattern. All the speckle patterns resulting from illumination of the sample at 
short time intervals is analysed by an autocorrelator which compare the light intensity in each spot over time159. 
Changes in speckle patterns are due to fluctuations in the intensity of scattered light which in turn are due to 
NPs undergoing Brownian motion. 
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Figure 7 – Schematic representation of the three main characterisation techniques (DLS, NTA and TRPS) 
measuring hydrodynamic diameter of NPs. DLS is a bulk technique able to rapidly assess NPs hydrodynamic diameter 
by detecting the light scattered in every direction by the all the particles in the sample. The diffracted light is typically 
detected at 90 or 173° and mathematically analysed by an autocorrelator. The instrument provides an intensity distribution 
in function of the particles size from which it can calculate a volume and a number distribution by using Mie theory. 
However, to precisely perform these conversions, knowledge about NPs refractive index is required. NTA measures the 
hydrodynamic diameter of individual NPs by employing a microscope and a camera to detect and record the light 
diffracted by a small volume of sample. Thus, NPs are visualised as bright spots (white spots in the black field) and 
followed in their Brownian motions (red lines = NPs trajectories) by the instrument software. The software counts 
individually the bright spots and, from their trajectories, it calculates NPs size (independent from their refractive index). 
NTA plots NPs concentration (particles/mL) over their size. TRPS is a Coulter-type counter which measures directly NPs 
size and concentration on a particle by particle basis. A voltage is applied across a tuneable pore, filled of electrolyte, thus 
generating an ionic current. The NPs, driven by this current, traverse the pore causing a transient blockade (yellow peaks). 
The magnitude of this blockade is linearly proportional to NPs volume and the number of peaks corresponds to the number 
of particles. TRPS plots NPs concentration (particles/mL) over their diameter. 
 
The analysis of these fluctuations by the instrument allow the generation of a correlation function which is 
used to calculate the diffusion coefficient (Dt) of NPs in the samples and thus derive their mean size through 
Stokes-Einstein equation (Equation 1): 
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Where “T” is the sample temperature, “η” it viscosity, “kB” the Boltzmann constant and “d” the particle 
diameter. To obtain the diffusion coefficient, the correlation function is mathematically treated. This treatment 
is especially complex for polydisperse samples which are more complicate to be analysed. Different algorithms 
have been developed to ease the interpretation of results and minimise the errors: Cumulants analysis, Non-
negative least squares (NNLS) and CONTIN159,160. 
The first value derived from the analysis of correlation function with the cumulants method is the z-Average 
diameter (Z Av) and it is correlated to a Polydispersity Index (PdI) which express the broadness of the size 
distribution. Traditionally in the NPs field, a sample is considered monodisperse when its PdI is at least lower 
than 0.2, even if a PdI lower than 0.1 is preferable152. These values are historically the most reported in 
bibliography and are defined by specific ISO regulations (ISO 13321 and ISO 22412)152,153. ZAv is suitable 
only for monodisperse samples and is highly sensitive to the presence of small portion of aggregates. This 
sensitivity can sometimes result as an advantage to assess monomodal NPs sample stability over time. 
DLS instruments can present results through different types of size distribution (Figure 7). Intensity 
distribution (obtained from different patented methods according to the employed instrument, i.e. NNLS 
method for Malvern Zetasizer) is obtained by plotting the relative intensity of light scattered by NPs versus 
size. This distribution is also very sensitive to agglomerates and knowledge on solvent refractive index (RI) 
and viscosity are needed. The intensity distribution can be converted to volume distribution or number 
distribution using the Mie theory153. Such conversions are necessary to compare DLS results with that of other 
techniques but they require a knowledge of the RI of the NPs, which is very difficult to be obtained. 
Beside NPs size, DLS is also able to assess NPs Zeta Potential (ZP). Indeed, the existence of electrical charges 
on NPs surface lead to the exhibition of a certain effects under the influence of an applied electric field. Thus, 
to determine NPs ZP, an electric field is applied to NPs dispersion and the velocity of particles moving towards 
the electrodes is measured normally using a laser interferometric technique. The electrophoretic mobility of 
NPs is then calculated, and from this, their ZP154. 
 
The main drawbacks of DLS lie in the necessity of using deconvolution algorithms to analyse the results, on 
its limited capacity to accurately describe polydisperse samples, in the need of knowing the RI and viscosity 
of  the sample and in its high sensitivity to the presence of larger particles in a sample159,161. 
Indeed, as the amount of scattered light varies strongly with the NPs size, a small number of large NPs scatters 
more light than a big number of small NPs. This phenomenon can significantly bias the results artificially 
shifting the intensity peak towards bigger diameters and thus leading to an overestimation of NPs size161. 
 
4.2. NTA 
 
NTA determines the hydrodynamic diameter of NPs in a similar fashion as DLS. Indeed, NTA uses both light 
scattering and Brownian motion to obtain NPs size distribution. However, while DLS is a bulk method, NTA 
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is a particle-by-particle technique that offers the ability to directly visualise, size and count nanoparticles162. 
An incident laser beam is passed in the sample chamber through a prism edged glass and illuminates a small 
volume of the sample (20 µL) (Figure 7). A pump is connected to the sample chamber to insure a slow renewal 
of NPs suspension and hence the analysis of “new” NPs. NPs are visualised as bright spots thanks to a 
microscope and their Brownian movements are registered thanks to a camera (Figure 7). NPs movements in 
x and y directions are analysed by the software and the NPs diffusion coefficient is determined. Also NTA 
uses Stokes-Einstein equation (Equation 1) to determine the hydrodynamic NPs diameter but, in contrast to 
DLS, there is no necessity of mathematical data deconvolution. Furthermore, the instrument is able to provide 
number distribution of NPs without the need of knowing their RI. This represents one of the major advantages 
of the technique over DLS. Moreover, the intensity of the individual bright spots corresponding to each NP is 
not an indication of their diameter. The diameter is calculated from the trajectories of the particles. Therefore, 
NTA does not suffer from the intensity weighting problems which strongly affect DLS leading to NPs size 
overestimation.  
Additionally, as the volume of solution analysed by the instrument is known and the NPs are counted during 
the measurement, the concentration of the sample in particles/mL can be calculated161 (Figure 7).  
Another very interesting feature of the instrument is the possibility to introduce a filter to the sample so that 
only fluorescent NPs (wavelength dependent from the selected laser source) are detected. This peculiarity 
allows the detection and the measurement of NPs sizes in complex solutions containing other scattering 
moieties besides NPs, such as biological samples (i.e. cell culture media)161. 
The detection limits of NTA depend on the sample and on the intensity of the diffracted light. For materials 
with high refractive index (i.e. colloidal gold and silver) is possible to accurately measure sizes down to 10-15 
nm. For very week scattering materials (i.e. polymers, liposomes) instead, the smallest detected particle is 
around 40 nm. The upper limit is found around 1-2 µm when the particles move too slow that the tracking of 
their trajectory became inaccurate. Concentrations in the range of 107 to 1010 particles/mL are needed to insure 
a correct assessment of NPs concentration. 
Despite all its advantageous features, also NTA have some limitations. The analysis requires a high dilution 
of the samples so that the NPs are distant enough to be detected by the software as different objects. This 
necessitates to increase measurement times in comparison to DLS to obtain statistically significant data. 
 
4.3. TRPS 
 
TRPS is a Coulter-type counter technique which is recently gaining more interest in NPs sizing. This technique 
provides direct measure of NPs size, concentration and surface charge on a particle by particle basis. 
Historically, resistive pulse sensor or coulter counters found their main application in automated cell counting 
and sizing and for many years the only possible application of this technique in particles field was restricted 
to microparticles159. Thanks to the recent advances in nanofabrication of pores its applications has been 
extended to NPs and the instrument demonstrated to be able to efficiently resolve polydisperse (multimodal) 
samples of close mean diameter159. 
A voltage is applied across a tuneable pore, filled of electrolyte, thus generating an ionic current. The NPs, 
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driven by this current, traverse the pore with a speed dependent on their ZP, causing a transient blockage in 
the ionic current (Figure 7). The magnitude of this blockade is linearly proportional to NPs volume 
(proportional to the cubic of NPs diameter according to Equation 2) allowing size determination with high 
resolution. 
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R is the pore resistance and D its diameter, d represents the particle diameter and L is the pore length for the 
simple case of a spherical particle and a cylindrical pore159. For more complex situations, additional parameters 
have to be taken into account163. 
The instrument is also capable of measuring NPs concentration by multiplying the NPs count rate by the fluid 
flow rate which is dependent to the pressure applied with the instrument. Additionally, NPs ZP can be 
measured on the base of the resistive pulse duration which allow the assessment of NPs electrophoretic 
mobility and the calculation of the ZP using Smoluchowski equation164. 
The main advantage over the traditional coulter counters is that the pore size can be adjusted in real-time 
depending on the NPs diameter by radially stretching the membrane. The pore is formed by mechanical 
puncture of a micron sized pore into an elastic membrane and its tuneability offers the possibility to increase 
the measurement sensitivity and resolution165. However, in contrast with the other techniques presented here, 
a calibration of the pore size with a standard NPs suspension is needed prior to each sample measurement thus 
increasing the measurement time. 
As for every other technique, also TRPS display some drawbacks. An inherent disadvantage of the technique 
is the issue of pore blockages due to particles too large to fit through the pore, to particles attracted by the pore 
surface and to the presence of small aggregates or bubbles. Such blockages can result in time-consuming 
cleaning processes and in the necessity of repeating the sample measurements several times. Moreover, some 
tiny NPs can be undetected because they do not create a significant resistive pulse event159. Additionally, the 
choice of the appropriate electrolyte is crucial because it has to be conductive enough to allow the measurement 
but it does not have to impact the sample stability (i.e. causing particles aggregation/agglomeration). 
 
4.4. SEM and TEM 
 
Electron microscopy (EM) is a technique which uses beams of accelerated electrons as illuminating source 
and electrostatic or electromagnetic lenses, to generate images. This technique has a much higher resolution 
(lower than 1 nm) in comparison to optical microscopy because of the much shorter wavelength of electrons 
(up to 100,000 times shorter) in comparison to visible light photons154. In EM, measurements are performed 
under ultra-high vacuum because the molecules which compose air can scatter electrons and therefore make 
the measurement impossible. It is important to highlight that EM techniques generally measure the sample in 
dried or frozen state thus leading to measure the dried mean diameter of NPs instead of the hydrodynamic one. 
The main and most used types of EM are SEM and TEM which principally differ for the portion of electrons 
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that is collected by the detector after contact with the sample. 
 
SEM is a surface technique and the specimen is scanned with a focused electron beam. When the electrons 
come in contact with the sample, part of their energy is lost through different mechanisms. This energy loss is 
converted in the emission of elastic scattering electrons, namely backscattered electrons, inelastic scattering of 
electrons, called low-energy secondary electrons, light emission (cathodoluminescence) or X-ray emission. 
All of them bring information about the properties of the sample surface allowing the reconstruction of sample 
topography and providing some information about sample composition. Among these emissions, the detection 
of the secondary electrons is the most common mode, achieving a resolving power of around 1 nm154.  
SEM measurement often requires a quite complex sample preparation. Firstly, the sample needs to be dried 
which may cause shrinkage or flattening of NPs thus altering their size154. Secondly, a coating of an ultrathin 
electrically conductive material is often required for non-conductive samples that tend to acquire charge and 
deflect insufficiently the electron beam leading to artefacts. Moreover, the vacuum together with the drying 
process may cause the formation of crystals or thin film of other dissolved species present in the sample and 
thus obscure some details. Conductive coating can be avoided by using low voltage mode of SEM operation. 
 
TEM is the most used EM technique for imaging nanomaterials. A high-voltage electron beam, usually 
produced by an electron gun, is transmitted through a very thin sample layer. Electrons are in part transmitted 
and in part scattered by the sample. The image is then focused onto an imaging device (fluorescent screen, 
photographic film, etc.)154. 
TEM allows imaging internal features of the sample and not only the sample surface as in the case of SEM. 
Moreover, it provides an even higher resolution than SEM and can be coupled to a wide variety of analytical 
techniques to acquire additional information. 
The main drawback of TEM lies in the need of extremely thin specimen sections (around 100 nm) to achieve 
electron transparency and often, for organic polymers, the use of staining with heavy atoms to achieve 
sufficient contrast. Negative stain TEM brings along the potential of artefacts159. Furthermore, the high energy 
electron beam can damage biological and polymer based samples166. The development of cryogenic 
preparation methods adapted to hydrated samples (i.e. high pressure freezing, freeze fractures, 
cryoultramicrotomy..) have further increased the sample preparation time but they have also considerably 
improved the ability of TEM to analyse objects, while maintaining optimum conditions that preserve the initial 
structure167. 
 
SEM and TEM microscopies are valuable techniques to acquire information on NPs shape. However, when it 
comes to statistical analysis of NPs size distribution, they are efficient (timely and costly) only if the process 
can be automated to measure a representative number of particles. The process automatization is anyhow 
possible only for very well dispersed materials, which is often not the case for NPs due to the formation of 
aggregates or agglomerates during the sample preparation for EM159. 
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5. Nanoparticles detection in cells 
 
Shedding lights on the interaction between NPs and living systems is of outmost importance in drug delivery 
applications. Multiple parameters (i.e. administration route, dose frequency and concentration, etc.) have to be 
carefully adjusted in order to increase the probability of reaching an active concentration at the target site. 
Indeed, once NPs are administered, they distribute inside the body possibly having to cross multiple barriers 
before being able to reach their target. Moreover, once the target is finally reached, NPs interact specifically 
with the cells basing on their physico-chemical properties. 
Composition, size, shape and surface properties of NPs are the key factors which mainly determine their ability 
to cross tissue barriers and their cell binding, uptake and intracellular fate. An inadequate knowledge of NPs-
cells interaction can determine the failure of the system. 
Thus, advanced imaging methodologies are employed to investigate the fate of engineered NPs when they 
come into contact with cells. 
Fluorescence microscopy together with electron microscopy represent the most widely used techniques in the 
intracellular NPs detection field.  
 
Fluorescence microscopy has proved over the years to be an essential tool in countless biomedical 
applications168. In particular, confocal laser scanning microscopy enables for 3D multicolour imaging in living 
cells, but its resolution is restricted by diffraction limit to around 200 nm depending on the wavelength and on 
the numerical aperture of the employed microscope. Thus, single NPs are not detectable. To overcome such 
limitation, a variety of super resolution techniques have been developed over the years169,170. Among them, 
structured illumination microscopy (SIM), stimulated emission depletion (STED), stochastic optical 
reconstruction microscopy (STORM) and photoactivation localization microscopy (PALM) are the most used 
to image cellular structures with sub-diffraction resolution and were successfully adapted also to NPs 
detection171. The main advantage of such techniques lies in the possibility of separately labelling NPs and cell 
membrane or subcellular compartments thus allowing unveiling NPs precise localisation within cells, together 
with their uptake mechanism171. SIM is the less resolutive of the listed techniques (lateral resolution  ̴100 nm 
and axial resolution ̴ 200 nm) and the data processing is quite complex, but it has the advantage of using 
standard organic dyes. STED displays a higher lateral resolution ( ̴ 30-50 nm) and is able to acquire images at 
high speed but it still has a limited axial resolution ( ̴ 30-600 nm), requires the use of specific organic dyes and 
a high label density172. Finally, PALM and STORM provide the highest resolution (both lateral and axial ̴ 10-
40 nm) but the image acquisition is quite slow, the data processing complex and they both need the use of very 
particular fluorescent dyes. PALM makes use of photo-activable proteins while STORM uses the photo-
switching of pairs of cyanine dyes or blinking cyanine dyes. All these dyes are prone to cross talk and requires 
high labelling density172. 
The use of labelling agents has greatly facilitated the investigation of complex biological interactions. 
However, in the case of NPs, the fluorescent dyes, either physically encapsulated or covalently grafted173,174, 
can lead to several inconveniences168. Indeed, the physical encapsulation of fluorescent probes is prone to the 
Introduction 
 
55 
leakage or even to the transfer of the fluorophore to cell membrane175–178 whereas the covalent linkage is more 
reliable, but it can lead to changes in the size, shape or surface properties of the particles. These changes are 
well known to alter the interaction (uptake and intracellular fate) of labelled-NPs with cells and tissues in 
comparison to plane NPs179–183. Of note, finding fluorescent dyes compatible with encapsulation or conjugation 
to NPs together with meeting the specific criteria for super-resolution techniques can be quite challenging thus 
complicating or even hampering the development of suitable labelled NPs. Furthermore, NPs detection in 
biological media can be hampered by cells autofluorescence, particles scattering  or photobleaching184. 
 
The other main imaging technique, extensively used to localise NPs in subcellular compartments, is TEM168. 
This technique possesses an impressively high spatial resolution (down to 0.1 nm) allowing discriminating 
subcellular compartments with very high definition. Indeed, this method was the first one to enable visualising 
molecular events such as NPs engulfment inside cells and to clearly image NPs precise subcellular 
localisation171. Moreover, TEM is sufficiently sensitive to differentiate isolated nanoparticles from the 
corresponding aggregates185. Despite the clear potential advantages of using such technique, a number of 
limitations remains. Indeed, biological samples need complex preparation including chemical fixation, 
dehydration and embedding in a polymer resin or freezing process (cryo-TEM) to allow stabilising the sample 
enough for ultra-sectioning185. Among these sample preparation processes, cryo-TEM is particularly 
convenient as it allows to reduce the presence of artefacts in comparison to chemical fixation. Nonetheless the 
long sample preparation and prolonged image analysis greatly limit the analytical throughput of this technique. 
In addition, TEM is only suitable for electron-dense NPs thus obliging to label organic particles (such as 
PLA/PLGA/PCL NPs) by encapsulating electron-dense material that can provide sufficient contrast186,187. 
 
It is of outmost importance to highlight that both fluorescence and TEM microscopies rely on the use of 
labelling agents or material modification in order to detect the particles internalised by cells. As a consequence, 
they provide an indirect observation of the object of interest through the signal of the label. Indeed, the moiety 
detected and followed by fluorescent or electron microscopy throughout the experiments is the molecular probe 
and not the particles itself. Thus, at any moment, the integrity of the NPs cannot be proven and the dye, 
separated from the particle, could be followed instead of the NPs. 
 
To overcome such problematics, there has been a tremendous interest, during the last 20 years, in developing 
innovative techniques, or combining the existing ones, to provide direct simultaneous imaging and chemical 
identification of NPs avoiding the use of labelling. This improvement could be particularly useful for the 
detection of polymeric organic NPs, such as the ones made of PLA, PLGA or PCL, which do not possess any 
contrast property. 
For example, nano-scale secondary ion mass spectrometry (NanoSIMS)188,189 in correlation with TEM190 has 
recently emerged for its ability to offer high imaging resolution (less than 100 nm)190 together with chemical 
characterisation. However, this technique is destructive, expensive, demand complex and time-consuming 
experimental procedure, and an isotopic labelling of the element of interest is still necessary. 
 
Introduction 
 
56 
The first technique able to  detect unlabelled polymeric particles in cells was Raman microspectroscopy, which 
couples Raman spectroscopy and optical microscopy, offering the possibility to perform imaging together with 
chemical analysis191. Using the Raman signal, described as a modulation of the scattered light by molecular 
vibrations, the subcellular architecture as well as intracellular dynamics of polymeric NPs could be 
scrutinised192. Some studies have also been performed on the intracellular degradation of such NPs and on the 
subcellular drug delivery191,192. Indeed, an important feature of this technique is the possibility to perform the 
measurements in liquid media and even on living cells in contrast for example with TEM193. 
However, also Raman microspectroscopy displays some limitations. In fact, its signal is usually overwhelmed 
by the large autofluorescence of the cells and irreversible photo-damages are induced to the sample when 
trying to circumvent this issue by increasing the acquisition time or the incident power194.  
Moreover Raman microscopy resolution is limited by light diffraction to around 300 nm -1 µm, depending on 
the excitation source168,195. Thus, particle agglomerates rather than individualised NPs are detected191,192,195. 
Therefore, given the small size of the polymeric NPs (usually less than 200 nm), part of information is lost168. 
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SECTION A: 
  
Combination therapy for tuberculosis treatment: pulmonary 
administration of ethionamide and booster co-loaded nanoparticles 
(Paper 1) 
 
 
General objectives 
 
Tuberculosis (TB) is one of the most life-threatening infections caused by an intracellular pathogen which is 
able to colonize and multiply inside alveolar macrophages in host lungs. 
In an attempt to develop an adapted treatment of TB, we report in this study the design of an engineered 
nanoparticulate drug carrier able to host a powerful drug combination. The drugs of interest in this research 
are ethionamide (ETH), a second line anti-TB drug with low therapeutic index, and its Booster (BDM41906), 
belonging to a family of molecules able to boost ETH bioactivation, thus having the potentiality of improving 
the current TB clinical outcome. Indeed, the clinical use of ETH is limited by its severe side effects and by the 
high doses need to obtain a therapeutic effect. 
The administration of the [ETH:Booster] pair is very challenging, as the two molecules possess completely 
different physico-chemical properties and biodistributions and are not soluble in biological-compatible 
solvents. Moreover, ETH administration is further hampered by its strong tendency to crystallize in aqueous 
media and the necessity to use large amounts of organic solvents to solubilize it. 
In this context, we have investigated the co-encapsulation of the [ETH:Booster] pair in nanoparticles made of 
biocompatible and biodegradable polymers such as poly(lactic acid) (PLA), poly(lactic-co-glycolic acid) 
(PLGA) or polymerized cyclodextrins (pCDs). PLA NPs coencapsulating [ETH:Booster] were successfully 
formulated by nanoemulsion and characterized with advanced complementary physico-chemical methods. 
 Despite their high drug loading (around 36% and 26% for ETH and Booster, respectively), PLA NPs could 
not totally avoid ETH crystallization during storage. 
On the other hand, pCD NPs displayed a lower drug loading but they could incorporate [ETH:Booster] at a 
molecular level (hampering ETH crystallization) by a “green” method totally solvent-free. 
The efficacy of the formulations was evaluated in TB-infected macrophages using an automated confocal high-
content screening platform, showing that the drugs maintained their activity after incorporation in the NPs. 
Given these positive results, the successful passage of the developed formulations through a Microsprayer®, 
a device for the endotracheal administration in rodents, was carefully assessed. The pCD NPs could be 
reproducibly passed through the device without any loss of material and were thus selected for in vivo studies. 
The pCD NPs suspensions could be administered directly into mouse lungs via the endotracheal route. We 
first show, using histology and flow cytometry studies, that repeated administrations of pCD NPs had no toxic 
effect on lung homeostasis. Then, in a mice model of M. tuberculosis infection, we obtained a dramatic 3-log 
decrease of the pulmonary bacterial load after 6 treatments as compared to untreated mice. 
This study paves the way for a future use of the CD-based NPs for the pulmonary delivery of the potent 
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[ETH:Booster] pair. With further developments, our approach could be used as a supplement to the standard 
 treatment to contain the M. tuberculosis pulmonary manifestations of the disease and to prevent its 
dissemination, especially for MDR-XDR cases. 
 
 
Graphical abstract - Endotracheal delivery of polymeric β-cyclodextrin nanoparticles loaded with ethionamide and one of its 
boosters (BDM41906) into mouse lungs infected by M. Tuberculosis. 
 
 
This multidisciplinary study was performed in collaboration mainly with the team of Dr. P. Brodin at the 
Pasteur Institute of Lille, partner of the European project “Cyclon Hit” which founded this PhD research. 
E. Pancani prepared, optimised and characterised the NPs used in the study, helped in dosing NPs drugs content 
by HPLC and assessed the NPs passage though the Microsprayer. Moreover, she actively participated in close 
cooperation with the Pasteur Institute of Lille in conceiving the in vitro and in vivo experiments, helped in the 
interpretation of the obtained results and contributed in writing the paper. 
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Section I - Nanoparticles development 
  
PLA/PLGA NPs – Nanoprecipitation method 
Several PLA and PLGA polymers were employed to prepare the nanoparticles by nanoprecipitation (P1, P2, 
P3, P4, see materials and method section). In all cases the formulated NPs were remarkably stable upon storage 
up to 5 months, with less than 5% size variation. The size variation over a period of 1 month is shown in the 
Supplementary Fig. S1. 
Interestingly no difference in the size evolution of NPs was shown between the formulation stored at room 
temperature or in the refrigerator (4°C). 
Supplementary Figure S8 – Stability of nanoparticles obtained by nanoprecipitation method over a period of 1 month 
(measured by DLS). The graph shows size stability of nanoparticles (charged or not) over 1 month. RT: storage at room 
temperature, 4°C: storage in the refrigerator. 
 
The first attempt of formulation has been performed using P1 (1.43 mg/mL polymer in suspension). The 
encapsulation of Ethionamide (ETH) alone was studied by trying to encapsulate increasing concentrations of 
this drug (from 0.07 to 0.71 mg/mL). The results are shown in the Supplementary Fig. S2. 
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Supplementary Figure S9 – Effect of increasing ETH concentration on EE% and DL% of nanoparticles 
formulated by nanoprecipitation with P1. The yellow star ( ) represents the formation of ETH crystals few days after 
nanoparticles preparation (ETH concentration of 0.71 mg/mL). 
 
Formulations up to an ETH concentration of 0.43 mg/mL were completely stable. In these conditions the 
highest achieved drug loading (DL) and encapsulation efficiency (EE) were 11 wt % and 36 wt %, respectively. 
Unfortunately, raising the amount of ETH to 0.71 mg/mL in the attempt to further increase DL and EE, the 
DL resulted unchanged and the encapsulation efficiencies decreased to 22 % (Supplementary Fig. S2). 
Moreover, increasing ETH amounts in the NP preparation procedure lead to the formation of drug crystals 
which progressively grew in the suspension media until being seen with the naked eye, few days after NP 
preparation (Supplementary Fig. S3). 
Supplementary Fig. S3 shows the decreasing of DL and EE (P1 and ETH concentration of 0.71 mg/mL) during 
the first 8 days after NPs formulation. The formation of crystals was observed after 5 days and corresponds to 
a further decrease in NPs DL and EE. 
ETH crystallisation in P1 NPs was avoided only at ETH concentrations below 0.71 mg/mL, which is 
insufficient for in vivo applications. Attempts to concentrate the NPs suspensions failed because of a strong 
aggregation in the absence of protective surfactants. 
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Supplementary Figure S10 -  DL% and EE% decrease during storage. DL and EE decreased during first days of  
storage  leading to the formation of crystals at the bottom of the flask (represented by the yellow star  in the figure) and 
to a decrease of both DL and EE.   
 
In an additional attempt to increase both DL and EE, a series of PLA and PLGA copolymers were used, with 
different molecular weights and compositions (P2, P3 and P4). In all cases, aggregation or drug crystallization 
occurred. Better results in terms of DL and EE (24 wt % and 34 wt %) were obtained with P3 and an ETH 
concentration of 1 mg/mL. However, crystallisation occurred after 5 days as for the other polymers. Moreover, 
co-encapsulating Booster did not improve ETH loading, as it was found that Booster had stronger affinity for 
the polymeric NP than ETH. As an example, at the ratios [ETH:Booster] [1:0.1] and [1:1], ETH DL were lower 
than 2 wt %. Interestingly Booster DL and EE during coencapsulation were significantly higher than ETH ones 
(9 % and 29 % wt respectively, for ratio [1:1]) showing a higher affinity of the Booster for the polymeric 
matrix.  
 
PLA NPs – Nanoemulsion method 
To address the challenge of coencapsulating ETH and Booster, a second method based on the formation of an 
emulsion, stabilized with polyvinyl alcohol (PVA), a surfactant approved for pulmonary administration, was 
set up using P4 (see material and methods section). 
An extensive study on mean diameter of PLA NPs obtained by nanoemulsion has been performed using the 3 
independent methods: PCS, NTA and cryo-TEM (see main text). The results show the importance of the use 
of different techniques to truly characterise nanoparticulate systems. Results are reported in Supplementary 
Table S1. It’s interesting to point out that no significant difference in the diameter of NPs has been found 
between empty PLA NPs and drug-loaded PLA NPs. 
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Supplementary Table S1 - Main characteristics of empty and drug-loaded NPs made of P4 by the nanoemulsion 
method. NP mean hydrodynamic diameters were determined by PCS and NTA. Nanoparticles dry diameter was 
determined by cryo-TEM and nanoparticle concentration was obtained by NTA. Concentration results given were 
obtained after 10,000 times dilution of each sample as prescribed to fit the instrument requirements and to allow the 
particle to move freely according to their Brownian motions. 
 
Formulation 
Mean diameter Concentration 
D PCS 
Z Average 
(nm ± SE) 
PdI 
PCS 
D PCS 
Number 
(nm ± SE) 
D NTA 
(nm± SD) 
Cryo-TEM 
NTA 
(particle/mL) 
NPs 254 ± 4 0.054 220 ± 10 176 ± 45 110 ± 50 1.01x109 
NPs [ETH] 267 ± 3 0.074 226 ± 10 176 ± 48 100 ± 40 0.88x109 
NPs [ETH:Booster] 
[1:0.1] 
258 ± 3 0.058 223 ± 10 180 ± 51 100 ± 50 1.03x109 
NPs [ETH:Booster] 
[1:1] 
274 ± 4 0.090 235 ± 11 178 ± 52 100 ± 50 0.89x109 
NPs [Booster] 277 ± 5 0.075 238 ± 11 171 ± 49 120 ± 55 0.91x109 
 
NPs formulated with the  nanoprecipitation method were remarkably stable upon storage more than 5 months, 
with less than 10 % size variation and a PdI still lower than 0.1. The size variation over a period of 1 month is 
shown in the Supplementary Fig. S4. 
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Supplementary Figure S4 – Stability of NPs obtained by nanoemulsion over a period of 1 month. No crystallization 
was observed during storage and no significant size or polydispersity changes (DLS) were found. 
 
pCD NPs – Stability and release properties 
The drug-loaded particles were stable upon storage and drugs were released only upon dilution of the NPs 
suspensions. Indeed, the drug molecules inside pCD NPs are in equilibrium with the ones in the suspension 
medium. Both ETH and Booster, poorly soluble in aqueous solution, strongly bound to pCD NPs. For instance, 
if the NPs are diluted ten times, one can calculate that around 90% of Booster will still be associated to the 
NPs. 
The mechanism of drug release from pCD NPs, based on a partition mechanisms, has been thoroughly 
described in our previous publications 1-3. 
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Section II - Phenotypic extracellular and intracellular assays and in 
vivo results 
 
To investigate the efficacy of drug-loaded NPs against M. tuberculosis, we used two phenotypic assays that 
are disease-relevant and amenable to high-throughput. The first one is a simple assay relying on the monitoring 
of fluorescence from a strain of M. tuberculosis that expresses the green fluorescence protein using a 
microplate photometer. The second is an image-based model that allows the multi-parametric quantification 
of M. tuberculosis replication inside its favourite niche, the macrophage. The dedicated protocol used for image 
analysis with the Columbus software is given in Supplementary S5 below. 
 
Supplementary Figure S5- Columbus script used for image analysis. Two colour-images were analysed. The red 
recorded on the channel “Exp1Cam3” was used for the nucleus and cytoplasm detection. The green recorded on the 
channel “Exp1Cam2” was used to detect the bacteria. ROI: Region of interest. 
Stack Processing : Individual 
PlanesFlatfield Correction : None
Channel : Exp1Cam3 Method : B
ROI : None Common Threshold : 0.5
Area : > 15 µm²
Split Factor : 5
Individual Threshold : 0.55
Contrast : > 0.2
Method : Common Filters
Remove Border Objects
Region : Nucleus
Channel : Exp1Cam3 Method : Standard
Population : Nuclei 2 Mean
Region : Nucleus
Select Population (3) Population : Nuclei 2 Method : Filter by Property
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In Supplementary Fig. S6 we point out that the % of inhibition in the presence of empty PLA and empty pCD 
is negligible (close to zero) independently from the concentration of the NPs, both in the intra- and extracellular 
assay. These results show that the antibacterial effect observed is due to the presence of ETH and Booster 
released from the nanoparticles since the unloaded nanoparticles were not able to impair bacterial replication. 
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Supplementary Figure S6- Effect of empty NPs on intra- and extra-cellular assay. (a) % of inhibition of bacterial 
RFU obtained with empty PLA made by the nanoemulsion method (solid circle) and with empty pCD (solid triangle). (b) 
% of inhibition of intracellular bacterial area (black points) and number of cells (grey points) obtained with empty PLA 
made by the nanoemulsion method (solid circle) and with empty pCD (solid triangle). 
 
In Supplementary Table S2 we present the results of 3 independent in vivo experiments after 2 weeks of 
treatment as described in the manuscript. In the 3 experiments we observed a significant decrease in the 
pulmonary bacterial load after treatment with ETH and [ETH:Booster] encapsulated in pCD NPs. 
 
Supplementary Table S2- Comparison of 3 independent in vivo experiments.  
Log10 CFU in lungs mean ± SD 
at 21 days post infection 
Control pCD [ETH] pCD [ETH:booster] 
Exp 1 9.15 +/- 0,44 7.83 +/- 0.59 * 5.77 +/- 0.27 *** 
Exp 2 7.51 +/- 0.16 6.25 +/- 0.28 *** 5.87 +/- 0.48 *** 
Exp 3 7.22 +/- 0.23 6.04 +/- 0.72 * 5.12 +/- 0.28 *** 
*:p<0.1. ***:p<0.001 
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Section III - Detailed Materials and methods 
 
Chemicals 
PLGA 75:25 acid terminated (P1) (MW: 37-84 KDa, 10P002), PLGA 50:50 ester terminated (P2) (MW: 70-
100 KDa, 10P016) and PLGA 50:50 acid terminated (P3) (MW: 5-20 KDa, 10P019) were kindly provided by 
PCAS (Expansorb, Aramon, France). PLA ester terminated (P4) (MW =10-18 kDa), PVA (87-90% 
hydrolyzed), DMSO-99.5%, ETH and amikacin were all purchased from Sigma-Aldrich. Injectable water was 
purchased from Cooper (Melun, France). Dichloromethane (DCM-Analar Normapur stabilized with about 
0.002% of 2-methyl-2-butene) and MeOH were purchased from Prolabo (Fontenay-sous-Bois, France). KCl 
(99%) was purchased from Alfa Aesar (Karlsruhe, Germany). 
The Booster named BDM41906 (5,5,5-Trifluoro-1-[4-(3-thiazol-2-yl-1,2,4-oxadiazol-5-yl)piperidin-1-yl] 
pentan-1-one) was synthesized as previously described 4.  
β-CD was kindly supplied by Roquette, Lestrem, France. pCD NPs of around 10 nm were produced as 
previously described 5,6 by crosslinking β-CD  under strongly alkaline conditions with epichlorohydrin (EP). 
Briefly, 100 g of anhydrous β-CD was solubilized overnight in 160 mL of NaOH 33% w/w solution. Then, 
81.52 g of EP was  rapidly  added  and the  reaction  was  stopped in  the  vicinity  of  the  gelation point by 
addition of acetone. The β-CD NPs, recovered by ultrafiltration followed by freeze-drying, contained 70% 
w/w β-CD, as determined by 1H NMR spectroscopy. 
 
Nanoparticle preparation 
Nanoprecipitation: encapsulation of ETH in PLA and PLGA NPs was carried out adapting a previously 
reported procedure 7. Briefly, 0.4 mL of DMSO solution containing 10 mg polymer (PLA or PLGA) and ETH 
(0.5 to 7 mg) were poured drop by drop in 7 mL of injectable water under magnetic stirring. In the case of co-
encapsulation, 3 mg (ratio 10:10) or 0.3 mg of Booster (ratio 10:1) were added to the DMSO solution. 
Nano-emulsion: preparation of PLA NPs was carried out as previously reported by Kumar et al. with slight 
modifications 8. Briefly, 10 mg of ETH were solubilized in 0.2 mL of MeOH and mixed to 1.5 mL of a 
dichloromethane (DCM) solution containing 20 mg of P4 in DCM. For the co-encapsulation of the synergic 
drugs pair, 10 mg of Booster, in case of 10:10 ratio, or 1 mg of Booster, in case of 10:1 ratio, were solubilized 
in the solution of PLA in DCM. Control empty NPs were prepared in the same conditions, except that the 
drugs were not added.  
The organic phase was poured into 4 mL of an aqueous phase (injectable water) containing 0.5% w/v PVA 
and emulsified 20 seconds (vortex). The mixture was then sonicated (Sonopuls HD 2070, BANDELIN 
electronic GmbH & Co, Berlin, Germany) at 20% power for 1.5 min, stopping the procedure each 30 seconds 
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to avoid the overheating and for 30 additional seconds to 10%. The resulting emulsion was left uncapped under 
magnetic stirring, checking the weight of the flask to monitor the evaporation of the organic solvents, until 
complete evaporation of DMC and MeOH. 
Drug encapsulation in “green” pCD NPs: encapsulation of ETH and Booster in pCD NPs was carried on 
without using any organic solvent, by mixing for at least 4 hours the NP suspensions with the drug powders. 
 
Nanoparticle characterization 
Size measurement by PCS and Zeta Potential measurement 
The average hydrodynamic diameter of the NPs was determined at 25°C, in triplicate, with an equilibration 
time of 60 s, using a Malvern Zetasizer® (Nano ZS90, Malvern Instruments S.A., Worcestershire, UK). For 
the measurement of method 1 formulations, Samples were analyzed without performing any dilution (method 
1) and with 1:10 and 1:100 dilutions in injectable water (as prescribed by ISO 22412) in the case of method 2. 
No significant differences were noticed in the hydrodynamic diameter of the two dilutions.  All autocorrelation 
functions have an intercept with amplitude equal to 0.9 or higher. Mean diameters were reported as Z Average 
(nm) ±SE (Standard Error - with a Polydispersity Index lower than 0.1) or as number mean diameter (nm) ±SD 
(Standard Deviation). 
The stability of the NPs prepared by nanoprecipitation and nanoemulsion was assessed at RT (25°C-storage 
conditions). The NPs mean diameters were monitored up to three months of storage at 25°C via DLS size 
measurements (see Supplementary Fig. S1 and S5). 
Also the Zeta Potential (ZP) of nanoparticles was measured in KCl 1Mm by Malvern Zetasizer©. Each sample 
was diluted 100 times and 1,000 times in KCl 1mM. Results are reported as ZP (mV) ± SD. 
Size measurement by NTA and concentration quantification  
Mean hydrodynamic diameter and concentration of the NPs were measured 5 times for 60 seconds at 25°C by 
NTA (NanoSight LM10, Malvern Instruments S.A., Worcestershire, UK, equipped with a 565 nm filter and a 
NanoSight syringe pump). NPs prepared by nanoprecipitation were diluted 2,000 times and the ones made by 
nanoemulsion 10000 times. Results are reported as mean diameter ± SD. 
Cryogenic transmission electron microscopy (cryo-TEM) 
5 µl of NPs suspensions (diluted 4 times in water) were deposited onto a 200 mesh holey copper grid (Ted 
Pella Inc.) and flash-frozen in liquid ethane cooled down at liquid nitrogen temperature. Cryo-TEM images 
were acquired on a JEOL 2200FS energy-filtered (20eV) field emission gun electron microscope operating at 
200 kV using a Gatan ssCCD 2048 × 2048 pixels. Several thousands of images were automatically acquired 
for each NP formulation to obtain representative results. 
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Drug sample preparation for drug(s) dosage  
To determine the amounts of ETH and Booster incorporated in PLGA NPs, 500 µL of NP suspensions were 
centrifuged at 17,000g for 15 minutes. Then, 200 µL of the supernatant were withdrawn to assess the quantity 
of non-encapsulated drug (indirect estimation). The NPs pellet was dissolved in 250 µL DMSO and dosed 
(direct estimation of the encapsulated drug). For the pCD NPs, aliquots of pCD NPs containing drug(s) were 
centrifuged at 5000 rpm for 10 min to remove unloaded drug(s). The supernatant containing the pCD NPs was 
then diluted with DMSO (1:1 volume ratio) and dosed by HPLC after further dilution in DMSO and/or with 
acetonitrile/water 45/55 v/v. 
All the samples were dosed by liquid chromatography-mass spectrometry (LC-MS-MS) and reverse phase 
HPLC (RP-HPLC). For LC-MS-MS analysis, a Waters Acquity I Class – Xevo TQD system using an Acquity 
BEH C18 column (50x2.1mm, 1.7 µm) at 40°C was used. The mobile phase at a flow of 600 µL/min was 
composed by two solvents: ammonium acetate 10 mM (Solvent A, spontaneous pH) and acetonitrile (CH3CN) 
with 0,1% HCOOH (Solvent B) (UPLC gradient of B= 0% at time 0.98% from minute 2.00 to 2.50 then 0% 
from minute 2.60) and its flow was 600 µL/min. 
Samples were prepared by diluting them 100 times in MeOH and then 100 times in a solution of MeOH 
containing the internal standards, then 1 µL of each sample was injected in the system. 
The RP-HPLC analysis were performed after dilution with the mixture acetonitrile/water 45/55 v/v using a 
Agilent HPLC system (Agilent 1100 Series) equipped with a C18 column (Kinetex 5u C18, 100 A, 
Phenomenex, and UV detector at λ = 280 nm. The chromatographic conditions were as follows: solvent A 
0.1% Trifluoroacetic Acid (TFA) in water and solvent B 0.1% TFA in acetonitrile; 0–2 min: 0%–20% B, 2–6 
min: 20%–45% B, 6–10 min: 45%-75% B, 10–15 min: 75%–0%. Flow rate: 1.0 mL/min at room temperature. 
In all cases, R2 values for both ETH and Booster were higher than 0.99. From the obtained data the DL and 
EE were calculated as shown in equation 1 and 2, respectively. The DL can be defined as the mass fraction of 
a NP that is composed of drug, while the EE can be considered as the fraction of drug effectively encapsulated 
into the NPs compared with the amount that was initially added during the particles preparation 8,9. 
(1) 100
)(
*)*(
(%) =
polymerofmg
drugedencapsulatofmg
DL  
(2) 100
)(
*)*(
(%) =
nformulatiothetoaddedinitiallydrugofmg
drugedencapsulatofmg
EE  
[**The amount of encapsulated drug has been calculated with a direct or indirect estimation, depending on the sample fraction considered] 
 
Bacteria and macrophages 
M. tuberculosis H37Rv strain constitutively expressing the green fluorescent protein (H37Rv-GFP) was used 
as a reporter for the replication assay. Bacteria were cultured at 37 °C for 16 days in complete 7H9 medium 
containing 0.5 % glycerol (50405, Euromedex), 10% Middelbrook oleic acid-albumin-dextrose-catalase 
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(OADC) (211886, Becton Dickinson), 0.05% Tween 80 (2002A, Euromedex) and 50 µg/mL hygromycin B 
(10687010, Invitrogen). In the day of the experiment, M. tuberculosis were washed with D-PBS Ca- Mg- 
(14190169, LifeTechnologies) 3 times with centrifugation at 5,000 RPM for 5 minutes and centrifuged at 700 
RPM for 2 minutes to remove clumped bacteria. Bacteria were resuspended in RPMI-1640 + glutamax 
(61870044, LifeTechnologies) containing 10 % heat inactivated fetal bovine serum (FBS) (10270106, Gibco) 
and titrated by measuring the optical density at 600 nm.  
Mouse macrophage RAW 264.7 (ATCC # TIB-71) were maintained at 37°C in RPMI-1640 + glutamax 
containing 10% FBS and were passed 3 times per week and used before passage number 7. Macrophages were 
harvested by using Versene (15040033, LifeTechnologies). 
 
Assay plate preparation 
ETH, BDM41906 and INH were diluted in DMSO (34943, Sigma-Aldrich) to 10 mg/mL and were dispensed 
in Echo-qualified 384-well low dead volume source plates (Labcyte). Echo 550 Series Liquid Handler 
(Labcyte) was used to transfer precise volumes between 5 and 500 nL from the Echo-qualified plate to the 
384-well clear-bottom polystyrene assay plates (781091, Greiner Bio-One) by using sound waves. All the 
conditions were backfilled with DMSO until 500 nL. Prior to addition of cells, 4.5 µL of cell medium were 
dispensed in the Echo-dispensed wells.  
NPs loaded with ETH or with the [ETH:Booster] pair were diluted in water to 0.2 mg/mL of ETH. 2-fold serial 
dilutions of the mother solution in a final volume of 100 µL were performed in sterile MilliQ water in a 384 
deep well “diamond plate” (P-384-120SQ-C-S, Axygen) in order to obtain a dose-response curve. Posteriorly, 
5 µL of the NPs were dispensed in the 384-well assay plates. 
 
Extracellular in vitro assay 
Bacteria were diluted at 2×106 bacteria/mL using complete 7H9 medium and 45 µL/well of bacterial 
suspension were added in 384-well assay plates. After 5 days incubation at 37°C, 5% CO2, extracellular plates 
were read using a fluorescence reader (Victor X3, Perkin Elmer) at excitation/emission of 485/535 nm for 0.1 
seconds/well with a small emission aperture and CW-lamp energy of 50,000.  The read-out, relative 
fluorescence units (RFU), versus the ETH concentration was then plotted using GraphPad Prism 5.0 software 
and the concentration required to inhibit 50% of the bacterial replication (IC50) was calculated by nonlinear 
regression analysis using the equation for a sigmoidal dose-response curve with variable slope. 
 
Intramacrophage in vitro assay 
For intracellular assay, bacteria were mixed with RAW 264.7 macrophages to prepare a suspension at 5×105 
cells/mL and 1×106 bacteria/mL (multiplicity of infection 2) in RPMI-1640 + glutamax containing 10% FBS. 
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After 2 hours of infection at 37°C with shaking (120 rpm), infected cells were washed with RPMI-1640 + 
glutamax containing 10% FBS by centrifugation at 1,100 rpm for 5 minutes. The remaining extracellular bacilli 
from the infected cell suspension were killed by a 1 hour 50 g/mL amikacin (A2324-5G, Sigma) treatment 
and then washed twice with RPMI-1640 + glutamax containing 10% FBS. Finally, 45 µL/well of cellular 
suspension was added in the 384-well assay plate and incubated during 5 days at 37°C, 5% CO2. Macrophages 
were then stained with 5 µM Syto 60 (S11342, Molecular probes) dye for 1 hour, followed by plate sealing, 
imaging acquisition and data analysis. 
 
Image acquisition  
Confocal images were recorded on an automated fluorescent ultra-high-throughput microscope Opera (Perkin 
Elmer). This microscope is based on an inverted microscope architecture that allows imaging of cells cultivated 
in 96- or 384-well microplates. Images were acquired with a 20X- water immersion objective (NA 0.70). A 
double laser excitation (488-nm and 640-nm) and dedicated dichroic mirrors were used to record green 
fluorescence of mycobacteria and red fluorescence of the macrophages on two different cameras, respectively. 
A series of 6 pictures at the center of each well were taken and each image was then analyzed using Columbus 
system version 2.5.1 as previously described 10 to extract the bacterial area and the number of cells.  
 
Intramacrophage assay data analysis 
The intracellular bacterial area was normalized with the negative control DMSO (0% inhibition) and the 
positive control INH at a concentration of 1 µg/mL (100 % inhibition) by converting it into a percentage of 
bacterial replication inhibition (% inhibition). % inhibition was calculated as shown in the equation 3.  
(3) % 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 = (1 −
Test bacterial area−INH bacterial area
DMSO bacterial area−INH bacterial area
) × 100 
This formula was used to normalize the “test bacterial area” from different experiments, in order to decrease 
potential bias in the results due to differences in the % of infection and bacterial growth between experiments. 
For each compound, a plot of % inhibition versus the ETH concentration was determined with GraphPad Prism 
5.0 software and the IC50 was calculated in the same way as in the extracellular assay. 
 
In vivo efficacy 
6-week old Balb/C female mice were purchased from Janvier (Le Genest-Saint-Isle, France) and were 
maintained in the animal house facility of the Pasteur Institute of Lille, France (Agreement B59-350009). The 
project received ethical approval by French Committee on Animal Experimentation and all experiments were 
performed in accordance with relevant guidelines and regulations. 
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Lung histology 
Infected or uninfected 8-week-old mice were divided in groups and endotracheally administered with water 
(vehicle) or pCD NPs (Fig 5a, Fig.6). 
At the determined end-point mice were euthanized, lungs were harvested and soaked in 4% formaldehyde 
(10% formalin solution, neutral buffered, HT501128, Sigma-Aldrich) for 24 hours, before being embedded in 
paraffin. Tissues were sliced with microtome and 5 µm sections were stained with Hematoxylin-Eosin (H-E) 
for light microscopy examination for anatomopathology.  
 
Flow cytometry 
Harvested lungs were cut into small pieces and incubated for 1 hour at 37°C with a mix of DNAse I (100 
μg/ml, , Sigma-Aldrich) and collagenase (1.6 mg/ml, Roche) 400 U/ml. Lung cells were washed and filtered 
before being incubated with saturating doses of purified 2.4G2 (anti-mouse Fc receptor, ATCC) in 200 μl PBS 
0.2 % BSA 0.02 % NaN3 (FACS buffer) for 20 minutes at 4°C to prevent antibody binding on the Fc receptor. 
Various fluorescent mAb combinations in FACS buffer were used to stain 3-5x106 cells. Acquisitions were 
done on FACScantoII cytofluorometer (Becton Dickinson) with the following mAbs from BD Biosciences: 
Fluorescein (FITC)-coupled HL3 (anti-CD11c), FITC-coupled 145-2C11 (anti-CD3), APC-coupled RB6-8C5 
(anti-GR1), phycoérythrine (PE)-coupled RM4-5 (anti-CD4), PE-coupled E50-2440 (anti-SIGLEC-F), APC-
coupled BM8 (anti-F4/80). APC-eF780-coupled M1/70 (antiCD11b) was purchased from eBiosciences and 
fixable viability dye eFluor 506 (eBiosciences) was used to gate viable cells. 
 
Efficacy studies 
8-week-old mice (4 mice per group) were inoculated with M. tuberculosis H37Rv via the intranasal route to 
106 bacteria in the lungs at day 0. On day 7, 9 and 11 after infection, NPs or INH were administered to mice 
using a Microsprayer® (MicroSprayer® Aerosolizer – Model IA-1C-M and FMJ-250 High Pressure Syringe, 
Penn Century Inc., Wyndmoor, PA). For the 1-week treatment and the 2-week treatment, administrations were 
on day 7, 9, 11 and on day 7, 9, 11, 14, 16, 18 respectively. Body weight were recorded after each treatment 
(Fig. 5b). To assess the reproducibility of NPs administration through the MicroSprayer®, the delivered doses 
of NP suspensions were collected in glass vials after each spray and were accurately weighed. Then the amount 
of the delivered drug was quantified by HPLC as already described.  
The protocol to administer the NPs in mice was adapted from a previously reported one 11. Briefly, mice were 
placed in isoflurane chamber (Aerrane®, Baxter SAS, France). Then, one mouse was placed on the back on a 
platform (Mouse Intubation Platform – Model MIP, Penn Century Inc., Wyndmoor, PA) with isoflurane mask 
and hanging on its teeth. The tongue was pulled out by a tweezer and a laryngoscope (Small Animal 
Laryngoscope for mouse – Model LS-2-M, Penn Century Inc., Wyndmoor, PA) was used to see the trachea 
and 50µL of suspensions were delivered inside the lung allowing to aerosolize 50 µL suspensions inside the 
lungs.  
At day 14 or 21, mice were euthanized and lungs were homogenized with MM300 bead beater (Retsch) and 
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eight ten-fold serial dilutions were plated onto 7H11 agar plates supplemented with 10% OADC. CFUs were 
determined after a three-week growth. Represented data are mean values ± standard deviation of one 
representative experiment from three independent experiments. Results for each independent experiment were 
summarized in Supplementary Table S2.  Statistics were performed using Student’s t-test and one-way 
ANOVA analysis. Same p-values for in vivo experiments were obtained with the two tests. *: p<0.1, **: 
p<0.01,***: p<0.001. 
 
Supplementary Video S1 – NTA video of a NP suspension obtained by nanoemulsion. NTA allows tracking each NP 
individually to determine its mean hydrodynamic diameter and the concentration of the sample. Indeed, the Nanosight 
instrument is able to track the Brownian motion of NPs, in order to determine its diffusion coefficient (Dt) and 
consequently calculate, using Stokes-Einstein equation the sphere-equivalent hydrodynamic diameter. The NP 
suspensions were diluted by a factor of 104 to fit the instrument requirements and to allow the particle to move freely 
according to their Brownian motion. More than 2000 NPs are followed in each experiment. 
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SECTION B: 
 
Efficient loading of ethionamide in cyclodextrin-based carriers offers 
enhanced solubility and inhibition of drug crystallization (Paper 2) 
 
 
General objectives 
 
The characterisation methods employed in Chapter I - Section A for PLA NPs were not adapted to describe 
the characteristics of pCD NPs with the exception of cryo-TEM. Indeed, pCD NPs have mean diameters of 
only around 10-15 nm and a high water content. Therefore, a complementary study has been performed here 
to unravel the type and strength of interactions occurring between ETH and pCD NPs, hereby exceptionally 
named pβCyD to distinguish them from CD which stand for circular dichroism. 
 
We explored here the possibility of incorporating ETH in a molecular state in two different CyD polymeric 
carriers by using a combination of spectroscopic techniques. As previously described, ETH suffers from poor 
solubility in water and strong tendency to crystallize which could be overcome thanks to the incorporation in 
pβCyD carriers by a green approach. The binding of ETH to the two polymeric βCyD carriers was investigated 
in neutral aqueous medium by means of circular dichroism (CD), UV–vis absorption titrations, solubility phase 
diagrams and fluorescence measurements and compared with the corresponding βCyD monomer. 
The first investigated polymer, obtained by crosslinking CyDs with epichlorohydrin (EPI), has relatively high 
molecular weight (200 kDa) and exists under the form of 10-15 nm NPs (pβCyD NPs), as reported in Chapter 
IA. These NPs could be highly concentrated in aqueous media (up to more than 200 mg/mL) highlighting the 
interest of using them for drug encapsulation instead of monomeric βCyD, which otherwise display a very 
limited aqueous solubility (around 17 mg/mL). pβCyD NPs increased by tenfold the apparent solubility of 
ETH (in agreement with the results in Chapter IA) up to 25 mM. Moreover, the formulation was stable up to 
six months of storage and ETH crystallisation could be totally prevented. 
Of note, we evidenced that ETH, once included in βCyD NPs, experiences a chiral environment resulting in 
an induced CD signal of the drug. Interestingly, ETH was found to be located not only in βCyD cavities, but 
also in confined microdomains inside the crosslinked NPs. Next, the binding constant of ETH with pβCyD 
NPs and monomeric βCyD were determined by means of optical time-resolved spectroscopic techniques 
affording information on the affinity of this drug for the polymers and the model monomer. 
To complete the study, a fluorescent pβCyD polymer labelled with fluorescein (FITC-pβCyD) was prepared 
in view of future in vitro experiments on carriers uptake and intracellular trafficking. Spectroscopic studies 
were performed for this polymer too, both in presence and absence of ETH. These studies highlighted the 
presence of interactions between FITC moieties and CyD cavities belonging to the same polymer 
(intramolecular) and to a different polymer chains (intermolecular). The spectral behavior of the compound 
was found to be dependent of ionization state of FITC and therefore of pH solution. Interestingly, the study 
evidenced that the labelling of pβCyD NPs did not hamper ETH encapsulation even if the binding constant 
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was found to be slightly lower probably due to lower number of available CyD cavities since a small amount 
of them was occupied by FITC moieties. Of interest, ETH complexation improved the fluorescent signal of 
FITC-pβCyD paving the way towards the use of this polymer to study intracellular trafficking of CyD carriers. 
 
This interdisciplinary work was conducted in collaboration with two partners of Cyclon Hit Project: ISOF of 
Bologna and CycloLab of Budapest. E. Pancani contributed to the experiments on ETH solubility and on the 
long-term stability of pβCyD NPs, to results analysis and to the writing of the paper. 
 
For supplementary Information see Annexes Section at the end of the manuscript. 
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Nanoparticles with high payloads of pipemidic acid, a poorly soluble 
crystalline drug: drug- initiated polymerization and self-assembly 
approach (Paper 3) 
 
 
General objectives 
 
The design of nanocarriers to efficiently load poorly soluble drugs with a high tendency to crystallize is a very 
difficult task. In this study we describe the challenges related to the incorporation of a typical example of such 
drugs, pipemidic acid (PIP), a pyridopyrimidine quinolone. Due to its physico-chemical characteristics, PIP 
administration is very challenging and limits its therapeutic applications. Nanotechnology could offer an 
opportunity to deliver this “old” drug in an optimized fashion.  
PLA/PLGA and pCD NPs are among the most employed drug delivery systems and were investigated here for 
PIP encapsulation. A series of PLA/PLGA formulations were prepared using the common nanoemulsion and 
nanoprecipitation methods and adjusting several formulation parameters with the aim of obtaining high PIP 
payload. However, PIP readily formed crystals during NP formation and presumably adsorbed at the NPs’ 
surface, resulting in burst release upon NP dilution no matter the selected parameters. As a consequence of the 
poor affinity of PIP for the biodegradable NPs, drug loadings were low (< 10 wt%). In addition, PIP did not 
show any affinity for pCD NPs and the apparent solubility of this drug was not improved at all. 
In this context, we used an alternative approach to PIP incorporation in NPs, consisting in coupling the drug 
to the chain end of another biodegradable polymer, PCL. Drug-initiated polymerization was successfully used 
to produce in a single step a PIP-PCL conjugate without the need of catalyst. PCL-PIP was thoroughly 
characterized by 1H and 13C NMR, IR and mass spectrometry to unambiguously describe its structure. The 
newly synthesized PCL-PIP was employed to prepare self-assembled NPs which were comprehensively 
characterized by a set of complementary techniques: dynamic light scattering (DLS), nanoparticle tracking 
analysis (NTA), tunable resistive pulse sensing (TRPS) and scanning electron microscopy (SEM). Noteworthy, 
the PIP content in the NPs was as high as 27 wt%. Unfortunately, due to the presence of a tertiary amide bond, 
PLC-PIP couldn’t be entirely enzymatically degraded and hence the antibacterial activity of PIP couldn’t be 
restored. With further studies, PIP-initiated polymerization of biodegradable esters could be a promising 
strategy to produce NPs with high PIP content.  The novel methodology established here could be applied to 
a variety of other active molecules. 
 
This study was performed in collaboration with Dr D. Desmaële of the Institut Galien, for the synthesis of 
PCL-PIP conjugate and with Dr M.F. Bernet-Camard of the EA4043 (UBaPS) for the studies on Salmonella 
Typhimurium. 
E. Pancani prepared and characterised (size, zeta potential, concentration, HPLC dosage) all the NPs 
formulated in the study. Moreover, she analysed the results, interpreted the data and wrote the manuscript with 
Dr R. Gref.  
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Graphical abstract 
 
Drug-initiated ring-opening polymerization of ε-caprolactone leads to the formation of a polymer which self-
assembles under the form of nanoparticles. Drug content reaches 27% (w/w). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The following paper and its supplementary information are published in Acta 
Pharmaceutica Sinica B – © 2018 Chinese Pharmaceutical Association and Institute of 
Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by 
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Figure S1. Optical image of PIP crystals in PLA/PLGA NPs. Typical example of PIP crystals formed in 
NPs suspension observed with 10 times and 40 times (zoomed panel) magnification in an inverted optical 
microscope over a Malassez chamber. 
 
 
 
Figure S2. PLGA PIP-loaded NPs observed by SEM. a: SEM micrograph. b: Histogram of the size 
distribution of the NPs showing a mean diameter d = 164 ± 27 nm. N (d) refers to the total counts and the scale 
bar corresponds to 500 nm. 
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Nanoemulsion method - PIP release upon dilution 
The release of PIP from NPs was thoroughly studied after progressive dilution in water and PIP 
content was lost within less than 5 minutes. Interestingly, there was a correlation between the amount 
of burst-released drug and the dilution factor. For example, the DL of NPs made using polymer P33 
(see Main text - method section 4.1) decreased from 8.7% to 4.1%, 2.4% and 1.7 wt% after 0, 10, 20 
and 50 times dilution, respectively. 
 
Nanoprecipitation method supplementary information 
The P19 NPs were formulated in presence and in absence of PIP. Interestingly, the size measurement 
of the obtained particles highlighted a 50-60 nm difference in the mean size of empty and loaded NPs. 
For example, in the case of a final P19 concentration of 5 mg/mL, the empty NPs displayed a size of 
170 ± 1.3 nm while the loaded ones of only 117 ± 1.6 nm (PIP/P19 ratio =1:10). The same behavior 
was evidenced also when increasing P19 final concentration to 10 mg/mL (or higher) (empty NPs= 
212 ± 2.3 nm, PIP NPs= 150 ± 2 nm). The same tendency was evidenced also when formulating the 
NPs by using other polymers.    
 
 
 
Figure S3. 13C NMR spectrum of PCL-PIP in DMSO-d6. 
 
 
Chapter II – Supplementary Information 
 
134 
 
Figure S4 - IR spectrum of PCL-PIP. 
 
 
 
Figure S5. IR spectra of PCL, PIP, PCL-PIP conjugate and PCL+PIP physical mixture. 
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Figure S56 - 1H NMR of decarboxylated caprolactone adduct (4) (see Fig. 2 main manuscript).  
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SECTION A: 
  
Introduction to AFM-IR technique 
 
 
1. Atomic force microscopy 
 
The invention of atomic force microscopy (AFM) in early 1980s has been a breakthrough in the history of 
nanotechnology allowing investigating the matter at the atomic scale. New impressive opportunities were 
opened in chemistry and physics as well as in biology and medicine. Its inventors, G. Binnig and H. Rohrer, 
were rewarded with the Nobel Prize for Physics in 1986. 
AFM is a type of scanning probe microscopy (SPM) able to investigate surfaces with a very high signal-to-
noise ratio and with an impressive resolution, in the order of fractions of nanometers. 
The AFM consists principally of a cantilever, a sample holder, a laser and a position sensitive photo detector. 
The cantilever and/or the sample stage are usually connected to piezoelectric elements that allow adjusting the 
cantilever - sample relative position in the x, y and z dimensions. The detector receives the laser beam reflecting 
off the cantilever and therefore provides a feedback on its deflection (Figure 1). A sharp tip is placed at the 
free-end of the cantilever which is typically made of silicon1. 
The tip of the cantilever is used to approach and scan the sample surface measuring its morphology at the 
atomic scale. When the tip enters in contact with the sample surface, attractive or repulsive forces are 
established between them, resulting in the cantilever deformation and thus in a change on its deflection. 
Therefore, an atomic scale phenomenon can be translated into a macroscale phenomenon (the cantilever 
deflection). This deflection is detected thanks to the laser diode reflected by the extremity of the cantilever into 
the photodiode detector (Figure 1). A feedback loop allows the system to react to the deflection changes, 
correct the cantilever z-position consequently maintaining it at a constant force or height over the sample.  
 
 
Figure 11 – Schematic representation of an AFM setting 
Chapter III – SECTION A – Introduction to AFM-IR technique 
 
140 
Of note, AFM resolution is limited only by the radius of the tip apex, routinely achieving resolutions lower 
than 20 nm and in some specific configurations down to atomic scale2. 
 
1.1. AFM imaging modes 
 
AFM can operate in different acquisition modes depending on the sample and on the desired application. 
Regarding the imaging applications of AFM, its acquisition modes can be mainly classified in two types: static 
(contact or non-contact) or dynamic modes (tapping mode, non-contact). This subdivision is performed on the 
base of the cantilever fixed or oscillating status3. Here, contact and tapping mode will be briefly illustrated. 
In contact mode the tip scans the sample surface by remaining in close contact to it. The sample surface profile 
is generated by operating in constant force mode. Indeed, the sample is scanned by exercising a constant force 
between the tip and the sample. The force is kept constant thanks to a feedback loop able to correct the 
piezoelectric positioning (with the application of the required voltage) adapting it to the surface of the sample. 
In this way, the desired deflection of the cantilever is maintained. The voltage applied by the feedback to the 
piezoelectric element is recorded as a function of the lateral position on the sample and it is thus used to 
generate an image of the sample surface (topography). The main drawback of this acquisition mode is due to 
the shear forces resulting from the contact between the tip and the sample during the scanning. Indeed, such 
forces can damage soft samples and/or distort the generated image. 
Consequently, the contact mode is limited to non-soft surfaces and to samples strong interacting with the 
support which cannot be moved by the tip scanning. 
To address this issue and extend the use of AFM to delicate samples, a second mode has been developed. As 
a matter of fact, in this mode, namely tapping mode, the cantilever oscillates at or near its natural resonance 
with an amplitude that should be higher than the curvature radius of the tip. Usually, the amplitude is in the 
range of 20-100 nm when the tip is not in the contact mode, and the tip impact the sample for a minimal amount 
of time. This reduces the interactions between the tip and the sample to the minimum required to correctly 
describe the sample surface and therefore also minimise the probability of damaging or altering the sample. 
The oscillation of the tip is generated by a force applied at the base of the cantilever by the piezoelectric 
element. The intermittent impacts between the tip and the sample cause an energy loss which results in a 
change of the cantilever oscillation amplitude, according to the surface topography. In presence of convexity, 
the oscillation amplitude of the cantilever decreases as a result of the reduction of the vibrating space. 
Otherwise, in presence of a depression, the amplitude increases. These amplitude changes are detected and the 
piezoelectric element is used to adjust the cantilever z-position to maintain a constant amplitude. Such 
amplitude changes are function of the lateral position of the cantilever and are used to reconstruct the 
topography of the sample. This last mode has the advantage of being suitable for delicate soft samples 
overcoming friction and adhesion that are typical of the contact mode3. 
 
1.2. AFM applications 
 
The unique versatility of AFM to image, probe and manipulate materials and its high resolution guarantee the 
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possibility to efficiently image a wide range of samples. Several AFM techniques have been developed to 
discriminate materials on the basis of various properties such as, for example, friction/adhesion, elasticity, 
flexibility, damping, optical, electronic and magnetic properties2. Indeed, AFM has evolved from simple 
imaging technique to a multifunctional toolbox by converting the AFM tip into a “lab on a tip” through specific 
surface modification4. Hence, multiparametric and multifrequency imaging technique could be developed5. 
Of note, the possibility to operate in liquid environment and at ambient temperature opened the possibility to 
use AFM techniques in the biological field, observing and manipulating biomolecular machinery in its native 
environment4. Time-lapse AFM, for example, could be used to observe dynamic processes at atomic, 
molecular and macroscopic scale in real-time accessing directly to the structure-function relationship of 
cellular nanomachinery4,5. Some applications of this mode include the study of the activity of RNA 
polymerase6, of the opening and the closure of the pores of a bacterial surface layer7, of microtubules 
formation8 and of conformational changes of channel-forming proteins8,9. AFM also offers the possibility of 
using single molecule modification (functionalising the tip with specific chemical groups or ligands5) to access 
directly to inter- and intramolecular interactions thus unravelling receptor-ligand interactions4 and protein 
folding and unfolding mechanisms10,11 (for example, the misfolding of proteins involved in neurodegenerative 
disease such as Alzheimer and Parkinson12). Another example of single-molecule analysis is the study of the 
molecular interactions occurring between a drug, or a drug delivery system, and its target opening fascinating 
avenues in pharmacology domain4,13,14. 
The AFM tip can be modified not only with single molecules (i.e. drugs and proteins), but also with single 
cells, viruses or bacteria to study their interactions with other cells at a molecular level. Thus, cells interactions 
in tumour metastasis and bacterial or viral attack towards cells could be deeply examined4. Indeed, space-
resolved AFM enabled mapping the nanoscale distribution of single cells adhesion proteins15 and antibiotic 
binding site16 giving insights on pathogen-host and drug-pathogen interactions. Interestingly, thanks to AFM 
it could be establish that different cell types display peculiar elastic properties17, enabling for example the 
distinction of cancer cells from healthy ones even when they have similar shape18,19. 
In recent years, correlative imaging techniques involving AFM have been developed and have drawn 
increasing attention5. Complementary techniques including optical or fluorescent microscopy, Förster 
resonance energy transfer, total internal reflection fluorescence and super-resolution were successfully coupled 
to AFM thus combining their advantages and enabling the access to additional information5. As an example, 
specific receptors, channels and transporters could be localised on cells surface thanks to their fluorescent 
labelling and then their nanometric structure could be unravel thanks to AFM. 
However, despite their countless applications and their undeniable advantages, the AFM and its related 
techniques briefly illustrated above were not able to provide unambiguous chemical analysis and identification 
of samples. 
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2. Infrared spectroscopy 
 
Infrared (IR) spectroscopy is undoubtedly one of the most important analytical techniques available to 
scientists. Infrared spectrometers have been commercialised since 1940s but the most significant advances in 
the field have come with the introduction of Fourier-transform spectrometer which dramatically improved the 
quality of the spectra and greatly minimized the time needed to obtain the data20. 
 
2.1. Principles of the technique 
 
The IR spectroscopy is a technique based on the vibrations of atoms in a molecule. Indeed, a molecule is made 
up of atoms linked by chemical bonds which can be seen as spherical masses connected with a spring which 
vibrate at a specific natural frequency. This frequency depends on the characteristics of both the atoms and 
their linkage and thus every molecule has its own peculiar vibrational frequency which can be used as a 
fingerprint to recognise it. Indeed, when energy in the form of IR radiation is applied to a molecule, the atoms 
start to vibrate. When the frequency of the IR radiation is equivalent to the one of the natural vibration of the 
molecule, absorption takes place and a loss of energy is observed in the radiation spectrum. 
Hence, IR spectroscopy measures the absorption (or transmission) of IR radiation by a sample as a function of 
wavelength (or frequency). Indeed, the IR radiation is an electromagnetic radiation in the wavelength region 
of 780 nm and 1000 µm, between the visible and the microwave ranges. 
The IR spectral region is normally divided into three main sub-regions: the near-infrared (NIR), the mid-
infrared (MIR) and the far-infrared (FIR), in function of their distance from visible light21. NIR wavelengths 
range goes from 0.78 to 2.5 µm (corresponding to 1300-4000 cm-1), MIR from 2.5 to 50 µm (corresponding 
to 4000-200 cm-1) and FIR from 50 to 1000 µm (corresponding to 200-10 cm-1). 
The wavenumber (ν) is defined as the number of waves in a length of 1 centimetre and it is related to the 
wavelength (λ) by: 
 
(1)       /1=  
 
This unit has the advantage of being linear with the energy of IR absorption. 
The absorption of IR radiation results in the transition of a molecule from its ground state to a vibrational state, 
typically the lowest available. To be absorbed, the incoming IR radiation must have the same frequency as one 
of the fundamental modes of the molecule of interest. A single vibrational transition is associated to a number 
of rotational energy states. The contribution of vibration and rotational states participate in giving to each IR 
absorption band its overall shape. 
There are two predominant vibration modes, the first involving the change in bond length, thus a change in the 
interatomic distances, and the second involving a change in bond angle. They are called stretching and bending 
modes, respectively. Both stretching and bending vibrations can be symmetrical or asymmetrical. Additionally, 
bending vibrations can also be in plane or out of plane. More energy is required to stretch a bond than to bend 
it, therefore stretching will always occur at higher frequencies than bending. In order for a molecule to show 
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IR absorption and thus be considered as IR-active, it must possess a particular feature which is the change of 
the dipolar moment of one or more of its bonds during the vibration. 
The interesting aspect of IR spectroscopy consist in the fact that functional groups absorb IR radiations in a 
spectral region (or range of frequencies) which is characteristic of the group, as a “signature”. This feature 
allows to employ IR spectroscopy to identify an unknown compound, to elucidate samples chemical structure 
and even to quantitatively analyse several known species. 
The MIR region is particularly interesting for the analysis of the vibration of chemical bonds in organic 
compounds as most of the fundamental transitions of their functional groups can be found from 4000 to 600 
cm-1. In a general way, the stretching vibration of single bonded atoms (X—H stretching region: mainly O-H, 
C-H, N-H) occur in the range 4000-2500 cm-1, the stretching of triply bonded (e.g. CC, CN) in the range 
2500-2000 cm-1 and the one of double bonded (e.g. C=O, C=C, C=N) in the range 2000-1400 cm-1. The 
frequency region below 1300 cm-1 in known as “fingerprint” region because it is generally composed of a 
series of sharp peaks, which are peculiar of a particular compound rather than of functional groups. 
In is important to highlight that the chemical environment of functional groups is fundamental and that the 
presence of electron donating or withdrawing groups, aromatic rings, the formation hydrogen bonds, etc. can 
produce changes in the frequency range of the characteristic group absorption band. Therefore, IR 
spectroscopy is able to provide a direct measurement of the influence of the environment on each specific 
molecule. 
Tables of the characteristic absorption frequencies exist, together with dedicated books, to assist in the correct 
assignment of the bands in a spectrum21,22. 
 
2.2. Brief instrumentation overview 
 
Early IR spectrophotometers employed monochromators containing a prism to disperse the IR radiation into 
its spectral components. 
The revolution in IR spectrometers occurred with the development of instruments based on interferometry and 
exploiting the mathematical process of Fourier-transformation. Fourier-transform infrared (FTIR) 
spectrometers dramatically improved the overall efficiency of the technique and are widely used nowadays.  
FTIR instruments grant a very high repeatability of data. 
FTIR spectrophotometers can be used with two types of configuration depending on sample’s nature; 
transmission and attenuated total reflexion (ATR). 
Transmission spectroscopy is the measurement of the IR radiation transmitted through a sample according to 
Beer-Lambert law: 
(2)    lC
I
I
TA =





−=−=
0
loglog . 
The absorbance (A) is the logarithm of the reciprocal of the transmittance (T) with T being the ratio of the 
intensity of the light transmitted by the sample (I) to the intensity of the light entering the sample (I0). 
Moreover, the absorbance of the sample is directly proportional to sample thickness and concentration and it 
can be calculated by multiplying sample concentration (C) by the pathlength (l) and by the molar absorptivity 
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(ε, constant of proportionality)20. 
The transmission mode requires the deposition of the sample on an IR-transparent support (typically zinc 
selenide – ZnSe - windows). The advantage of transmission lies in the fact that the IR radiation pass through 
all the sample layer enabling a good bulk qualitative information. Quantitative analysis can be performed by 
mixing precise amounts of sample with KBr powder (which is IR-transparent in the MID-IR), produce a thin 
film/disc of a known thickness by using a press and determine the molar absorptivity (ε) of the sample with a 
calibration curve. 
However, transmission is hardly applicable for highly absorbing or opaque powders, for soft polymers or 
powders and for samples containing particles of sizes which may scatter light resulting in an attenuation of the 
IR beam not associated with sample absorption. 
To tackle these inconveniences, the ATR mode can be a solution. In the ATR approach, the sample is placed 
on a crystal transparent in the IR, made of a material with no water solubility and with a high refractive index 
(like ZnSe covered with a diamond layer). The IR beam is directed into the crystal at an angle greater than the 
critical one and it undergoes a total reflection thanks to the difference of refractive index at the interface crystal-
sample21. 
It has been shown that, although the internal reflection of the IR beam is total, an evanescent wave is created 
at the interface with the sample. This evanescent wave, extending beyond the prism into the sample, loses a 
part of its energy at the specific absorption wavelengths of the sample. The resulting attenuated IR beam is 
measured, plotted in function of the wavelength and an absorption spectrum is thus produced.  
ATR advantageously requires little or no sample preparation and it can be used on a wide range of sample 
types. However, it primarily provides information on samples surface or on the sample fraction in closest 
contact with the prism as the penetration of the IR beam into the sample is very small (typically between 0.5 
and 2 µm depending on the prism material and on the wavelength)23. Therefore, ATR does not provide bulk 
information unless the sample is very homogenous and does not interact with the prism. Moreover, a high and 
homogenous contact between the prism and the samples is required to obtain good quality spectra. The ATR 
is thus not suitable to measure hard materials which cannot be crushed in powder to achieve sufficient contact 
with the prism. 
 
2.3. IR spectroscopy life-science applications and coupling to other analytical techniques 
 
One of the advantages of IR spectroscopy consists in its versatility and in the ability of obtaining spectra 
rapidly and reproducibly from a wide variety of samples in liquid, solid or gaseous state.  
This technique has thus found application in almost all the fields of science. In particular, IR spectroscopy can 
play an important role in identifying molecules of interest in different domains such as organic and inorganic 
chemistry, polymer science and biology20. Indeed, this technique has proved its significance in life science for 
the study of biological samples including in particular lipids24, proteins25–27 and nucleic acids20,28. Moreover, 
in the last decades, the number of studies involving more complex systems have raised. IR spectroscopy can 
be used for diagnostic purposes on sample such as diseased tissues and microbial cells29–32. 
For all these applications, FTIR can be used as a stand-alone non-destructive analytical method but it has also 
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been successfully coupled to several other analytical techniques to combine their advantages and obtain 
complementary information21. 
For example, FTIR spectroscopy has been combined to separation methods such as gas or liquid 
chromatography where it is used as a detector to identify the eluted molecules33–36. 
Moreover, FTIR has also been coupled to destructive techniques such as thermal analysis methods (e.g. 
thermogravimetric analysis - TGA) to measure and characterise the gaseous products which evolve from 
sample heating (evolved gas analysis – EGA) 37–39. 
One major advance, which opened the way to the analysis of small samples with important applications in 
polymer chemistry and life-science, is the coupling between IR spectroscopy and microscopy, namely IR 
microspectroscopy. Despite numerous improvements, the achieved resolution of commercially available 
microspectrometers was limited to the range from λ to 3λ, thus depending mainly on the illuminating 
wavelength (λ) and secondly on the instrument configuration (i.e. numerical aperture of the objective)2,40–42. 
The resolution of microspectrometers could be increased to approach 1 µm by coupling to Synchrotron 
beamlines43 or thanks to the recent advances in optics and array detectors44,45. However, nowadays no IR 
microspectrometer could reach a sub-micrometer resolution which clearly constrains the applications of this 
technique. 
 
 
3. Atomic Force Microscopy in InfraRed (AFM-IR) 
 
The intriguing potentialities together with the major limitations of AFM and IR spectroscopy, as stand-alone 
techniques were described in the previous paragraphs. While the first is able to provide high resolution images 
(up to fractions of a nanometre), it lacks in providing chemical characterisation. Vice versa, the second offers 
the unambiguous chemical identification of compounds, but lacks in resolution (limited by the diffraction). 
The original idea of atomic force microscopy in IR (AFM-IR) of Dazzi et al was born in 2005 46 from the 
ambition to combine the advantages of both techniques and bring the power of IR spectroscopy below the 
diffraction barrier. 
AFM-IR is a technique which couples an IR pulsed laser with an AFM to allow the detection of photo-thermal 
effects. Importantly, the absorption spectra measured with AFM-IR has been proved to well correlate with 
traditional FTIR spectra collected in transmission mode42. 
 
3.1. First setting: bottom-up IR illumination (nanoIR) 
 
The first setting of AFM-IR instrument (nanoIR), shown schematically in Figure 2, has been developed in 
2005 by Dazzi et al.46, patented in 2007 together with the american company Anasys Instruments and a bench-
top version of the instrument was commercialised in 2010 47. 
In this configuration, the sample is placed on a IR transparent prism (ZnSe) and AFM is used in contact mode. 
The sample is illuminated bottom-up by the IR beam (tuneable optical parametric oscillator, OPO, as IR 
source) in total reflexion, thus an evanescent wave is produced with a depth in the sample proportional to the 
wavelength (same as ATR-FTIR explained in section 2.2)46.  
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Figure 12 – Schematic representation of the nanoIR initial configuration 
 
Once the sample is irradiated by IR light, it absorbs energy at specific wavelengths and produces a 
photothermal response. Indeed, when IR photons are absorbed by the sample, a part of the energy of the excited 
state is converted into heat when the samples molecules relax back to the ground state. This heat is converted 
into a local temperature increase which results in a thermal expansion of the absorbing region of the sample. 
This thermal expansion is detected by the AFM tip in contact with the surface as a shock, inducing the 
oscillation of the cantilever on its eigenmodes. The cantilever deflections, which follow a ringdown mode, are 
recorded by the AFM detection system. In contrast with other previous techniques48, the AFM tip was used 
here to detect surface deformation rather than temperature increase thus providing sub-wavelength resolution. 
The group of Dazzi demonstrated that the amplitude of cantilever oscillation is directly proportional to the 
absorbance of the sample42,49. Moreover, they demonstrated from the theoretical point of view that the 
resolution of the technique is given by the size of cantilever tip apex. 
Two kinds of acquisition are available with the system. The position of AFM tip can be fixed, while the laser 
is subsequently tuned at different wavenumbers. The amplitude of cantilever oscillation is measured as a 
function of the wavenumber, hence obtaining an IR absorption spectrum of a precise location (local spectrum) 
in the sample (Figure 3a). Alternatively, the tip can scan the sample surface, while the laser wavenumber is 
set at a fixed value. In this case, the chemical cartography of a sample region is obtained, together with the 
sample topography. The amplitude of cantilever deflection is measured at each point and plotted against the x-
y tip position on the sample surface, thus showing the absorbing region of the sample at the selected 
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wavenumber (Figure 3b). This is possible as the IR absorption is characteristic of each molecule and functional 
groups as extensively explained above (Section 2.1).  
 
 
Figure 13 - Acquisition modes of AFM-IR. a) First mode = Local IR absorption spectrum obtained from measuring the amplitude of 
AFM cantilever oscillation as a function of wavenumber. b) Second mode = AFM topography of an eukaryotic cell and IR cartography 
of the amide I band of the same cell (1660 cm-1). Partially adapted with permission from Anasys Instrument. 
 
A complete study of the maximum resolutions of this instrumental setting has been performed50. The lateral 
resolution has been confirmed dependent only to the curvature radius of the cantilever tip and consisted of 
around 10-20nm. On the other hand, the minimal thickness to obtain a significant deflection amplitude and 
thus a significant signal/noise ratio (vertical sensitivity) was found to be in the range of 50 and 100 nm. 
 
Such resolution limits have been further improved mainly by increasing the system sensitivity using two 
strategies; the resonance enhanced mode (and consequently the change of laser source) and the lightening rod 
effect. 
Both strategies have been investigated and proved efficient by the group of Dr. Belkin at the University of 
Texas51,52. The resonance enhanced mode consisted in tuning the repetition rate of the laser to match one of 
the contact mode resonances of the AFM cantilever. In this way, the cantilever changes from a decaying 
transient oscillation (ringdown) into a continuous wave oscillation (Figure 4)2.  
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Figure 14 – Comparison of the cantilever ring-down oscillation obtained in the case of conventional AFM with the cantilever 
continuous wave oscillation obtained when working in resonance enhanced mode. Adapted with permission from Anasys 
Instrument. 
 
This continuous oscillation mode, namely resonance enhanced mode, allowed a much more efficient detection 
of the sample expansion and hence an increase in the instrument sensitivity. The laser source has been replaced 
in order to maintain the cantilever continuous oscillation. Indeed, the OPO has a repetition rate fixed at 1 KHz 
which is insufficient to control the resonant contact mode of the cantilever (resonant at around 100 KHz). 
Therefore, a quantum cascade laser (QCL), whose repetition rate can reach 500 KHz, has been used instead of 
the OPO. Moreover, a feedback loop has been added to the instrument to adjust the repetition rate of the laser 
to the one of the cantilever at any moment. This first modification of the instrumental setting allowed 
improving the instrument resolution (especially in the z direction)51. 
The second strategy studied by Belkin’s group was the lightening rod effect which consists in the exaltation 
of the electrical field between the cantilever tip and the support by using metal coatings. 
In order to explain this second strategy, we have to introduce the newest setting of nanoIR instrument. 
 
3.2. New setting: top-down IR illumination (nanoIR-2) 
 
The major innovation of nanoIR-2 configuration is the change in the way of irradiating of the sample2. The IR 
irradiation is not anymore performed through the prism (from bottom-top) but the laser is instead focused from 
top-down in proximity of the cantilever tip (Figure 3). The advantage of this configuration lies in the fact that 
the prism is not anymore necessary and thus the deposition of the sample can be performed on a wider range 
of substrates. 
Moreover, the feedback loop and the QCL source where used in order to take advantage of the improved 
resolution allowed by the resonance enhanced mode. 
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Figure 15 – NanoIR-2 configuration  
 
This new setting was the one used by Belkin’s group to prove the efficacy of lightening rod effect in 
combination with the enhanced resonance mode52.  
The lightening rod effect is a complex phenomenon. It is basically obtained thanks to the use of a metal-
coated (gold-coated) tip and sample substrate. These coatings allowed the focalisation and intensification of 
the local electric field, generated by the incident IR radiation, at the apex of the cantilever tip, thus increasing 
the technique sensitivity. 
Coupling the two effects has enabled obtaining spectra on single monolayer of maximum 2 nm thickness and 
chemical imaging on samples as thin as 5 nm2,52. 
 
Despite all the undeniable advantages offered by AFM-IR, it cannot be neglected the fact that, as for every 
other technique, also this one comes with some limitations. After all, there is no such thing as the perfect 
technique in science. The coupling between the IR and AFM caused the loss of some of the characteristic 
advantages offered by AFM. As already discussed above, one of the most appealing feature of AFM is the 
possibility to study samples in liquid media and to examine even living organisms, such as cells and bacteria. 
These features are partially lost in AFM-IR as the sensitivity of the technique is dramatically deteriorated when 
used in aqueous environment53. Indeed, water is a strong IR absorber and scatter along the majority of MIR 
range. Moreover, in the regions where water absorption is not elevated per-se (for example, around 1500 cm-
1), water remains usually the major compound in the investigated samples and its signal overwhelms all the 
other signals. 
 Thus, water hamper the measurement by masking the IR signal coming from the sample. Moreover, the 
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performances of the technique in water are highly decreased because of the strong mechanical damping of 
cantilever oscillations. Therefore, samples analysed by AFM-IR were dehydrated previously to their analysis. 
When performing the experiments under these controlled conditions, AFM-IR has proved its invaluable 
usefulness in the last ten years in a countless number of applications (see section 3.4). 
However, the possibility of studying samples in their native aqueous environment rather than in air, thus 
avoiding their dehydration process which can lead to sample modifications/deformations, is very appealing. 
Some pioneering attempts of AFM-IR nanospectroscopy in water have been performed in 200854 on cells and 
more recently in 201753 on poly(methyl methacrylate) layers with quite promising results. However, these 
results are still preliminary and the literature on the subject is restricted to few examples. Further studies are 
needed to acquire more data and confirm such promising results 
 
3.3. Comparison of AFM-IR with related techniques 
 
In the last 20 years, IR-based techniques were developed in the attempt to provide subwavelength images. 
Despite some very exciting results, the usefulness of these technique is essentially limited to UV-VIS and the 
applications to IR range still have to address significant challenges. 
The most notable ones are scattering scanning near field optical microscopy (s-SNOM)55 and tip-enhanced 
Raman Spectroscopy (TERS)56–58. 
The fundamental difference between AFM-IR and both techniques consist in the fact that the first measures 
the absorbed light, whereas the other two measure the light scattered by the sample. Therefore, both s-SNOM 
and TERS ideal samples are strong light scatterers, feature which is especially important in the case of TERS.  
Indeed, the main drawback of TERS lies in the necessity to increase its sensitivity by using special field-
enhancing tips to reach satisfying amounts of scattered light. The key limitation of such tips is the difficulty to 
obtain a sufficient and reproducible enhancement factor. 
While AFM-IR measures directly the absorption of the sample, s-SNOM measure the amount of scattered light 
from the sample which depends not only from the sample absorption but also from the complex optical 
properties of the tip, the sample and the substrate2. As a consequence, a complex modelling of 
radiation/tip/sample interaction together with interferometric detection are needed in order to limit the band 
distortions and peak shifts. In addition, s-SNOM bands are sensitive to sample thickness and to substrate-
induced band shifts. 
Moreover, AFM-IR possess another unique characteristic feature over s-SNOM and TERS.  S-SNOM and 
TERS allow gaining information only in the top layers of the samples as they enable probing only few 
manometers around AFM tip. In contrast, AFM-IR is able to investigate the sample to a maximum depth of 1-
2 µm2, potentially allowing reaching invaluable information of complex systems, such as particles or molecules 
embedded in a matrix or in a cell. 
 
3.4. AFM-IR applications 
 
Thanks to its unique features, AFM-IR has found an important number of applications in a wide range of fields 
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allowing the discrimination of sample details “invisible” to bulk techniques or confirming their results at the 
nanometer level2. 
The technique was successfully applied in resolving and describing the features of complex polymer 
blends59,60, co-polymer and/or multi-layer films61–63, polymer nanostructures64, polymer-drug blends65 and 
several biomedical and pharmaceutical materials66–68. Additionally, the instrument could also provide 
information about sample stiffness variation together with the topography and the IR mapping42,59. Moreover, 
AFM-IR technique allowed to distinguish amorphous and crystalline domains and establish the molecular 
orientation of polymer chains in individual electrospun nanofibers42,69. 
Another key application of this technique is the study of the degradations of medical devices such as tubing, 
blood bags and catheters. The aging-effects of polymer and additives, which compose these devices and that 
are often in contact with body fluids, are a major concern in the medical industry as they represent a potential 
health risk for patients70,71. Interestingly, AFM-IR enabled the detection of very low quantities of lubricant (4 
nm thickness) leaked from polyurethane catheters over time72. 
Furthermore, AFM-IR significantly contributed to the better understandings of research problems in life-
science. Some of the main applications in this field consisted in the chemical subcellular imaging and 
spectroscopy of bacteria, viruses and mammalian cells73,74. For example, the production and localization of 
biopolyester or lipid vesicles inside different species of bacteria could be thoroughly characterized75–78. Other 
investigations involved the study of the interaction between nanodiamonds and cells79 and the structure and 
disposition of light-harvesting lipids in plants80. Moreover, thanks to this technique, studies were conducted 
about bone proteins and minerals81, microdroplets82 and the unravelling of protein secondary structure83,84 
including studies of the connection between β-amyloid conformation and neurodegenerative diseases85. 
Correlative studies between AFM-IR and luminescence microscopy were also performed to localize the 
distribution of a hormone inside cells. The correlation between the two techniques was possible thanks to the 
synthesis by click-chemistry of a double-labelled version of the hormone (by using an organometallic molecule 
for IR detection together with a luminescent probe for UV-VIS detection) which enabled the detection of the 
molecule by the two systems86. Unique results were obtained on tissue samples such as skin and hair sections. 
The ratio between IR mapping or spectral bands, characteristic of two different sample components, enabled 
the determination of the relative concentration of the component of interest in the tissue and to study its 
distribution87,88. 
Finally, the AFM-IR versatility is proven as a broad range of other diverse research areas could benefit from 
its use. Just to name a few, the technique could be applied to the study of semiconductors89, solar cells90,91, 
plasmonic resonators92,93 and cultural heritage94. 
 
In all research applications, until today, the AFM-IR technique has been used in contact mode, independently 
from the employed instrument setting (nanoIR or nanoIR-2). Recent advances on nanoIR-2 introduced the 
possibility to acquire IR mapping and spectra in tapping mode instead of contact mode. This innovation is 
particularly meaningful as it extends the use of nanoIR to the study of soft materials or non-surface-adhesive 
samples, whose analysis was practically impossible until now. In the next section (section B) of this chapter 
the development and application of tapping AFM-IR are reported for the first time. In our case tapping 
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AFM-IR proved to be an invaluable asset to enable imaging and characterization of single NPs which in 
contrast were crushed or displaced in contact mode and therefore practically impossible to study. 
Moreover, tapping mode allowed us to study drug distribution within each single nanoparticle and have access 
to invaluable information inaccessible to any other characterization technique. 
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SECTION B: 
  
Tapping AFM-IR: a powerful new tool to unravel the structure of 
individual drug-loaded polymeric nanoparticles (Paper 4) 
 
 
General objectives 
 
The studies reported in the previous chapters highlight the importance of an in-depth characterisation of NPs. 
Complementary techniques should be employed with the aim of obtaining a picture as clear as possible of NPs 
structure and on its component localisation. However, we have to deal with the limitations of the existing 
techniques which imply that some conclusions can only be indirectly assessed by assembling the information 
provided by each technique, such as building a puzzle. Moreover, the existing techniques give only bulk 
information but cannot assess if the samples are homogeneous. 
In an attempt to go beyond the state of art in the NPs characterisation and to confirm the conclusions drawn 
by combining the results of the other characterisation techniques, an original nanospectrocopic technique was 
here applied. This method, namely AFM-IR, combines the high resolution provided by atomic force 
microscopy (AFM) with chemical characterisation offered by IR spectroscopy. AFM-IR is able to track the 
location of each sample component by using its specific IR spectra as a fingerprint. 
A comprehensive overview of AFM-IR and its originating techniques has been given in the section A of this 
chapter (Chapter III) placing emphasis on its advantages and versatility. 
The study presented here aimed at employing AFM-IR to unravelling the structure of empty and drug-loaded 
PLGA NPs. However, the results obtained by trying to map the NPs chemical composition by AFM-IR in 
contact mode were inadequate despite the fact that some promising images could be collected. Indeed, PLGA 
NPs poorly adhered to ZnSe and CaF2 windows notwithstanding the efforts we deployed in improving NPs 
adherence. The adhesion on gold surface was slightly improved but was still not strong enough to avoid 
crushing and pushing the NPs with AFM-IR tip. 
These adhesiveness issues could be addressed thanks to the recently developed tapping mode of AFM-IR 
which was applied here for the first time. Indeed, the tapping mode allowed extending the use of the technique 
to soft and non-adhesive samples such as PLGA NPs. 
A comparison of the two modes on NPs imaging clearly proved the superiority of tapping mode and a technical 
and theoretical explication of this new mode were provided here.  
Thanks to this innovation, invaluable information could be collected on PLGA NPs structure. A peculiar band 
of each NP component was selected and used as a fingerprint for its localisation within NPs structure. The 
surfactant corona surrounding NPs could be imaged here for the first time. Moreover, when applying the 
technique on PIP-loaded PLGA NPs, developed in Chapter II, the surface localisation of PIP could be 
confirmed, thus explaining the drug burst-release. A clear colocalization of PIP and NPs surfactant could be 
evidenced. It is worth noting that PIP was incorporated at only 1 % with respect to NP weight but AFM-IR 
could still identify it. Furthermore, the soft exploration by tapping AFM-IR allowed detecting NPs as small as 
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10-20 nm. 
These findings have particular relevance in the NPs domain because this approach could be extended to other 
NPs systems. To the best of our knowledge, this technique is the first one able to provide such precise 
information about NPs components localisation on a particle by particle basis and with such high resolution. 
 
This innovative study was performed in collaboration with the group of Dr A. Dazzi of the LCP of Orsay, 
which developed the AFM-IR, and with the society “Anasys Instrument” from Santa Barbara (USA) which 
commercialise the instrument. 
E. Pancani prepared and characterised the NPs used for the study, contributed to design and perform the AFM-
IR experiments, to interpret the obtained results and to paper writing. 
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ABSTRACT  
 
AFM-IR is a nanospectroscopic technique which combines the high-resolution of AFM and the possibility to 
unambiguously identify studied components by infrared (IR) spectroscopy. This well-established photothermal 
technique has been used in contact mode in various fields of applications. However, its use for the investigation 
of soft non-adhesive samples remains limited. We present here for the first time the setup of AFM-IR in tapping 
mode. After describing its theoretical basis, applications were developed in nanotechnology for the 
investigation of non-adhesive polymeric nanoparticles (NP). The design of optimized drug-loaded NPs with 
sizes lower than 200 nm necessitates a deep understanding of their morphology and composition, with special 
emphasis on drug location and corona presence. Up to now, the preferential locations of NP components were 
hypothesized according to experimental results, but it was not possible to verify these suppositions by directly 
visualizing NP composition. Here we show that tapping AFM-IR allows not only to visualize the location of 
the NP hydrophilic shells, but also to locate the drug. Pipemidic acid, a highly crystalline antibiotic, was 
incorporated at only 1 wt%. In spite of the challenge, the location of the drug was clearly identified using its 
specific IR fingerprint. The drug preferential location in the NP corona was established. Moreover, small NPs 
of 8-20 nm could be studied, highlighting the good resolution of the method. 
The following paper is under preparation for submission in Analyst. 
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These studies pave the way towards the use of tapping AFM-IR as exquisite tool to control the quality of NP 
formulations based on individual NP detection and component quantification.  
 
Key words: nanoparticle; corona; tapping AFM-IR; drug identification; chemical characterization 
 
  
 
 
 
Infrared (IR) spectroscopy is one of the most powerful and widely employed analytical techniques able to 
directly probe the molecular vibrations of a broad variety of samples. IR spectra can indeed be advantageously 
used to specifically identify chemical species.  
To achieve spatially localized measurements, IR spectroscopy was historically firstly coupled to optical 
microscopy. However, microspectroscopic techniques are limited to a spatial resolution in the micrometer 
range. Therefore, to bring the power of IR spectroscopy below the diffraction barrier, a classical atomic 
microscope (AFM) was coupled to an IR laser about ten years ago1. The resulting hybrid technique, called 
AFM-IR, combines the nanoscale spatial resolution provided by AFM together with the chemical 
characterization offered by IR spectroscopy. Indeed, the AFM cantilever is used as a detector to locally sense 
the photo-thermal expansion of the sample resulting from IR absorption. 
The  signal detected by AFM-IR was proved to be proportional to the absorption coefficient of the sample1,2 
and the technique was able to investigate matter with a resolution of around 10 nm3–5.  
Since its development, this technology has been employed to characterize a wide collection of samples in 
different domains4 and has rapidly emerged has a powerful and versatile tool.  
Nevertheless, AFM-IR was used so far exclusively in contact mode thus impairing its application to samples 
with particular geometries and to soft or loosely adhesive samples. Indeed, the contact between AFM tip and 
sample surface is essential to detect the photo-thermal expansion. 
The will to overcome such limitation and extend the technique application to those challenging samples 
motivated the development of an AFM-IR able to perform the IR acquisition in tapping mode. The tapping 
AFM-IR setup is presented in this study for the first time and the key physical phenomena involved in the 
detection of IR absorption during non-linear interaction are described. 
 
The second main breakthrough of this study was the first-time application of the newly developed technique 
to nanotechnology domain and, in particular, to sensitive weekly surface-adhesive polymeric biodegradable 
NPs. 
 
Nanotechnology provides the opportunity to organize matter at the nanometer scale, elaborating intriguing 
reservoirs able to release their drug cargo in a controlled manner at targeted sites in the body 6–8. It 
revolutionized drug delivery by allowing transcytosis of drugs across biological barriers to reach (intracellular) 
targets. Nowadays, poly(lactic acid) (PLA) and poly(D,L-lactic-co-glycolic acid) (PLGA) polymers are the 
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most employed biomaterials to elaborate drug nanocarriers. Approved by the Food and Drug Administration 
(FDA), they were demonstrated to be biocompatible and biodegradable. Several drug-loaded 
nano(micro)particles are already on the market9,10 and intensive research is focused on developing novel 
optimized nanocarriers.  
 
The design of drug-loaded nanoparticles (NPs) with sizes lower than 200 nm necessitates a deep understanding 
of their morphology and structure with a special emphasis on drug location and physical state. Indeed, a drug 
located near the NP surface would be released in a “burst” manner whereas controlled release can be achieved 
with drugs incorporated in the intermingled polymeric chains forming the cores11–13. Besides, a deep 
knowledge on the NP corona chemical composition and structure is also of main interest as the NPs’ surface 
is the theatre of many complex interactions with the living systems14. This information is generally obtained 
by using surface analysis techniques such as X-ray photoelectron spectroscopy (XPS) or secondary ion mass 
spectrometry (SIMS) or by indirect methods such as measuring the electrophoretic mobilities, the 
hydrophobicity and/or mobility of polymer chains forming the corona. However, direct methods give only 
bulk information but cannot assess if the samples are homogeneous.  
In this context, there is a tremendous interest to develop a method to both visualize individual NPs and 
characterize their chemical composition, enabling detecting the locations of both drugs and coronas. 
In this study, we show that this arduous challenge can be addressed by using the developed tapping AFM-IR. 
We will demonstrate that the soft exploration provided by the technique allowed perfectly imaging loosely-
adhesive and spherical PLA/PLGA NPs, without distorting or displacing them. Simultaneously to the 
topographic information, tapping AFM-IR allowed the localization of each constituent of the NPs, by detecting 
their specific IR response, thus unravelling their chemical composition. 
The presence of a hydrophilic surfactant corona around NPs core was here directly demonstrated for the first 
time. The high-resolution of the technique was verified as the morphology and the chemical composition of  
NPs/micelles as small as 10 nm could be investigated. Moreover, to test the method up to its limits a drug of 
interest was incorporated at only 1% with respect to NP weight. Despite the challenge, the location of the drug 
could still be identified.  
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RESULTS AND DISCUSSION 
 
 
Tapping AFM-IR 
 
AFM-IR description 
 
The AFM-IR technique combines an infrared source with an Atomic Force Microscope. The infrared source 
is typically a tunable pulsed infrared laser which can be tuned through the mid IR range, but this technique has 
also been demonstrated using sources extending into the visible range15. The infrared light is focused to a spot 
coincident with the AFM tip. In the original AFM-IR technique3,1 the infrared laser was pulsed at a low 
repetition rate, typically 1 kHz, with a fast pulse in the few ns range. When the sample absorbs the infrared 
light, it heats and rapidly expands causing an impulse to the AFM probe which causes the AFM cantilever to 
oscillate at its contact resonant frequencies. The amplitude of the contact resonant frequencies is proportional 
to the absorption in the sample and so by tuning the laser a IR spectrum can be collected which correlates well 
with traditional FTIR spectra. 
A later improvement to the AFM-IR technique made use of faster pulsing laser sources such as Quantum 
Cascade Lasers (QCLs) in which the repetition rate can be varied over a broad range.  This technique is 
typically referred to as resonance enhanced AFM-IR16.  In this technique the repetition rate of the laser is tuned 
to match a contact resonance of the AFM cantilever.  As opposed to the traditional technique in which a single 
laser pulse is used to induce a ringdown in the cantilever, the repeated laser pulses tuned to the contact 
resonance will drive a larger oscillation amplitude into the cantilever. This improves the sensitivity of the 
technique allowing for the measurement of thinner samples down to as thin as a single monolayer. 
 
Tapping AFM-IR setup 
 
In both techniques mentioned above, in order to detect the IR absorption of the sample the AFM must be in 
contact with the surface of the sample.  This is typically not a problem for collecting point spectra in which 
the AFM tip is held at a fixed location on the sample surface and the wavelength of the IR source is tuned over 
its range. This is true as long as the sample is not particularly soft or mobile. For collecting IR images, in which 
the IR source wavelength is fixed and the AFM tip is scanned across the sample surface, imaging in the contact 
mode can be more problematic. For soft or mobile samples, the tip can deform or displace the sample leading 
to inaccurate results. 
This problem was also faced in the early days of Atomic Force Microscopy and led to the development of the 
tapping mode, in which the tip is not in continuous contact with the sample surface but taps, making 
intermittent contact with the sample surface. This allows highly reproducible imaging of a broader range of 
samples even if they are very soft or loosely adhered. Tapping mode is typically performed by driving the 
AFM cantilever at its fundamental free resonance, bringing the AFM tip down close enough to the sample 
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surface that the oscillation amplitude is limited by contact with the sample surface and using a feedback loop 
to map the sample topography by maintaining the amplitude as constant17. 
Tapping AFM-IR (Figure 1) was developed using principles from heterodyne or multifrequency AFM in 
which multiple flexural eigenmodes of the AFM cantilever are excited or measured to enhance the sensitivity 
of the probe sample interaction and measure mechanical properties of the sample18–20.  Tapping AFM-IR is 
typically performed in a similar fashion as standard tapping mode by tapping at the fundamental free resonance 
but in addition the laser is pulsed at the tip-sample location at higher repetition rates.  
 
  
Figure 16 – Setup of the NanoIR2s (Anansys Instrument) in tapping mode. 
 
Similar to the resonance enhanced AFM-IR, the laser pulsing, if at an absorption of the sample, will induce 
heating and an oscillating expansion of the sample surface. The highest signal would be achieved by pulsing 
the laser directly at the second cantilever resonant frequency. In this case the oscillation amplitude would be 
enhanced by the quality factor of the AFM cantilever at this mode. The challenge with this operating mode is 
that there is a small but non zero absorption of the IR illumination in the AFM cantilever as well as a non local 
contribution from the heating of the sample due to the large spot size of the IR illumination. This results in a 
large background signal obscuring the local measurements of the sample chemistry at the tip location. In order 
to achieve local measurements a heterodyne approach is used in which the repetition rate of the laser is set to 
the difference frequency of the fundamental and second flexural eigenmodes of the AFM cantilever. The non-
linearity of the force interaction in the tapping mode mixes the tapping oscillation with the sample expansion 
at the difference frequency generating amplitude at the second mode of the cantilever. An alternate approach 
to this measurement is to perform the tapping oscillation at the second mode of the cantilever and sense the IR 
absorption using the fundamental mode.  In either case the signal is then dominated by the local signal at the 
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tip sample contact and the spatial resolution is only limited by the AFM tip radius. Measurements using this 
technique have demonstrated spatial resolution of   better than 5 nm. 
 
Tapping AFM-IR theory 
 
Tapping AFM-IR is based on heterodyne detection like the acoustic AFM techniques developed decades 
ago20,21. In our case, the photothermal effect is detected by the second tapping mode of the cantilever. The 
transduction of the photothermal expansion into the second tapping mode is predominantly due to the non-
linear contact between the tip and the surface19. In the following theory we will focus on the case of tapping at 
the fundamental free resonance and measuring at the 2nd mode but the theory is applicable to the alternate 
operational modes. The motion equation of the second mode can be written as: 
      (1) 
where z is the motion of the 2nd tapping mode, 2 the pulsation of the 2nd mode,  the damping, m* the 
associated mass of the 2nd mode and Fts the interaction force between the tip and the surface. 
A Fourier Transform can directly give the amplitude of the 2nd mode z. 
      (2) 
The interaction force Fts can be expressed like the first non-linear term of the of the Hertzian contact 
expression19: 
Fts(t)=-2c ts (Õ(t )A1 cos(w1t +j1))* d(t -nT1)åéë ùûu0(t)    (3) 
 
where ts is the non-linear term of elasticity, A1 the driving amplitude of the 1rst mode, 1 the phase of the 1rst 
mode, T1 is the period of the 1rst mode, u0 the photothermal expansion and Õ the box distribution 
corresponding to the time of contact  of 1rst mode. 
The Fourier transform of the interaction force leads to the following expression: 
   (4) 
 
where a0 is the maximum of the thermal expansion, tp the duration of the laser pulse and p corresponds to the 
repetition rate of the laser. 
Replacing expression (4) into the expression (2) and reducing the amplitude to his modulus we finally find the 
expression of the amplitude of the 2nd mode: 
    (5) 
 
where Q2 is the quality factor of the 2nd tapping mode. 
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The amplitude of the 2nd mode is proportional to the driving amplitude A1 and also to the thermal expansion 
a0. This last parameter is probably the most important because it demonstrates that spectra obtained by the 
tapping AFM-IR are directly equivalent to those from the FTIR measurement like the spectra obtained by 
AFM-IR technique. Even if the detection is linked to non-linear interaction between the tip and the surface, 
the source of 2nd mode excitation a0 is proportional to the absorbance3 making the spectra of this technique 
perfectly reliable for infrared spectroscopy analysis. 
 
 
Contact versus tapping AFM-IR 
 
AFM-IR is a well-established photothermal technique2 which has been used for more than a   decade to perform 
IR spectroscopy and imaging at the nanometer scale on a large variety of samples4. The measurement of the 
thermal expansion was achieved until now in AFM contact mode, dramatically limiting the types of samples 
which could be studied. Indeed, the contact mode on soft materials will have limited resolution and particulate 
samples can be readily displaced by the AFM probe. PLA/PLGA NPs are typical examples of non-adhesive 
samples, challenging to be analyzed by AFM-IR in contact mode. Hence, they were used here to compare the 
usefulness of AFM-IR in both modes to unravel their structure. 
Therefore, PLA NPs were prepared by a nanoemulsion method, as previously described22 and characterized 
by two complementary techniques, dynamic light scattering (DLS) and nanoparticle tracking analysis (NTA) 
(Table S1 - Supplementary Information). Their mean hydrodynamic diameters were 170 ± 45 nm and they 
displayed a polydispersity index lower than 0.1, indicating a narrow size distribution. The NPs were 
comparatively imaged by AFM-IR in contact and tapping modes Figure 2). When using applied forces in the 
equivalent range, as expected, the NPs appear crushed in the contact mode whereas they can be well imaged 
in the tapping one (Fig. 2 A and B). 
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Figure 17 - Comparison of contact AFM-IR (A) and tapping AFM-IR (B, C) chemical map on PLA NPs and illustration of NPs 
drying process (D). The NP topography variations are represented by the 3D. The color code represents the absorption distribution of 
the ester carbonyl band of PLA at 1760 cm-1 (red corresponds to a strong absorption and green to no absorption) and of the C-H bending 
band of PVA at 1415 cm-1 (blue corresponds to a strong absorption and green to no absorption). Schematic representation of the drying 
process of a PLA NP on an AFM support (D). 
  
 
Moreover, in contact mode, the AFM tip displaced the NPs, making the observations very challenging.   
In contrast, the tapping mode enabled to precisely image the PLA NPs unravelling their typical 3D spherical 
shape, without any deformation caused by the tip (Figure 2B). 
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In addition to the topography profiles, AFM-IR in tapping mode allowed the acquisition of precious 
information about NPs chemical structure (Figure 2B and C). Indeed, the NPs, made of PLA, are stabilized 
by a surfactant, polyvinyl alcohol (PVA), which confer them colloidal stability. The IR specific absorption of 
each component were used as fingerprints to detect their location within each NP. It was hypothesized that 
PLA and PVA assemble in a core-shell structure during NP formation23–25. Indeed, it was demonstrated that 
during NPs formation, PVA chains remain entangled in the PLA/PLGA core in such a way that they cannot 
be removed, even by extensive washing24. The parameters that affected the amount of residual PVA include 
the concentration of the surfactant and the type of organic solvent used in the preparation procedure23. The 
residual PVA incorporated at the NPs’ surface reached up to 13% w/w26 and influenced the properties of the 
NPs such as size distribution, Zeta potential, surface hydrophobicity, drug loading and cell interaction27.  
In the case of the PLA NPs studied here, the thickness of the hydrated PVA shell was determined to be of 
around 40 nm according to a set of complementary experiments including cryo - transmission electron 
microscopy (cryo-TEM), nanoparticle tracking analysis (NTA) and dynamic light scattering (DLS)22. 
However, despite the numerous experimental indirect evidences that point towards the arrangement of 
PLA/PLGA and PVA in a core-shell structure, this peculiar conformation could not be visualized and therefore 
undoubtedly proved yet. 
 
In the light of these considerations, AFM-IR in tapping mode was used here in an attempt to unravel the NPs 
structure.  
To map the NPs’ components distribution, two specific IR regions were selected as fingerprints for PLA and 
PVA (see IR spectra in Figure S1 - Supplementary Information). In the case of PLA, multiple characteristic 
bands were visible and the very intense ester carbonyl one at 1760 cm-1 was selected. In the case of PVA, the 
choice of a peculiar band was limited by the presence of few IR peaks most of which overlapping those of 
PLA. Fortunately, a small C-H bending band at 1415 cm-1 stood out and could therefore be employed to 
univocally assess the PVA presence.  
These two bands were thus employed to acquire IR chemical maps of PLA NPs and to track the distribution 
of their two components (Figure 2). 
The IR absorption of PLA and PVA is represented through a color code in the three 3D topographies of Figure 
2. The green corresponds to no IR absorption whereas the red and the blue to PLA and PVA IR absorption, 
respectively. By comparing panel A and B, it is clear that the IR acquisition of PLA obtained by tapping AFM-
IR resulted much more accurate and uniform in comparison to contact mode and that the absorbing region 
fitted well with the NPs’ position in the topography. Thanks to the tapping mode, the IR signal of PLA could 
be clearly detected within the entire NP volume.  
 
From the NP characterization point of view, the most important finding made available thanks to the new 
tapping mode was the possibility to identify their PVA shell (Figure 2B and C) thus proving for the first time 
the core-shell structure of the PLA/PVA NPs. 
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Interestingly, the detected PVA corona (Figure 2C, blue signal) had a thickness of around 15-20 nm and was 
found to be principally located at the NP borders, especially in the regions where the NP were in contact with 
the support. Of note, the obtained PVA thickness was about half the one previously obtained for these NPs in 
their hydrated state (40 nm22). This could be due to the drying process and the hypothesized mechanism is 
illustrated in Figure 2D. 
Indeed, during drying, PVA chains are progressively dehydrated and thus flattened on the NP surface or 
deployed on the AFM substrate. Therefore, the thickness of the corona, which is most likely uniform in the 
hydrated state, is altered and deformed in dried conditions as schematized in Figure 2D. The PVA chains 
prone to accumulate in the confined space between the NP and their substrate are thus more easily detectable. 
Indeed, located closer to the gold substrate, PVA chains are strongly affected by the local electric field 
intensification due to the tip-surface interaction which locally increase the IR sensitivity28. On the contrary, 
PVA chains at the top of the NPs are flattened during drying and thus less detected.  
 
It can be concluded that tapping AFM-IR was adapted to the investigation of non-adhesive and soft core-shell 
NPs allowing imaging their shell, despite the PVA low signal (Figure S1, Supplementary Information). 
The only drawback of this new acquisition mode, noticed during the IR mapping acquisition, lies in the fact 
that the power of the IR laser needed to be increased by a factor of 3 as compared to the traditional contact 
mode configuration. This makes the tapping AFM-IR more “aggressive” towards the samples, leading to the 
necessity to pay particular attention to avoid sample overheating during IR cartography acquisition. However, 
by carefully controlling the laser power, NPs could be imaged without any damage or deformation. 
 
 
Application of tapping AFM-IR to the characterization of drug-loaded NPs  
 
The design of a successful drug delivery system requires not only a deep knowledge of the core-shell structure, 
but also of the drug location within the carrier which highly influence the drug release profile. Indeed, drugs 
located in the NPs’ top layers are prone to be released in an uncontrolled “burst” manner, whereas those 
intermingled with the polymeric chains in the cores are presumed to be released in a controlled fashion11–13. 
Besides, NP suspensions might contain drug aggregates, micelles or nanocrystals difficult to be separated. In 
this context, the assessment of drug distribution on a one-by-one NP basis appears as one of the most 
fascinating and ambitious goals in the drug delivery field. It was our aim to test here the ability of AFM-IR in 
the tapping mode to reach this challenging objective. 
 
In many cases, drugs are incorporated in low amounts (less than 10 wt%) in NPs, rendering their detection by 
AFM-IR even more complicated. This was the case with pipemidic acid (PIP), a first generation quinolone, 
which attracted interest for encapsulation in NPs with the aim of restore its clinical use29. Indeed, 
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nanoencapsulation of such “old” drugs could offer a tremendous opportunity to deliver these drugs in an 
optimized manner conferring them “a new life” 30–33. 
In this optic, our group previously reported a comprehensive study on PIP incorporation in PLA/PLGA NPs34. 
The very low aqueous solubility of PIP35 and its high tendency to crystallize made its incorporation in NPs 
particularly arduous, as it was already reported for other crystalline drugs such as busulfan or 
tamoxifen11,13,36,37. 
A series of PLA/PLGA copolymers and formulation techniques were previously tested and a PLGA polymer 
with a 50:50 lactic:glycolic ratio and a relatively low molecular weight (see Method section) was reported to 
be relatively effective in PIP encapsulation34. Therefore, the PIP-PLGA NPs were chosen here for further 
studies using AFM-IR. 
 
Characteristic IR bands of each NPs’ component in their bulk form were selected by recording their IR spectra 
in the 2000-1000 cm-1 range. The IR spectra of PLGA, PVA and PIP are illustrated in Figure 3. 
 
 
 
Figure 18 – IR spectra of bulk PLGA, PVA and PIP. In blue: spectrum of PLGA characterized by the ester 
carbonyl band at 1760 cm-1 and C-H bending of CH2 and CH3 around 1500-1300 cm-1. In black: spectrum of PVA 
showing in the 1500-1300 cm-1 range the C-H bending but with different positions compared to the PLGA. In red: 
spectrum of PIP showing characteristic carbonyl bands at 1640 cm-1 (carboxylate C=O asymmetrical stretching), 
1615 cm-1, N-H bending at 1570 cm-1 and C=O (carboxylate) symmetrical stretching at 1360 cm-1. 
 
PLGA showed characteristic bands at 1760 cm-1, 1425 cm-1 and 1398 cm-1 similar but not identical to the ones 
evidenced for PLA. Among these bands, all suitable for AFM-IR investigation, the one at 1425 cm-1 was 
selected. Indeed, the ester carbonyl band at 1760 cm-1 was so intense, that it saturated the chemical map, not 
allowing to easily map the chemistry. 
The selection of a PVA specific absorption band was more challenging. Indeed, the C-H bending bands in the 
region 1500-1300 cm-1 were shifted in PLGA as compared to PLA (Figure 3 and Figure S1), thus overlapping 
with the PVA signal at 1420 cm-1. As no exclusive IR band could be attributed to PVA, the 1415 cm-1 
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wavenumber, where PVA absorbs stronger than PLGA, was selected as fingerprint for PVA detection, .  
Similarly, the carbonyl signal at 1640 cm-1 was selected to detect the presence of PIP, as no other component 
of the NPs absorbs in this region. 
 
Unloaded PLGA NPs 
 
Firstly, the empty PLGA NPs (mean diameter of 140 ± 40 nm - Table S1, Supplementary Information) were 
investigated to verify if the selected 50:50 PLGA co-polymer granted the NPs the same core-shell structure 
already proved for PLA NPs. Despite the absence of an IR band exclusively attributable to PVA, the tapping 
AFM-IR revealed interesting information about the chemical distribution of PLGA and PVA polymers within 
single NPs. The chemical mapping and spectra recorded on such particles are presented in Figure 4. 
The chemical map at 1425 cm-1 (Figure 4B), where the signal of PLGA is preponderant over PVA, shows a 
strong absorption only in the NP core, as the signal is clearly included in the black dotted line delimiting the 
NP topographical borders.  In contrast, it is interesting to notice that, when taking into consideration the 
mapping at 1415 cm.1 (Figure 4D) where PVA signal is prevalent, an absorption can be notice not only in the 
NP core but also on the substrate surface around it. Indeed, a thin layer of approximately 15 nm (comparable 
to the one already evidenced in the case of PLA NPs) was detected outside the dotted line delimiting the NP 
core. The comparison of these two mappings lead to the conclusion that the PVA is surely located around the 
NPs, as already reported for PLA NPs, but its presence or absence in the particle core and on their top could 
not be surely ascertained. Indeed, while around NPs an absorption signal could be detected exclusively at 1415 
cm-1 and could thus be attributed to PVA, in the inner core of the particles an absorption at both wavenumbers 
(1415 and 1425 cm-1) was clearly present. Therefore, the respective contribution of PLGA and PVA to such 
absorptions could not be clarified. 
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Figure 19 – AFM-IR study of empty PLGA NPs. A) Topography image of the PLGA NPs. B) Tapping AFM-IR map at 1425 cm-1 
corresponding to a strong absorption of PLGA and very weak absorption of PVA. C) Phase image of the NPs revealing the significant 
shift produced by the topography effect. D) Tapping AFM-IR map at 1415 cm-1 corresponding to a weak absorption of PLGA and 
strong absorption of PVA. This map shows clearly that the PVA is localized around the NP. E) Infrared spectra obtained by tapping 
AFM-IR at 2 positions: on the NP (orange arrow corresponding to orange spectrum) and on the NP border (pink arrow – pink spectrum). 
 
To complete the study, a map at 1760 cm-1 was recorded and was found to exhibit the same PLGA distribution 
as in the 1425 cm-1 map (Supplementary Information, Figure S2) thus validating once more the selection of 
1425 cm-1 as PLGA fingerprint. 
 
However, for some NPs, a lack of intensity with a moon croissant shape was revealed in the chemical maps 
(Figure 4B and D). The IR signal at the upper part of the big NP in the center of the region of interest (ROI) 
is not complete and do not match well the NP topography. The phase image (Figure 4C) corresponding to 
these maps can clearly explain this effect. Given the important size of this NP (around 160 nm), the tip contact 
change considerably during the IR mapping acquisition thus leading to an excessive and sudden phase change.  
As a consequence, the synchronicity of the 1rst mode does not match the laser pulse, making the 2nd excitation 
mode down to zero. In our experimental settings, the AFM set point of the driving tapping mode (1rst) was 
regulated to produce a soft contact (80% of free amplitude) thus avoiding an excessive pressure on the NPs. In 
fact, a possible strategy to minimize these phase problems could be to increase the contact between the tip and 
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the sample by decreasing the set point, hence reducing the phase effect. 
 
Besides allowing the chemical characterization of relatively big PLGA NPs (of around 160 nm), the tapping 
AFM-IR proved its sensitivity and high-resolution by enabling the additional observation of smaller objects. 
These small NPs or micelles, with sizes of around 10-20 nm, could be well imaged and chemically mapped 
without displacing or crushing them. Indeed, successive topography images of the ROI were identical. 
Of interest, these small objects displayed a larger absorption at 1415 cm-1 (main signal of PVA) than at 1425 
cm-1 (main signal of PLGA). This clearly shows that the smallest objects have a higher PVA content. This 
characteristic could indicate a PVA-PIP micelle-like structures of these objects.  
 
In addition to chemical mapping, AFM-IR is able to record IR spectra at specific locations within the sample. 
For instance, Figure 4E illustrate the spectra obtained in the middle of one NP and on its corona. The IR 
spectrum in the center of the NP shows non-ambiguously the 3 main bands characteristic of PLGA at 1763 
cm-1, 1425 cm-1, 1398 cm-1. The specific PVA band at 1420 cm-1 could be clearly observed in the NP corona. 
These IR spectra are consistent with the FTIR ones recorded on the bulk NP components (Figure 3) and with 
the hypothesis made so far. These spectra enabled confirming once more the identity of the two NPs component 
and their respective location. 
 
Drug-loaded PLGA NPs 
 
Once the presence of a PVA corona around the PLGA NPs was confirmed, PIP-loaded NPs were prepared and 
characterized by tapping AFM-IR aiming at unravelling PIP location. Whatever the preparation method 
(nanoemulsion or nanoprecipitation)34, the final loadings after dilutions in water (necessary for AFM 
investigations) were of only 1 wt%, underlining the low affinity of PLGA for PIP.  
Given this challenging background, it was interesting to investigate drug location by tapping AFM-IR and test 
if this technique would be sensitive enough to detect PIP at such low loadings.  
The PIP NPs obtained by nanoemulsion and nanoprecipitation techniques were characterized separately to 
assess the influence of NPs preparation on the components distribution. 
 
Nanoemulsion technique 
 
Firstly, the PIP-loaded PLGA NPs prepared by nanoemulsion (mean diameter = 140 ± 40, Table S1, 
Supplementary Information) were investigated and showed similar core-shell features as the unloaded 
ones (Figure 5B and C) exhibiting a PVA coating of around 15-20 nm thick.  
In addition, a cartography at 1640 cm-1 (Figure 5D) was performed to detect the antibiotic location. 
This map enabled the acquisition of intriguing information indicating clearly that PIP is exclusively 
localized around the PLGA NPs forming a shell with a thickness of around 15-20 nm corresponding well 
to the location of the PVA corona (Figure 5C and D). These results suggest a co-localization of PIP and 
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PVA in the NPs’ coronas. Of note, this preferential location was hypothesized in our previous studies, 
based on the fact that PIP behaved as a surfactant during NPs preparation34. Tapping AFM-IR enabled 
here to clearly visualize the location of both drug and surfactant in the shells thus validating the previous 
hypothesis. 
Moreover, the total lack of PIP signal in the NPs’ core confirmed the low affinity of the drug for the PLGA 
polymeric matrix thus explaining the extremely low drug loading and “burst” release from the shell 
previously reported34. Interestingly, no significant PIP IR absorption could be evidenced on the top of the 
NPs as already reported in the case of PVA for unloaded PLA NPs. Presumably, as suggested in the case 
of PVA (Figure 2D), the slow drying of the corona flattens the PVA shell together with the associated 
PIP which eventually accommodated in the confined interstice between the NPs and their support 
(Supplementary information - Figure S3), hence conferring the peculiar IR absorption pattern visible 
in Figure 5D. 
 
 
Figure 20 – AFM-IR study of PIP-loaded PLGA NPs prepared by nanoemulsion. A) Topography of PIP-loaded 
nanoemulsion PLGA NPs. B) Tapping map at 1425 cm-1 corresponding to the strong absorption of PLGA. C) Tapping AFM-IR 
map at 1415 cm-1 corresponding to a weak absorption of PLGA and strong absorption of PVA. The presence of a PVA absorbing 
region outside the NPs core borders is here clearly visible. D) IR Map at 1640 cm-1 showing the spatial distribution of the PIP co-
localized with PVA in the corona around the PLGA NPs core. E) Average IR spectra of PIP corona (cyan arrow – cyan spectrum) 
and PLGA particles (pink arrow – pink spectrum). 
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Again, tapping AFM IR proved to be able to efficiently map not only large NPs but also small objects of 
about only 8 nm thus emphasizing the high-resolution of the technique (Figure 5B). As in the case of 
unloaded NPs, the smallest object had the highest PVA content. In all cases, the cores were devoid of PIP. 
 
Furthermore, IR spectra were recorded on NPs cores and coronas (Figure 5E) 
The pink averaged spectra recorded on the biggest PLGA NP core (showed the two specific bands of 
PLGA at 1425 cm-1 and 1398 cm-1. 
On the other hand, the average spectra of the NPs corona (Figure 5E – blue line) reveal the presence of 
the PIP which produce an absorption band at 1645 cm-1. Interestingly, the second band of the doublet 
characteristic of the pure antibiotic and visible at around 1615 cm-1 in FTIR spectra of bulk PIP (Figure 
3) is not detected anymore in NPs. This is most likely due to different molecular environment experienced 
by PIP when located in NPs corona and to PIP very low concentration. Indeed, this is witnessed by the 
appearance of a unique absorption band at 1550 cm-1, which do not correspond to PIP FTIR spectra, and 
by the presence of a broad band in the 1425 cm-1 region which do not resemble PLGA ones and which 
could hence be generated by a shift of the PVA band typically found at 1415 cm-1 as a consequence of its 
interaction with PIP. These bands most likely belong to a complex mixture of both compounds enforcing 
the hypothesis of a strong affinity of PIP for PVA. 
 
Nanoprecipitation technique 
 
In the case of the nanoprecipitation, the distribution of PIP represented by the mapping at 1640 cm-1 
(Figure 6D) is similar to the one in the NPs prepared by the nanoemulsion. In both cases, the antibiotic 
appears to be located only around the NPs.  
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Figure 21 – AFM-IR study of PIP-loaded PLGA NPs prepared by nanoprecipitation. A) Topography of PIP-loaded 
nanoprecipitation PLGA NPs. B) Map at 1425 cm-1 corresponds to a strong absorption of PLGA. C) Phase image associated to 
the topography showing a small edge effect on each NPs. D) Map at 1640 cm-1 shows the distribution of the PIP around the 
nanoparticles. E) Average infrared spectra of PIP corona (cyan arrow – cyan spectrum) and PLGA nanoparticles (pink arrow – 
pink spectrum). 
 
Indeed, PIP forms a corona around the NPs and small particles of around 10 nm could be detected. Of 
note, due to the smaller size of the NP prepared by nanoprecipitation as compared to nanoemulsion (126 
± 26 nm and 150 ± 40 nm, respectively – see Table S1, Supplementary Information) the phase shift 
was also sensibly smaller (Figure 6C and Supplementary Figure S4)  
The average spectrum obtained on the NPs core (pink spectrum) reveals exclusively the presence of PLGA 
characteristic bands at 1762 cm-1, 1425 cm-1 and 1396 cm-1 (Figure 6E). Thus, the absence of PIP in NPs 
core is confirmed. The average spectrum of the corona shows a mix of PIP and PVA spectra as we can 
easily detect the PIP band at 1635 cm-1, the PVA one at 1420 cm-1 and the additional band at 1550 cm-1, 
which presence was already highlighted in the corona of PLGA NPs obtained by nanoemulsion. It is worth 
pointing out that the carbonyl band of PIP is found at 1635 cm-1 in the case of nanoprecipitation and at 
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1645 cm-1 in the case of nanoemulsion. This shift is probably due a different environment experienced by 
the antibiotic when interacting with the PVA.  
 
In a nushell, tapping AFM-IR enabled for the first time the visualization of the PVA corona around 
PLA/PLGA NPs core and its presence was detected in loaded and un-loaded NPs prepared either by 
nanoemulsion or by nanoprecipitation. Moreover, a preferential localization of PIP in the PVA corona 
was detected despite the low drug loading (around 1 wt%) of the analyzed NPs. 
 
 
Conclusion 
 
The development of AFM-IR in tapping mode is reported in this study for the first time and the key physical 
phenomena involved in the detection of IR absorption were described. The amplitude of the signal detected by 
the AFM as a consequence of sample photothermal response was demonstrated to be proportional to sample 
absorbance despite the non-linear interactions occurring between the tip and the sample. 
The development of this new mode allowed extending AFM-IR application to loosely-adhesive or sensitive 
sample, such as polymeric NPs, which were very difficult or impossible to analyze in contact mode. 
Thus, tapping AFM-IR was used here to unravel the structure of NPs possessing a hydrophilic PVA shell and 
a PLGA core. A crystalline drug, PIP was incorporated at a loading of only 1 wt%. In spite of this challenge, 
the location of the drug could be clearly identified based on its specific IR fingerprint. The drugs’ preferential 
location in the hydrophilic coronas was assessed here for the first time. Moreover, objects (NPs or micelles) 
as small as 10-20 nm were detected and successfully imaged. These studies pave the way towards an in-depth 
characterization of both NP composition and drug incorporation. 
With further investigations, tapping AFM-IR could be an exquisite tool to control the quality and the 
composition of NPs on a particle by particle basis and could give access to information inaccessible with other 
techniques. 
 
 
METHODS 
 
Chemicals 
 
PLGA 50:50 acid terminated (MW=5-20 KDa, 10P019) was kindly donated by PCAS (Expansorb, Aramon, 
France). 
PLA ester terminated (MW:10–18 kDa), PVA (88% hydrolysed) and pipemidic acid (PIP) were purchased 
from Sigma-Aldrich (Saint-Quentin Fallavier, France). Injectable water was purchased from Cooper (Melun, 
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France), while dichloromethane (DCM -Analar Normapur), methanol (MeOH) and acetone from Prolabo 
(Fontenay-sous-bois, France). The solvents were all analytical grade. 
 
Nanoparticles synthesis and characterization 
 
Nanoemulsion method - Biodegradable PLGA NPs were prepared by an oil-in-water emulsion method using 
PVA as a surfactant. Briefly, 20 mg of PLGA were dissolved into 1.5 mL of DCM and the organic phase was 
poured into 4 mL of injectable water containing 0.5% w/v PVA and vortexed for 20 s. For drug-loaded NPs, 
4 mg of PIP together with 0.2 mL of MeOH (which helped solubilising the PIP) were added to the PLGA 
organic phase, previously to the phase mixing. The emulsion was sonicated with a sonicator probe (Sonopuls 
HD 2070, BANDELIN electronic GmbH & Co, Berlin, Germany) at 20 % power for 1.5 min in ice bath to 
avoid overheating. The emulsion was sonicated again at 10 % power for 30 s. Organic solvent was evaporated 
at room temperature under gentle magnetic stirring.  
Nanoprecipitation method – 50 mg of PLGA were solubilised in 2.5 mL of acetone. The polymer solution was 
added to 5 mg of PIP powder. As PIP is poorly soluble in acetone, 0.4 mL MeOH were added to completely 
solubilize the drug. Then, the organic phase was added drop-wise into 5 mL of 0.5% PVA aqueous (injectable 
water) solution under continuous vigorous magnetic stirring leading to the instantaneous precipitation of the 
polymer under the form of NPs. The organic solvent was evaporated at room temperature under gentle 
magnetic stirring. Duration of solvent evaporation was controlled. 
 
The average hydrodynamic diameter of the NPs was determined at 25°C by Nanoparticle Tracking Analysis 
(NTA) (NanoSight LM10, Malvern Instruments S.A., Worcestershire, UK) after a 10,000 times dilution in 
injectable water. Each sample was measured 3 times, consisting of 5 recordings of 60 s each. Results were 
reported as mean diameter ± SD (standard deviation). Additionally, the mean hydrodynamic diameter was 
measured with an equilibration time of 60 s using a Malvern Zetasizer® (Nano ZS90, Malvern Instruments 
S.A., Worcestershire, UK). Sample dilutions with injectable water were performed according to ISO 22412. 
Mean diameters were reported as Z Average (nm) ± SE (Standard Error - with a PdI lower than 0.1). All 
experiments were performed in triplicate. 
 
AFM-IR 
 
The AFM-IR data reported in this study were obtained using a NanoIR2s (Anasys Instrument) coupled with 
a multichip QCL source (MIRcat-QT, DAYLIGHT solutions; peak powers up to 1W; average powers up to 
0.5W and wavelength repeatability < 0.1 cm-1) covering the range from 1325 cm-1 to 1960 cm-1 of the mid-
IR region) with a tunable repetition rate (up to 500 kHz). An Au-coated silicon probe (tapping AFM-IR 
cantilever, Anasys - spring constant 0.03 N/m) was employed to avoid effects linked to the IR absorption of 
the silicon. Topography and IR maps were treated using MountainsMap 7.3 software and the spectra were 
filtered using a Stavitsky-Golay algorithm (order 3 polynome using 5 points). 
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FTIR spectrocopy 
 
Transmission-FTIR spectra of NPs components were obtained by using a Brüker Vertex 70 FTIR spectrometer 
(MCT detector, cooled down by liquid nitrogen). Each NPs component was solubilized in a suitable solvent, 
deposited on 20 mm ZnSe windows and dried with nitrogen flow. Spectra were recorded in the range of 2000-
1000 cm-1 with an accumulation of 100 scans and a resolution of 4 cm-1.  
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Table S1 - Hydrodynamic diameter of unloaded and loaded NPs. NP mean diameter was determined by 
both DLS and NTA. For DLS measurements data are reported as Z average and as number distribution to allow 
the comparison with NTA results. 
 
Formulation 
Mean diameter 
DLS 
Z average 
(nm ± SE) 
PdI 
DLS 
Number average 
(nm ± SD) 
NTA 
(nm ± SD) 
Unloaded PLA NPs 255 ± 4 0.059 228 ± 66 170 ± 45 
Unloaded PLGA NPs 244 ± 2 0.064 208 ± 60 140 ± 40 
PIP-loaded PLGA NPs 
(nanoemulsion) 
229 ± 3 0.067 189 ± 58 150 ± 40 
PIP-loaded PLGA NPs 
(precipitation) 
161 ± 2 0.079 117 ± 34 126 ± 26 
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Figure S22 – IR spectra IR of bulk PLA and PVA in the range 1500-1300 cm-1. In green: spectrum of PLA 
characterized by C-H bending of CH2 and CH3. In black: spectrum of PVA showing its C-H bending bands 
which have different positions compared to the PLA. Indeed, the PVA band at 1420 cm-1 stand out from the 
PLA spectrum and could thus be used as a fingerprint to undoubtedly detect PVA localization. 
 
 
 
Figure S23 - AFM-IR study of empty PLGA NPs (complementary to Figure 4, Main text). A) Topography 
image of the PLGA NPs. B) Tapping AFM-IR map at 1760 cm-1 corresponding to a very strong absorption of 
the carbonyl ester group (C=O stretching) of PLGA. 
 
 
 
Figure S24 - Schematic representation of the deposition and drying process of a PIP-loaded PLGA NP 
on an AFM support. During the drying process, PVA chains are progressively dehydrated and thus flattened 
on the NP surface or deployed on the AFM support. The thickness of the corona is therefore sensibly reduced 
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and deformed during the drying phase. The PIP, which has an affinity for PVA, follows PVA chains movement 
and ispreferentially deposited at the NP border in the interstices with the support. 
 
 
 
Figure S25 - AFM-IR study of PIP-loaded PLGA NPs prepared by nanoemulsion (complementary to 
Figure 5, Main text). A) Topography of PIP-loaded nanoemulsion PLGA NPs. B) Phase image associated 
to the topography showing the croissant moon shape effect which explains the lack of intensity in IR 
cartographies. 
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SECTION C: 
 
Tapping AFM-IR: a versatile method to determine the drug content of 
each polymeric nanoparticle 
 
 
In the previous section of this chapter, the capability of the recently developed AFM-IR tapping mode to 
efficiently image and chemically characterise PLGA NPs was demonstrated, addressing the challenges related 
to the non-adhesive character of these NPs on the AFM supports. The superiority of the NPs 3D topography 
obtained by tapping AFM-IR was striking when compared with the one acquired by contact mode. 
The technique provided the fascinating opportunity to prove the existence of a PVA corona and thus the core-
shell structure of both empty and drug-loaded NPs. Moreover, the preferential PIP surface localisation, 
hypothesised in Chapter II to explain the drug burst-release upon water dilution, was confirmed thanks to 
tapping AFM-IR. Indeed, PIP was clearly shown to co-localise with PVA in the NPs corona but was not 
detected in the PLGA core. This finding, together with the PIP spectral changes, occurring when the drug was 
localised in the corona (in comparison to free-PIP), further corroborated the conclusion that this drug has a 
strong affinity for PVA and practically no affinity for PLGA. 
The possibility to access to NPs components precise localisation on a particle by particle basis is invaluable in 
the drug delivery domain. 
 
Given the very satisfactory results obtained on PLGA NPs, in this last section the abilities of tapping AFM-IR 
were further tested in collaboration with the team of Pr. Alexandre Dazzi. Thus, the features of the PCL-PIP 
NPs, developed and characterised in Chapter II, were explored here at the nanoscale level. The first objective 
of the study consisted in proving PIP localisation in the particle core. To do so, the IR spectrum of the bulk 
PCL-PIP conjugate was employed to identify the specific fingerprints of PCL and PIP (Figure 1). 
 
 
Figure 26 - IR absorption spectra of PCL-PIP conjugate. Principal panel: spectral range 4000-650 cm-1. Upper-left panel: 
zoomed region of the spectrum in the range between 1800 -1550 cm-1. 
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The ester carbonyl band at 1732 cm-1 (C=O stretching vibration) was assigned to PCL and chosen as its 
signature whereas the tertiary amide band at 1630 cm-1 (C=O stretching vibration) was selected for PIP. Indeed, 
as shown in Chapter II, each PIP molecule is conjugated to a chain of about 10 PCL units through an amide 
III bond. These selected bands were employed to register IR cartographies on a series of PCL-PIP NPs. An 
example of the obtained results is shown in Figure 2. 
 
 
Figure 27 - AFM-IR study of PCL-PIP NPs. a) Topography image of PCL-PIP NPs. b) Tapping AFM-IR map at 1732 cm-1 
corresponding to the ester carbonyl band of caprolactone units (laser power 1.85%) c) Topography image of PCL-PIP NPs. This image 
shows clearly that the two topographies (a and c) are identical and that the first IR acquisition did not damage the NPs. Indeed, the 
parameters of the instruments were carefully set in order to avoid overheating of PCL which possess a low melting point (around 60°C) 
thus degrading very easily. d) Tapping AFM-IR mapping at 1630 cm-1 corresponding to the absorption of PIP (laser power 1.85%). 
This map reveals the colocalization between PCL and PIP thus confirming that PIP is successfully located inside NPs. e) spectra 
obtained by tapping AFM-IR in multiple locations inside the NPs. All the spectra confirm that PCL and PIP are colocalized. 
Topography colour grading: 0-100 nm. IR mapping colour grading = 0-2 Arbitrary Units (A.U.), from green to pink. 
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The first interesting observation which can be formulated by looking at the topography images (Figure 2) is 
that PCL-PIP NPs do not look spherical like PLGA ones (see Chapter II). Indeed, by taking the bigger NP as 
example, the topography maximum height corresponds to 100 nm whereas its width is of around 500 nm. Thus, 
the NP appears flattened on the support surface. One may argue that this flattening effect could be a 
consequence of tapping AFM-IR scan and that this new tapping mode is not as adapted as previously claimed 
to sensitive samples. However, it is interesting to point out that SEM investigations revealed the same 
morphological features (Chapter II). Given the similar shapes observed by the two techniques, two hypotheses 
can be formulated. Firstly, a non-spherical shape of these NPs could be assumed. To ascertain this hypothesis 
and complete the study, Cryo-TEM experiments (without drying) will be carried out in the future. 
The second and most likely hypothesis is that the flattening effect observed with the two techniques is caused 
by NPs deposition and drying process on the two supports (gold for AFM-IR and silicon wafer for SEM). In 
fact, in the case of both techniques, NPs flattening was observed only for PCL-PIP NPs and not for PLGA 
ones, which undergo to the same sample preparation procedures. Consequently, the phenomenon must be 
connected to the physico-chemical properties of PCL. Indeed, PCL displays a much lower glass transition 
temperature (Tg) and melting point (MP) when compared to both PLA and PLGA polymers. PCL has a Tg of 
about -60 °C whereas the one of PLA and PLGA is in the range of 40-60 °C (Introduction – Section 3.1). 
Similarly, a consistent difference is evidenced in the case of MP which is around 170 °C for PLA/PLGA and 
around 60°C for PCL. These differences can explain the sensitivity of PCL NPs to the drying process and 
surface deposition which conversely do not impact on PLA/PLGA NPs. 
It is important to highlight that the low PCL melting point could potentially be an obstacle in the 
characterisation of PCL-PIP NPs, hampering the possibility of performing multiple acquisitions on the same 
ROI at different wavenumbers in order to acquire the desired information. Indeed, the first IR mapping of NPs 
could be sufficient to damage them preventing further investigation. 
However, by comparing the two topographies of Figure 2, where the one in panel C was obtained after a first 
IR mapping at 1732 cm-1, it can be observed that they are almost identical and that no alteration is visible. 
Indeed, the laser power of AFM-IR could be conveniently tuned to enable the acquisition of multiple chemical 
mappings of the same NPs without distorting or melting them. 
 
The most interesting results of this investigation are visible in the IR mappings of Figure 2 (2B and 2D) which 
clearly show that PCL and PIP absorption signals are perfectly overlapping. Herein, PIP was clearly localised 
inside NPs and co-localised with PCL. These images confirm unequivocally that the PIP covalent conjugation 
with the PCL polymer was a successful strategy enabling to finally obtain drug-loaded NPs.  
Of note, it is important to highlight that, although PVA was used as surfactant in NPs formulation, its IR signal 
could not be detected and no PVA corona was evidenced during these investigations, contrary to the results 
presented in Chapter III Section B on PLA/PLGA NPs. Two hypotheses can be formulated to explain this 
discrepancy. Firstly, there was a difficulty to find an IR wavenumber suitable as PVA fingerprint, because its 
bands were overlapped by PCL-PIP absorption. Secondly, when trying to use the same strategy employed in 
Chapter IIIB for PLGA NPs and record the cartography at 1415 cm-1 (where PCL-PIP contribution is less 
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important) no PVA accumulation could be detected neither around NPs nor in other locations of the sample. 
This can be explained by a lower affinity of PVA for PIP-PCL. This hypothesis could be further confirmed by 
a quantification of the PVA content in the NPs by colorimetric methods set up in our group1. Alternatively, it 
will be interesting to perform further studies by replacing PVA with other surfactants, such as Pluronic, 
approved by the FDA and which use is already reported for the efficient formulation of PCL NPs2–4. 
 
One of the most ambitious goals in the drug delivery domain is the assessment not only of the drug localisation 
but also of its amount. It would be revolutionary for the development and the study of nanoparticulate systems 
to be able to determine their loading on a particle by particle basis.  
Thus, this study reports the first steps towards the determination of the amounts of each component in 
individual NPs.  To do so, we took advantage of the unique information provided by the tapping AFM-IR.  
The IR maps of PCL-PIP NPs were employed to calculate a ratio between each compound of interest.  
Indeed, these NPs were formulated by employing a PCL-PIP conjugate synthesised by a drug-initiated 
polymerization reaction (Chapter II). In this reaction the caprolactone monomer was used as a solvent for the 
reaction. It should be kept in mind that trace of water in the reaction medium and even some impurities can 
also initiate the polymerisation reaction, leading to the formation of poly(e-caprolactone) homopolymers. This 
has been well described in studies dealing with the acid-initiated caprolactone polymerisation, highlighting the 
obtention of polymers with different chain ends but similar molecular weight which were very difficult to be 
separated by chromatographic methods5. Very probably, this could be the case here, with the synthesis of a 
majoritary PCL-PIP component and some trace PCL homopolymer. In other words, NPs are prepared of blends 
of PCL-PIP (major component) and PCL (minor compound). Therefore, knowing the lack of affinity between 
PCL and PIP it will be of high interest to investigate by AFM-IR if each NP has the same PIP content, or if 
there is a different segregation of the blocks.  
 
It should be kept in mind that the global composition of PCL-PIP was accurately determined by NMR 
indicating a molar ratio of one PIP molecule per 10 caprolactone units. By analysing several NPs, the global 
composition determined by NMR should be found also by AFM-IR. 
  
In order to calculate the molar ratio of PCL and PIP through the recorded IR maps, the relative force of the 
absorption peaks of interest must be determined by measuring the absorption coefficient “α” which varies in 
function of the wavenumber. 
The measure of α has been performed in collaboration with Dr. Emmanuel Dartois (Institut d’Astrophysique 
Spatiale, Paris-Sud University) by using an IR microscope (Thermo Scientific Nicolet iN10). A thin layer 
(around 1 µm) of the bulk compound PCL-PIP has been created with the help of a compression cell made of 
synthetic diamond. This experiment was delicate because of the elasticity of PCL-PIP copolymer which was 
difficult to be compressed to form a smooth, flat layer, essential to allow a precise evaluation of both the layer 
thickness “l” and α. 
Once a flat surface was obtained, α could be determined from the principal interference fringe distance of IR 
light created by the optical index changes between the diamond support and the polymer which are measured 
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by the IR microscope according to the Beer-Lambert law: 
 
(1)      le
I
I
T −==
0
 
where T is the transmittance, “I” the intensity of the light transmitted by the sample and “I0” the intensity of 
the light entering the sample. “I0” is known whereas T and I were directly measured from the sample. The 
unknown parameters of the equation are hence “l” and α. “l” could be measured as follows: 
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where “RI” is the refractive index of the polymer, that in this study has been approximated to the one of PCL 
(=1.439)6, and “Δν” is the principal interference fringe distance, measured directly by the instrument. With the 
measured l, α could be derived for each wavenumber from the inversion of equation 1: 
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and is shown in Figure 3. 
 
 
Figure 28 – Absorption coefficient (Alpha=α) as function of the wavenumber. 
 
The values of α for the two wavenumbers at which the NPs cartographies were recorded (1732 cm-1 for PCL 
and 1630 cm-1 for PIP) where derived from Figure 3 and a 1.9 PCL/PIP ratio resulted between them. This 
means that in the studied material, the PCL part produces an IR signal 1.9 times more intense than the 
PIP moiety. 
This factor has been taken into account in the further investigations to determine for each NP its molar  
PIP:PCL ratio, which should be globally close to 1. 
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Subsequently, for each NP, the cartography at the two wavenumbers of interest have been individually 
analysed by using MountainsMap 7.3 software and the IR signal at each wavenumber has been integrated over 
the IR signal area. Thus, the NPs integrated signal, expressed in arbitrary units (A.U.) per nm2 (A.U./nm2), was 
obtained, as shown in Figure 4. 
 
 
Figure 29 – Graphical representation of IR signal integration (A.U./nm2) of a single NP at a certain wavenumber. The IR 
intensity in z (A.U.) is integrated over the IR signal area (nm2).  
 
Then, the ratio between NPs IR integrated signal at 1630 cm-1 and the one at 1732 cm-1, corrected by the α 
factor ratio, has been calculated for 10 different NPs. Moreover, when on the same NP a different laser power 
was employed to acquire the two cartographies, their signal was normalised by taking the relative power into 
account. 
The PIP/PCL ratio mean value corresponded to: 
 r(PIP/PCL) = 1 ± 0.4. 
The ratio calculated from the IR cartographies was very close to the theoretical one (=1) thus proving that 
tapping AFM-IR could provide a relative quantification of the drug/polymer ratio on a particle by particle 
basis. However, it can be noticed that the standard deviation of the measurements is quite important.  
Indeed, these studies needs to be completed on a higher number of NPs to have better statistics. 
 
Another possible explanation of the variability of r between the particles consist in the formation of crystalline 
microdomains of PCL and/or PIP embedded in an amorphous matrix. The AFM tip encounters domains  
more or less rigid which make difficult to control the contact between the AFM tip and the sample. Tapping 
AFM-IR signal, which is measured on the 2nd tapping mode (Chapter III Section A), is highly dependent to 
the tip-sample contact, hence when the last is not constant, it interferes with the correct detection of IR-induced 
sample thermal expansion. With further studies the data acquisition could be improved by adjusting the 
parameters (i.e, the setpoint) with the purpose of minimising the contact variations. 
It is worth to highlight that this hypothesis is corroborated by the spectra in Figure 2E. Indeed, it can be 
observed that the maximum of the amide C=O band (used as PIP fingerprint) is not constant at 1630 cm-1 but 
varies of few nanometres depending on the considered spot. This is also most likely explained by the presence 
of crystalline domains in the different regions of the NPs. This complicates the data treatment as the 
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cartography has been acquired at 1630 cm-1 which is not the maximum of the band for the entire NPs, thus 
introducing an error which further increase the measurement standard deviation. 
In addition to these factors, the variability between the measurements was also increased by the fact that the 
integration of NPs surface was complicated by their irregular form.  
 
Despite the method reported here certainly needs to be further developed, the tapping AFM-IR was 
demonstrated here to enable reaching, for the first time, the challenging goal of determining the drug/polymer 
molar ratio on individual NPs. These findings represent the first step towards particle by particle quantification 
opening tremendous opportunities in the nanomedicine field. 
 
Conclusions and perspectives 
 
In this section it was demonstrated that the newly developed tapping AFM-IR represents a powerful and 
versatile tool to improve our knowledge of NPs structure. 
The successful incorporation of PIP thanks to its conjugation to PCL and its localisation inside the formed NPs 
was here undoubtedly confirmed. Moreover, the investigation suggested the absence of PVA corona around 
these NPs which could explain their lower stability in comparison to PLGA NPs. 
Moreover, a first strategy was presented here to allow the determination of drug/polymer molar ratio on a 
particle by particle basis. With further study the current approach could be improved and a more precise 
quantification could be achieved. 
The drug quantification on a particle by particle basis could represent a revolution in the drug delivery domain 
allowing the determination of NPs homogeneity and the eventual relationship between the colloidal properties 
of the particles, (such as their size) and their drug loading.  
Tapping AFM-IR stands out as an invaluable tool in NPs development and its use could be extended in the 
future to other kind of NPs helping in unravelling their nanoscale structure. 
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High resolution label-free detection of biocompatible polymeric 
nanoparticles in cells (Paper 5) 
 
 
General objectives 
 
The design of efficient drug nanocarriers necessitates a deep understanding of their interaction with targeted 
cells. Indeed, size, shape and surface properties of NPs play a key role in establishing their internalization 
pathway as well as their intracellular fate. 
The detection of NPs with sizes lower than 200 nm, such as PLGA NPs, inside cells is usually enabled by 
high-resolution imaging techniques which require appropriate labelling. Unfortunately, the addition of a dye, 
either physically entrapped or covalently linked, to NPs often alter their physicochemical properties and 
biological fate. Such techniques enable only indirect detection of NPs; indeed, they detect the dye, rather than 
the NPs themselves. Moreover, no high-resolution method allows the precise detection, together with the 
identification of the chemical composition of single NPs in cells, which is of outmost interest to gain insights 
on their fate. 
Here we address these challenges by using AFM-IR in contact mode. AFM-IR was reported here for the first 
time as a reliable, non-destructive and direct method able to locate precisely each PLA NPs within cells, by 
using the specific IR response of their constitutive polymer. This response was employed as a fingerprint to 
enable the unambiguous chemical identification of the nanoparticles. 
A correlative study between confocal fluorescence microscopy and AFM-IR was conducted to prove the 
reliability of the technique. To do so, fluorescent rhodamine (Rho)-NPs were prepared. Rho-NPs 
internalisation in cells was confirmed by using confocal fluorescence microscopy. Then, the exact same cell 
was subsequently analysed by confocal microscopy and by AFM-IR. The images of NPs obtained by the two 
techniques were in excellent agreement. These results were further confirmed on non-labelled PLA NPs. 
Thus, AFM-IR allowed ascertaining the chemical composition of nanoparticles of around 170 nm inside a cell 
without the need of any labelling and with a high lateral resolution.  
The novel methodology established here could be applied to a variety of NPs containing one or several active 
molecules. Indeed, combinatorial drug therapies emerge among the most promising strategies to treat complex 
pathologies such as cancer and severe infections. Thus, advanced imaging methodologies are needed to 
investigate the fate of engineered NPs containing drug combinations inside cells. In this context, with further 
studies, AFM-IR could become a powerful tool to unravel the fate of each individual unlabelled nanoparticle 
inside cells. 
 
This study was performed in collaboration with the group of Dr A. Dazzi of LCP in Orsay and with the help 
of Dr. M.F. Bernet-Camard of the EA4043 (UBaPS) for the in vitro experiments. E. Pancani performed the 
NPs preparation and characterisation, the in vitro experiments and fluorescence confocal imaging. Moreover, 
she contributed in performing the experiments for the correlative imaging, in performing data processing and 
in paper writing.
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1. Nanoparticles (NPs) characterisation 
 
 
The NPs size distribution was evaluated by using two techniques: i) dynamic light scattering (DLS) and ii) NP 
tracking analysis (NTA). The results are reported in Supplementary Table S1. NTA has been previously shown 
to be the most adapted technique to estimate the hydrodynamic diameter of PLA/PLGA NPs1. Indeed, NTA 
has the advantage of tracking the Brownian motion of each individual NP, in order to determine its diffusion 
coefficient (Dt) and consequently calculate, using Stokes-Einstein equation (equation 1), the sphere-equivalent 
hydrodynamic diameter (d): 
 
 
d
Tk
D Bt
3
=    (1) 
 
The sample temperature “T” and viscosity “η” are known and kB is the Boltzmann constant2. 
It is thus not necessary to know the refractive index (RI) of the material that compose the NPs. On the other 
hand, the hydrodynamic diameter calculated by DLS is dependent to the RI of the NPs. As a consequence, 
DLS can often lead to an overestimation of NPs size due to the fact that the largest NPs scatter more light than 
the smaller ones thus shifting the measure to higher values2,3 and explaining the difference in size between 
number distribution determined by DLS and NTA. However, given the DLS sensitivity to detect large objects 
such as NPs aggregates, this technique remain the ideal method to study the NPs suspension stability1. 
 
 
Supplementary Table 1. Main characteristics of fluorescently labelled and un-labelled NPs. NP mean 
diameter was determined by both DLS and NTA. For DLS measurements data are reported as Z average and 
also by number distribution to allow the comparison with NTA results. Concentration results correspond to 
the concentration (particles/mL) in the NP suspensions, measured after diluting 10,000 times the samples to 
allow the NPs to move freely according to their Brownian motion without impeding each other. 
 
Formulation 
Mean diameter Concentration 
DLS 
Z average 
(nm ± SE) 
PdI 
DLS 
Number 
average 
(nm ± SD) 
NTA 
(nm ± SD) 
NTA 
(particles/mL) 
Rh-PLA NPs 260 ± 4 0.063 233 ± 63 172 ± 48 6.3x1012 
Non-labelled 
PLA NPs 
255 ± 4 0.079 218 ± 65 175 ± 47 8.6x1012 
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2. Label-free imaging of PLA NPs in THP-1 cells 
 
 
 
 
 
Figure 2. Visualisation of internalised PLA NPs with nanoIR. AFM topography of a THP-1 macrophage 
(Topography colour grading = 0-1.4 µm) (a). IR map at 1770 cm-1 showing internalised PLA NPs (indicated 
by black arrows) (IR mapping colour grading = 0-70 A.U.) (b). The scale bar represents 10 µm. 
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Pharmacy is the science and the technique of preparing and dispensing drugs. Indeed, drugs are a fundamental 
component of both the traditional and the modern medicine.  
One of the major examples of serendipity in science, and more precisely in pharmaceutical field, was the 
discovery of antimicrobial agents at the beginning of the 20th century (Fleming 1928) which led to a true 
revolution in humans’ everyday life. Their introduction made far-reaching changes in the treatment of bacterial 
infections1. Diseases which were previously deadly became harmless. Several natural and synthetic molecules 
have been introduced in the clinic since then and until the 1970s. Indeed, this period of time is generally named 
the “golden era” of antibiotics. However, the rate of discovery of new antimicrobial agents has dramatically 
decreased since 1980s. The perception of infectious diseases as a “yesterday problem” have caused a decline 
in investment in the R&D of antibiotics and pharmaceutical companies have focused on other research areas 
with a higher commercial return2. 
However, in the last decades, the onset of AMR phenomenon is jeopardizing again human health. This does 
not only have a strong impact on the treatment of infectious diseases but it also undermines the safety of 
medical interventions such as cancer chemotherapy, organ transplantation, invasive or non-invasive surgery 
procedures and patients intubation which are de-risked by effective antibiotic prophylaxis and treatments2. 
In this context intracellular infections represent one of the biggest dangers.  
To tackle this global crisis, the development of NPs, which can protect antibiotics and increase their efficacy, 
represent a promising and clever therapeutic strategy. Moreover, NPs gained ever-growing interest as a tool to 
overcome the drawbacks of traditional therapeutic agents such as low solubility, poor bioavailability and 
unfavorable physico-chemical properties. 
Medical researchers and formulation scientists are committed to the hunt for efficient drug delivery systems 
which design and improvement are areas of intensive ongoing research. 
This PhD work has focused particularly on the development and advanced characterisation of two polymeric 
carriers; polyester (PLA, PLGA, PCL)-based and CD-based NPs. 
As already pointed out in the introduction to this work, these two drug delivery platforms stand out among the 
others for their ability to encapsulate challenging drugs overcoming their limitations as free molecules, for 
their tailorable properties, for their advantageous biodegradable and biocompatible characteristics and for the 
well-established safety profile. The first two chapters of this work allowed a comparison between pCD NPs 
and PLGA NPs, by studying the encapsulation abilities of these two systems towards different challenging 
drugs, namely the therapeutic [ETH:booster] pair and the first-generation quinolone, PIP. 
The first objective of this research consisted in improving the efficacy of [ETH: booster] pair for the 
combination therapy of TB. Indeed, TB is one of the most threatening diseases caused by an intracellular 
pathogen resulting in 1.8 million deaths annually3. The progressive discovery and spread of MDR TB and 
XDR TB strains have reached the level of a global emergency4. TB, being a chronic disease, necessitates an 
intensive and long antimicrobial therapy which causes frequent side-effects encountering low patient 
compliance. Given this alarming situation, growing efforts have been perpetrated in optimising the use and the 
efficiency of existing treatments and in developing new approaches.  
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The recent discovery of the family of boosters of ethionamide (ETH), a 2nd line anti-TB drug with poor 
therapeutic index, has opened new opportunities for a more efficient treatment of TB5,6. Herein, we focused 
on one of the molecules of this family, BDM41906, namely Booster. 
The aim of this study consisted in the co-encapsulation of [ETH:Booster] in polymeric NPs to allow their 
administration directly in mouse lungs, the major site of Mtb infection, by means of a Microsprayer® device. 
Indeed, these two molecules as free drugs have important limitations such as a completely different biological 
distribution and bioavailability and the impossibility to be solubilised in a solvent compatible with pulmonary 
administration which could allow a more efficient treatment of this respiratory disease. 
The efficient co-incorporation of these molecules had to overcome several technological barriers. Indeed, the 
formulation process was complicated by the difficulty to find a common solvent for the two molecules and by 
the strong tendency of ETH to crystallize.  
After a thorough formulation study, polymeric PLA NPs containing both drugs have been successfully 
prepared by an optimised nanoemulsion technique. They displayed reproducible sizes, a low polydispersity 
and the crystallization of ETH during storage has been overcome. However, slight temperature changes during 
storage could still induce crystallisation. Of note, despite monodisperse NPs could be obtained by 
nanoprecipitation without the use of surfactant, the presence of these stabilizing molecules was necessary to 
insure a better drug encapsulation andavoid the rapid formation of ETH crystals during storage. 
The average mean diameter of the obtained NPs has been thoroughly characterized using three complementary 
techniques: DLS, NTA and cryo-TEM. This work highlighted the importance of NPs characterisation with 
multiple techniques to obtain an overall picture of their physico-chemical features. This enables avoiding the 
misinterpretations that could be induced by taking into consideration only a single technique7,8.  Indeed, in this 
specific case, NTA appeared to be the most adapted method to perform a realistic estimation of NPs diameter 
in their hydrated state. By comparing and analysing the results obtained with the three techniques, it was 
concluded that DLS led to an overestimation of NPs hydrodynamic diameter due to its intrinsic sensibility to 
the presence of a small number of large NPs. This population, although minor, was sufficient to bias the results 
shifting the NPs mean diameter towards bigger values (i.e. from a mean diameter value of 178 nm to 235 nm, 
obtained by NTA and DLS, respectively). On the other hand, cryo-TEM allowed obtaining valuable 
information about NPs morphology, but the experimental conditions inherently lead to flatten the surfactant 
corona onto the NPs surface, thus leading to a measurement of their dried diameter rather than their 
hydrodynamic (hydrated) one. Consequently, the mean diameter (around 100 nm) obtained by statistical 
analysis of TEM images was sensibly lower than the one obtained by both NTA and DLS. Interestingly, DLS 
sensitivity to big objects resulted advantageous when evaluating NPs suspension stability during storage 
allowing the immediate detection of NPs aggregates. The developed drug-loaded NPs were found to be stable 
during storage for at least three months. High encapsulation efficiencies (76±5 wt% and 51±8 wt%) were 
obtained, together with important loadings (36±4 wt% and 26±3 wt%) for ETH and Booster respectively. 
Despite the positive features showed by drug loaded PLA NPs, the formulation was not totally satisfying. 
Indeed, the formation of tiny ETH crystals was still observed during storage. 
Therefore, to overcome the technological challenge of completely avoiding ETH crystallization, a different 
approach was attempted by encapsulating this drug at a molecular level using polymeric β-CDs (pCD) NPs.  
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Indeed, thanks to their peculiar truncated-cone structure, CDs are able to act as molecular containers by 
accommodating drug molecules inside their hydrophobic cavity. Noticeably, pCD NPs combine the advantages 
offered by native βCDs together with the higher aqueous solubility offered by their polymeric form and they 
have thus been employed to increase the apparent water solubility of several drugs9–11. 
The pCD NPs enabled an efficient one-step incorporation of both ETH and Booster by “green” procedure. 
Both drugs could be loaded into pCD NPs by simple incubation of drug powders with a water suspension of 
NPs. In this way, ETH apparent aqueous solubility could be increased of around 10 times without the need of 
any organic solvent. In particular, pCD NPs at a concentration of 200 mg/mL were able to incorporate up to 5 
mg/mL of both ETH and Booster totally preventing ETH crystallisation. Of note, a water solution containing 
40-50% DMSO was needed to solubilise an equivalent amount of ETH.  
In the specific case of ETH, pCD NPs resulted more advantageous in comparison to PLA ones thanks to their 
capability of incorporate drugs in a molecular state thus totally hampering the drug crystallisation. 
Interestingly, the two drugs could be hosted by pCD NPs without impeding each other.  
Of the three methods used in this study (Chapter I – Section A) to deeply characterize PLA NPs size, only 
TEM (TEM micrograph after freeze fracture) was adapted also for gaining insights in the characteristics of 
pCD NPs. Indeed, these NPs were too small (5-10 nm) to be described by the other techniques. 
Therefore, a complementary study (Chapter I – Section B) has been performed simultaneously to elucidate 
the strength of the interactions between ETH and pCD NPs and the localisation of ETH molecules inside NPs 
structure. This interdisciplinary study has been conducted in collaboration with two partners of Cyclon Hit 
consortium: ISOF from Bologna and CYCLOLAB from Budapest. 
ETH-pCD NPs interactions were investigated by means of solubility phase diagrams, circular dichroism and 
UV-VIS absorption titrations. Native βCD were employed as a reference. Spectroscopic titrations of ETH with 
both pCD NPs and native CDs evidenced small changes in the absorption spectra of ETH most likely due to 
the alcohol-like environment experienced by the drug in the presence of the carriers. This confirmed the 
presence of an interaction between the CDs and the drug. 
Further information about the interactions existing between this drug and the carrier were provided by circular 
dichroism spectroscopy (CircD). Since ETH is not chiral, it is not endowed by CircD signal. However, after 
addiction of the carriers, a quite intense CircD signal, characterized by a negative peak at 280 nm (in 
correspondence of the absorption maximum) and a positive band at 320 nm (with an intense shoulder at 380 
nm), appeared. This signal was similar in intensity and shape for both native CDs and pCD NPs but not 
identical. Particularly, the relative intensities between the main bands were not the same. These findings 
suggested a different complexation environment depending on the carrier and not involving exclusively the 
CDs cavity. Indeed, if the only interactions occurring between ETH and the carriers were host-guest type the 
CircD spectra would be the same for CDs in their monomeric or nanoparticulate form. The spectral differences 
are justified by assuming that, in the case of pCD NPs, ETH can locate both in the hydrophobic alcoholic CD 
cavities and in other confined spaces inside the tiny NPs formed by the crosslinked polymer. 
Moreover, CircD spectra allowed the calculation of the equilibrium binding constant which resulted slightly 
higher for the complexes formed by ETH and pCD NPs assuming in both cases a 1:1 complexation 
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stoichiometry. 
Additionally, phase solubility studies were performed to support the conclusions of spectroscopic studies 
regarding the affinity between ETH and the two carriers. The apparent solubility of ETH increased linearly 
with growing monomeric CD concentration up to a limit of 15mg/m. Indeed, the low aqueous solubility of 
monomeric βCD was the limiting factor in this study. In contrast, since pCD NPs solubility is considerably 
higher, a continuous linear increase of ETH apparent solubility was observed. The binding constant 
(log(K1:1/M-1) around 2) calculated from phase solubility diagram were in agreement with the ones derived 
from the spectroscopic study. 
Interestingly, phase solubility studies with pCD NPs confirmed an increase of around 10 times in ETH apparent 
solubility (against the 2-fold improvement provided by monomeric βCD). Of importance, [ETH]-loaded pCD 
NPs were stable more than 6 months thanks to the ability of CDs to encapsulate drugs at a molecular level so 
that it cannot self-assemble in crystals anymore. Taking into consideration the overall findings of the current 
study, the use of pCD NPs resulted highly advantageous over monomeric βCD for ETH complexation and the 
interactions occurring between the drug and its host were unraveled. 
 
In vitro tests were performed on both PLA and pCDs loaded formulations in collaboration with the Pasteur 
Institut of Lille (Chapter I – Section A) on extracellular as well as on intracellular Mtb. The efficacy of the 
two drugs was not impaired by their encapsulation. 
For the first time, an automated confocal high-content screening platform was employed for the evaluation of 
NPs efficacy on Mtb infected cells. Moreover, it is worth highlighting that the automated confocal microscope 
allowed monitoring the viability of the macrophages during the experiments. Importantly, no sign of 
cytotoxicity was evidenced in vitro.  
Given these satisfactory results, in vivo tests on Mtb-infected mice were performed on both formulations. 
An important limiting step of the in vivo study was the assessment of NPs compatibility with the 
Microsprayer®, the device employed to endotracheally administer the solutions to mice. Indeed, pulmonary 
administration in animals is more challenging than in humans. Whereas in humans, the administration of the 
medication is possible by self-dispensation and without any stress or pain, in animals, it has to deal with 
important technical limitations. Most of methods available for pulmonary delivery in animals do not allow a 
precise dose deposition and/or are extremely invasive for the animal. In this frame, Microsprayer® has proved 
to be the most efficient and reliable device allowing precise bilateral drug deposition together with a limited 
animal suffering. Unfortunately, not all the suspensions are compatible with this system. 
The two developed NPs formulations were repeatedly passed through the device and the reproducibility of 
their delivery was assessed. PLA NPs were not uniformly dispensed by the Microsprayer® leading to high 
variability of ETH content in each spray. Thus, the study of their in vivo efficacy was compromised. 
On the contrary, pCD NPs could be efficiently and reproducibly administered using the device. In fact, 98 ± 
0.7 wt % of the NPs suspension was recovered after passage through the Microsprayer® and the amount of 
ETH in each spray was highly reproducible (99 ± 4%). The safety and the efficacy of pCD NPs were assessed 
on healthy and infected mice, respectively. 
Of main importance. pCD NPs were demonstrated to be non-toxic after repeated pulmonary administrations 
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(6 administrations in total). Even if a mild increase in the number of macrophages and CD4 T-cell infiltrates 
was highlighted, both the histological studies and flow cytometry did not evidence any major modification of 
the composition of the immune cell subsets. This is a remarkable finding of this project as, up to now, no study 
in the literature deals with the repeated administration of high doses (500 mg/Kg/day) of polymeric NPs in the 
lungs. The demonstrated safety of pCD NPs opens the way for the pulmonary delivery of other drugs to treat 
respiratory diseases. 
Remarkably, when pCD NPs containing the [ETH:Booster] combination were administered to infected 
animals, they led to a dramatic 3-log decrease in lungs CFU in comparison to untreated animals after only 6 
administration. This effect was clearly visible in the histological sections of animal lungs. Predictably, when 
the same treatment schedule was administered orally no antibacterial effect could be observed.  
It is worth highlighting that the treatment developed in this study enabled reaching with 6 endotracheal doses 
of [ETH:Booster] loaded NPs the same anti-microbial effect of 18 oral doses of ETH. The reduction of the 
number of administration has the potential to decrease the systemic side effect of ETH thus increasing the 
patients’ compliance. 
With further studies, this green strategy could be used as a supplement to the standard treatment helping to  
contain TB pulmonary manifestations and it could be extended to the encapsulation of other more recent and 
more powerful  booster molecules12, or of other anti-TB drug combinations. It is worth noting that these studies 
proved that pCD NPs are an excellent platform for co-entrapment of drugs, hence their use could be extended 
also to the encapsulation of tandem drugs for the treatment of other diseases. 
The PLGA and pCD NPs were then challenged for encapsulation of a second drug of interest (Chapter II). 
The study aimed to improve the action of pipemidic acid (PIP) against intracellular infections such as the ones 
caused by the enteropathogen Salmonella Typhimurium (S.Typhimurium). The choice of this drug has been 
made with the idea of giving a “new life” to this old antibiotic by encapsulating it in NPs and delivering it in 
an optimised manner13,14. Indeed, PIP belong to the first generation quinolones which are no longer used in 
therapy because of their unfavourable physico-chemical profiles, lower tissue penetration and narrower 
antibacterial spectrum in comparison to the following generations of quinolones15. PIP was selected over parent 
drug molecules, belonging to the same generation, for its reported better activity against some intracellular 
bacteria such as Pseudomonas aeruginosa, E. coli and  S.Typhimurium 16,17. Similarly to ETH, PIP is poorly 
soluble in water and it has a strong tendency to crystallise. Therefore, also PIP encapsulation was particularly 
challenging. 
 
To address this issue, NPs were prepared by using a series of PLA and PLGA copolymers with different 
characteristics (lactic:glycolic ratios, molecular weights and terminal groups). The two more common 
formulation methods, nanoemulsion and nanoprecipitation, were compared and multiple preparation 
parameters (such as PIP wt%, solvents ratio, polymer concentration, etc) were adjusted in the attempt to 
optimise PIP loading. 
All the employed polymers could successfully form monodisperse NPs with both formulation methods. In 
particular, when varying the kind of polymer, nanoprecipitation technique produced NPs with a wider size 
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range than nanoemulsion (Z average determined by DLS; 110–270 nm vs 200-270 nm, respectively) but the 
PdI of the single formulations remained lower than 0.1 (indicating their narrow distribution). These findings 
suggested that nanoprecipitation method was influenced by the polymer change at a higher degree than 
nanoemulsion. However, even by adjusting multiple formulation parameters and by testing several different 
polymers, PIP was still poorly entrapped, the presence of drug crystals was often detected by optical 
microscopy and the drug was burst-released upon the dilution of the NPs suspensions. The maximum drug 
loading achieved was higher in the case of nanoprecipitation (11% for polymer P33) although PIP crystals 
were formed in the NPs suspension. Indeed, neither of the two formulation methods could grant a high PIP 
loading together with the prevention of its crystallisation. In two only cases the prevention of crystals formation 
was effective: i) by preparing NPs with nanoemulsion technique replacing the sonication with the 
homogenisation or ii) by nanoprecipitation using the polymer P19 until a maximum PIP/P19 ratio of 1:10. 
However, NPs formed in the first way were considerably larger in size (around 400 nm), polydisperse and PIP 
burst-release was observed upon dilution. NPs formed the second way, instead, displayed a very low drug 
loading (around 1 wt%). 
In addition, both formulation techniques presented burst-release problems after dilution in water and an 
interesting correlation was found between the amount of burst-released drug and the dilution factor. This 
phenomenon, whilst not wanted, gave some suggestions about the reasons of the unsatisfactory results obtained 
for PIP encapsulation. Indeed, these findings implied a preferential localisation of PIP on the surface of NPs, 
as already reported for other crystalline drugs18–20, and a low affinity between PIP and the polymer employed. 
Most likely, PIP has stronger affinity for PVA, the surfactant that stabilizes the NPs, than for the polymeric 
matrices. 
The location of PIP on NPs surface and its affinity for PVA was firstly hypothesized when nanoemulsion was 
employed and it was further corroborated when formulating the NPs by nanoprecipitation.  Indeed, when using 
nanoprecipitation technique, blank NPs had considerably higher sizes than the loaded ones prepared in the 
same experimental conditions. This indicate that, possibly, PIP plays a role as a co-surfactant, reducing the 
size of the NPs. Moreover, as previously mentioned, in some circumstances nanoprecipitation granted the 
absence of PIP crystals in spite of the fact that the drug loading was really low. Noticeably, in that case, the 
concentration of PIP in the suspension media was 1.5 mg/mL, 5 times more than its water solubility (around 
0.3 mg/mL). The most likely explanation is the formation of PIP/PVA micelles, which is in line with previous 
studies showing that the surfactant used to produce NPs by nanoprecipitation can also form micelles in the 
suspension media21,22. These findings highlighted once more the affinity between PIP and PVA which probably 
helped solubilizing the drug. In a nutshell, PIP and PVA played a key role in the NPs formation. 
Indeed, the study of the contribution of each component in the frame of nanoprecipitation method was very 
fascinating. When the solvent containing the polymer and PIP is added dropwise to the surfactant aqueous 
solution, the solvent diffuses and mix with the aqueous phase. Nanoparticles formation is governed by 
interfacial turbulences between the solvent and the non-solvent when the supersaturation of the polymer is 
reached. Local fluctuation in the polymer concentration leads to the formation of nucleation sites which further 
grow by sticking other polymer molecules from the surrounding solution to form monodispersed NPs. 
When the growing NPs encounter a surfactant molecule, its growth is arrested and the surfactant molecule is 
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often entangled within the polymeric matrix of the NP. The results of this study suggest that PIP act as a co-
surfactant with PVA cooperatively blocking the growth process. Thus, a higher number of smaller NPs is 
formed, explaining the size difference between loaded and blank particles when all the experimental 
parameters were identical. This co-surfactant action also supports the idea of PIP localisation at NPs surface. 
Given the unsatisfactory results obtained with PLA/PLGA NPs and the persistent presence of PIP crystals, the 
same approach as for ETH in the previous study was attempted. PIP incorporation at a molecular level was 
investigated by using pCD NPs. Despite some promising results were reported in the literature23 and despite 
the fact that pCD NPs already proved their abilities in increasing the aqueous solubility of other crystalline 
drugs, PIP did not show any affinity for these NPs and the loadings were lower than 1 wt%. 
Some interesting considerations can be made by comparing the results obtain with ETH and PIP during this 
PhD research. Despite their similar physico-chemical behaviour, these two drugs showed very different 
affinities for the two NPs systems. In the case of ETH, even though PLA NPs granted a higher drug loading 
(around 36%) they could not totally hamper ETH crystallisation. Thus, pCD NPs resulted the most effective 
carrier in spite of their lower loading (2.5 wt%) thanks to their ability to stabilise ETH at a molecular level. In 
the case of PIP instead, pCD NPs were totally ineffective in increasing the apparent solubility of this drug 
which remained lower than 1 mg/mL (drug loading lower than 1 wt%). Moreover, PIP did not show a 
satisfactory affinity also for PLGA and the loadings remained much lower than the ones obtained for ETH. 
These is no such thing as a universal drug carrier, thus pCD NPs which resulted very effective in one case, 
completely failed in the other. 
 
These findings point out how the physico-chemical properties of drugs can heavily impact on their interaction 
with the carriers. Therefore, there’s a necessity of adapting the formulation strategy to the peculiarities of each 
drug molecule (even when the physico-chemical properties of two drugs seem similar). Consequently, the 
work of medical researchers and formulation scientists can be very intriguing but also very challenging. 
In light of the reported results, in the specific case of PIP, the physical encapsulation was not successful with 
any of the two studied NPs platforms. For this reason, new strategies were employed in collaboration with Dr 
Desmaële (Institut Galien of Paris). Firstly, PIP structure was chemically modified through O-methylation in 
an attempt to avoid PIP crystallisation and to increase the drug affinity for the polymeric NPs. The derivative 
completely avoided PIP crystallisation, however its affinity for the NPs and hence the drug loading were very 
low (less than 1 wt%). 
In this context, the idea was to covalently link PIP to a biodegradable polymer to form a prodrug able to self-
assemble in NPs. An original drug-initiated polymerization technique was employed to produce such conjugate 
in a single step and without the use of catalysts. PCL was preferred over PLGA as it has been previously 
showed that it can polymerize in a controlled manner without catalysts forming monodisperse polymers with 
controlled and adjustable molecular weight24. A PIP-PCL conjugate was successfully formed with a 
drug:polymer molar ratio of 1:10. The structure of this prodrug was thoroughly characterised by 1H and 13C 
NMR, IR and mass spectrometry leading to the conclusion that the polymerisation occurred on the piperazine 
free amino group of PIP.  
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The conjugate was shown to be able to self-assemble in round-shaped (SEM determination) NPs with the 
nanoemulsion method. NPs could be successfully obtained by employing 100% of the PCL-PIP conjugate or 
by mixing it at 50:50 ratio with PLGA. Furthermore, different surfactant amounts (0.5% and 1%) were tested. 
The maximum drug loading was obtained for 100% PCL-PIP NPs which contained around 27 wt% PIP. All 
NPs where characterised with four complementary and advanced techniques: DLS, NTA, TRPS and SEM. 
NTA and TRPS are both interesting particle by particle methods even if based on completely different 
principles. These two techniques are able to determine at the same time the particles mean diameter and their 
concentration. NTA and TRPS were in good agreement regarding the size of all measured PCL-PIP NPs (i.e. 
130 ± 37 and 126 ± 52 nm, respectively).  
DLS and SEM led both to an overestimation of NPs size for different reasons. As previously explained, DLS 
is particularly sensitive to the presence of small amounts of big particles hence shifting the size distribution 
towards higher values (around 200 nm). Regarding NPs sizes estimated by SEM, the overestimation (values 
of around 300 nm) was most likely caused by the sample preparation. Indeed, PCL-PIP appeared to be flattened 
on the support surface. This effect, which was not evidenced in the case of PLGA NPs, can be ascribable to 
different physico-chemical properties of PCL-PIP conjugate, such as glass transition and melting temperatures. 
These NPs resulted to be stable for around 10 days and further experiment could be performed to increase their 
long-term stability. However, the bioconjugate did not degrade in the presence of enzymes because of the 
tertiary amide conjugation.  
Further studies are focused on the synthesis of novel PCL-PIP conjugates able to be degraded to release PIP. 
It would be then very captivating to establish if such PCL-PIP NPs would be able to optimise the delivery and 
increase the efficacy of PIP towards intracellular bacteria. Moreover, if this approach will be proved effective 
it could be easily extended to other more active molecules of quinolones family or to other drugs. 
The formulation studies performed within this work provided fairly clear indications about the importance of 
the interactions between each component of NPs to obtain a successful carrier. A deep understanding of the 
morphology and structure of the NPs, on their corona and core composition and on the location of the drug is 
crucial to explain the obtained results and to move forward in the formulation process. It has been shown how 
the localisation of the drug at the surface of NPs can induce a burst release whereas controlled release could 
be obtained if the drug was entangled in the NPs polymer matrix. However, these conclusions have been drawn 
from experimental results or have been obtained using surface analysis (such as XPS or SIMS) or indirect 
methods (such as electrophoretic mobilities, hydrophobicity and mobility of polymer chains). No technique 
able to visualise and thus prove the truthfulness of these conclusion was available until now for PLA/PLGA 
NPs and for all the nanocarriers which do not possess any particular contrast properties (such as a fluorescent 
component or electron density). Therefore, at least formally, these findings can still be considered as 
hypothesis. Moreover, the available techniques can give only bulk information but cannot assess if the samples 
are homogeneous. 
Similarly, the surfactant corona around PLA/PLGA NPs, which is considered a certitude in drug-delivery 
domain, has never been visualised and therefore its presence was never undoubtedly proved. 
In the light of these consideration, formulation scientists have always been fascinated and interested in the 
development of a method able to visualise the individual NPs and provide at the same time their chemical 
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composition and the incontrovertible localisation of each NP component. 
 
The main ground-breaking novelty of this PhD lies in demonstration of the possibility to address all these 
challenges and obtain the desired information by applying an original IR nanospectroscopic technique to NPs 
characterisation (Chapters IIIB and C). These studies have been performed in collaboration mainly with the 
LCP of Orsay, where the technique was developed, and with the society “Anasys Instrument” which 
commercialise the instrument. This technology, combining the spatial resolution offered by atomic force 
microscopy (AFM) together with the chemical characterisation provided by IR spectroscopy, is called AFM-
IR and is employed here for the first time to unravel the structure of PLA/PLGA NPs.  
A literature overview about the technique is given in the Chapter IIIA. Briefly, the nanoIR-2 setting of AFM-
IR, used in this work, consists of a tuneable IR laser focused on the sample near an AFM tip. When the sample 
absorbs the IR radiation at specific wavelengths characteristic of the sample functional groups, the absorbing 
region of the sample undergo a thermal expansion which is detected by the AFM tip. Two types of acquisition 
are possible. In the first mode, the position of AFM is fixed while the laser is tuned subsequently at different 
wavenumbers allowing recording the absorption spectrum of that precise spot (local spectrum). In the second 
mode instead, the laser is set at a specific wavenumber and the AFM tip is moved on the sample surface. As a 
consequence, the chemical cartography of the scanned region is obtained, together with its topography.  
This technique already proved its usefulness in several fields of science but until now it has been used 
exclusively in contact mode. Thus, the characterisation of soft and surface loosely-adhesive samples was 
impossible or was complicated by multiple sample preparation steps to improve the adhesiveness of the sample 
to the support. A typical example of such problematic material is indeed PLA/PLGA NPs which were almost 
impossible to be imaged in contact mode as they were either crushed or displaced during acquisition.  
The will to overcome such limitation and extend the technique application to challenging samples motivated 
the development of an AFM-IR able to perform the IR acquisition in tapping mode. 
The tapping AFM-IR setup, developed by Anansys Instrument, was presented in this study (Chapter IIIB) for 
the first time and the key physical phenomena involved in the detection of IR absorption during non-linear 
cantilever-sample interaction were described. 
The abilities of the newly developed technique were then tested on unloaded PLA NPs. As expected, the 
superiority of the tapping mode over traditional contact was striking when investigating these particles. The 
tapping mode could perfectly describe the 3D typical profile of NPs together with simultaneously providing 
precious chemical information about their structure (Figure 2A, B, C – Chapter IIIB). 
Indeed, to achieve the unique goal of unravelling PLA NPs chemical features, a characteristic IR band was 
chosen as a fingerprint for each NP component (PLA and PVA) and it was used to detect specifically their 
localisation and distribution within the sample. Therefore, FTIR spectra of bulk materials between 2000 and 
1000 cm-1 were recorded. The strong ester carbonyl band at 1760 cm-1 (C=O stretching) was selected as 
signature for PLA presence, whereas a small C-H bending band at 1415 cm-1 could be univocally attributed to 
PVA and used as its signature. 
Fascinatingly, the chemical mappings recorded in tapping mode at the selected wavenumbers allowed directly 
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visualising for the first time the PVA corona surrounding the PLA core. Thus, the existence of the NPs core-
shell structure was here finally undoubtedly proved. Interestingly, the detected PVA corona had a thickness of 
around 15-20 nm. Of note, the comparison of NTA (hydrodynamic diameter) and cryo-TEM (dry diameter) 
results reported in the Chapter IA on the same unloaded PLA NPs suggested a thickness of this corona of 
around 40 nm. Therefore, a discrepancy between the two sets of experiments is evident. Nonetheless, this 
difference can easily be explained by the fact that while NTA values were obtained on hydrated NPs, the AFM-
IR measurements were performed on dried NPs. Thus, the PVA chains were progressively dehydrated during 
the drying process (Figure 2D Chapter IIIB) and flattened on NPs surface, considerably decreasing the 
corona thickness. 
Given these very promising results, a more ambitious goal was set in the study. Indeed, as previously pointed 
out, the design of a successful drug delivery system requires a deep knowledge of the drug location within the 
carrier, which highly influence the drug release profile. This was especially evident in our studies on PIP-
loaded NPs. Thus, these particles were chosen for tapping AFM-IR investigations. In particular, the PIP NPs 
formulated with PLGA polymer P19 were selected for their low drug loading (less than 1wt%) together with 
their ability of avoiding PIP crystallisation which were thoroughly discussed above. Tapping AFM-IR 
provided the fascinating perspective of confirming by direct visualisation the hypothesis formulated during the 
NPs development, such as the PIP localisation on NPs surface and its affinity for PVA.  
Once more, a IR signature for each component was selected thanks to FTIR spectra. PLGA (P19) was detected 
at 1425 cm-1 (C-H stretching) while the band at 1760 cm-1, previously employed for PLA localisation, was 
discarded because it saturated the chemical mapping. The selection of a PVA specific absorption band was 
more challenging. Indeed, the PVA signal at 1420 cm-1was overlapped by PLGA bands. As no exclusive IR 
signal could be attributed to PVA, the 1415 cm-1 was chosen as wavenumber for PVA detection because it was 
the only region where the PVA was a stronger absorber than PLGA. PIP displayed multiple interesting peaks 
but only a few were not overlapping with PLGA and PVA. Hence, its carboxylate band at 1639 cm-1 was 
selected. 
A complete set of chemical mappings and spectra were recorded for empty PLGA NPs and for PIP-loaded 
ones, formulated by both nanoemulsion and nanoprecipitation methods. Of note, objects, NPs or micelles, as 
small as 10 nm could be detected and chemically mapped thanks to tapping AFM-IR. 
Despite the absence of a wavenumber exclusively attributable to PVA, a surfactant corona could still be 
visualised around the PLGA core in both loaded and unloaded NPs. Fascinatingly, regardless of the difficult 
circumstances, the tapping AFM-IR managed to further confirm PVA identity by recording IR spectra directly 
on the thin NPs corona. 
Moreover, the principal purpose of the study was achieved, as PIP could be clearly localised within NPs 
structure. Indeed, the tapping mode allowed the study of drug distribution within each single NP and gave 
access to invaluable information, inaccessible to any other characterization technique. The hypothesis 
formulated in Chapter II could be here clearly confirmed: PIP was detected around NPs and it was co-
localised with the PVA corona. These findings indeed validated the hypothesis that the drug was located at 
NPs surface explaining the burst-release upon dilution. Of note, the PIP spectral changes, detected when the 
drug was localised in NPs corona, in comparison to pure PIP, further reinforced the idea of a strong affinity 
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between this drug and PVA. 
Therefore, tapping AFM-IR demonstrated to be an exquisite tool able to visualise individual NPs and to unravel 
their chemical composition detecting the locations of both drug and corona without distorting or displacing 
them. 
 
In an attempt to challenge this technique even more, another very ambitious and fascinating goal was set in 
this project and some preliminary results were reported in Chapter IIIC. The aim was the assessment not only 
of drug localisation but also of its amount. Indeed, it would be revolutionary for the development and the study 
of nanoparticulate systems to be able to determine their loading on a particle by particle basis. 
The PCL-PIP NPs were selected as sample of choice to move the first steps towards the determination of 
drug/polymer ratio. Indeed, in PCL-PIP conjugate, the drug and the polymer are advantageously covalently 
linked and the global composition of the copolymer is known thanks to NMR experiments (10 PCL units for 
each PIP molecule). Therefore, it would be of high interest to investigate by tapping AFM-IR if each NP has 
the same PIP/PCL ratio (theoretical ratio: 1 PIP molecule for every PCL chain). 
Firstly, the efficient encapsulation of PIP in NPs was investigated by recording the IR mappings at the specific 
wavelength of PCL (ester carbonyl at 1732 cm-1) and PIP (tertiary amide carbonyl of the PIP-PCL linkage at 
1630 cm-1). The obtained cartographies showed clearly that PIP was perfectly colocalised with PCL ester 
signal, confirming unequivocally its localisation inside NPs. Thus, PIP covalent conjugation with the PCL 
polymer was a successful strategy enabling to finally obtain PIP-loaded NPs. 
Interestingly, these NPs displayed a less spherical shape in comparison to PLGA ones and a quite flattened 
profile. These results are in good agreement with the ones evidenced by SEM images. Indeed, the flattening 
effect observed with the two techniques was most likely caused by the NPs deposition and drying process on 
the supports. As the phenomenon was limited only to PCL-PIP NPs, it must be connected to the physico-
chemical properties of PCL (glass transition temperature and meting point) which make it more prone to 
deformation during sample drying. 
Secondly, the IR mappings obtained on 10 different NPs were analysed to estimate PIP/PCL ratio. To do so, 
the absorption coefficient (α) of the bands of interest (1732 cm-1 and 1630 cm-1) was measured by using an IR 
microscope and the PCL portion of the conjugate was found to produce an IR signal 1.9 times more intense 
than the PIP moiety. Then, the signal of each IR cartography at the two wavenumbers were integrated over the 
IR signal area (Chapter IIIB). The ratio between the integration at 1630 cm-1 and the one at 1732 cm-1 was 
calculated (after correction by α factor = 1.9). 
The PIP/PCL ratio mean value corresponded to 1 ± 0.4 and was thus very close to the theoretical one. However, 
a high variability was found between the particles (high SD of the measurement). This variability was probably 
so high for two main reasons. Firstly, the presence of PCL chains devoid of PIP end group was hypothesised. 
Indeed, the presence of small traces of water during the PCL-PIP conjugation could have initiated the 
polymerisation reaction in place of PIP. Therefore, some traces of PCL homopolymer could be present in the 
final conjugate, thus explaining the interparticle variability. The other possible explanation consists in the 
presence inside particles of crystalline microdomains of PCL and/or PIP embedded in an amorphous matrix. 
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Such more or less rigid domains could make difficult to control the contact between the AFM tip and the 
sample during the images acquisition interfering with the correct detection of IR thermal expansion. 
In a nutshell, despite the method reported here certainly needs to be further developed, the tapping AFM-IR 
was demonstrated to enable reaching, for the first time, the challenging goal of determining the drug/polymer 
molar ratio within individual NPs.  
The estimation of the amount of drug on a particle by particle basis could lead to very remarkable advances in 
nanomedicine. The homogeneity of the particles drug loading as well as its dependence on formulation 
parameters could be studied for each single NP. This would open to the possibility of a better understanding 
of formulation processes and to the chance of facilitating NP design. 
Of note, this approach could be extended to a wide range of NPs, other than polymeric ones (hybrid organic-
inorganic, liposomes, lipid nanoparticles, etc). 
 
Once NPs have been successfully prepared and characterised, their interactions with the living systems 
represents a critical step in their development and in the determination of their effectiveness. Scientist must 
possess a deep understanding of such interactions to be able to improve and optimise nanocarriers efficacy. 
Therefore, different imaging techniques are nowadays available to track the NPs fate inside cells and tissues.  
The most commonly employed techniques are fluorescence microscopy and transmission electron microscopy. 
Despite their differences, they have a common point. Both microscopies require NPs labelling with a 
fluorescent dye or an electron dense material, respectively, to enable NPs detection. Indeed, organic particles, 
such as PLA/PLGA ones, do not possess any contrast properties to be distinguished from the surrounding. 
However, the modification of NPs with a dye is known to possibly cause changes in their size, shape or surface 
properties which can alter their interactions with cells and tissues25–27. In fact, NPs surface is the theatre of all 
the complex interactions with the living media28. Moreover, dyes which are not covalently linked to the NP 
could leak out or even be transferred to cell membranes. 
The key limitation of the use of labelling lies in the fact that what is observed and followed during experiments 
is the label and not the object of interest. Therefore, such techniques provide only an indirect measurement 
and at any time they cannot insure that the NP is still intact. 
In this context, there is a tremendous interest to develop a label-free method for NPs detection in living systems. 
Some progresses have been performed in this direction with the development of Raman microspectroscopy. 
Although Raman could detect unlabelled polymeric particles, its resolution is limited by light diffraction to 
300 nm-1 µm depending on the excitation source. This enables the detection of particle agglomerates rather 
than individualised NPs. 
The bottleneck represented by the detection of individual unlabelled PLA/PLGA NPs could be overcome 
thanks to AFM-IR. Here (Chapter IV), AFM-IR was proved to be a reliable, non-destructive and direct 
method able to locate NPs of around 170 nm within cells with a high lateral resolution, by taking advantage of 
the specific IR response of their constitutive PLA polymer. The very intense ester carbonyl band of PLA NPs 
could be used as a fingerprint for their detection as it clearly stands out against the carbonyl stretching band of 
cellular constituents. 
A correlative study between confocal fluorescence microscopy and AFM-IR was conducted to prove the 
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reliability of the technique. Firstly, fluorescent NPs of 170 nm were developed by using a small percentage of 
rhodamine-labelled PLA (Rh-PLA) polymer. Rhodamine was covalently linked to PLA to avoid any leakage. 
Then, Rh-PLA NPs were incubated with macrophages and their successful internalisation in the cells was 
proved by confocal microscopy. 
Subsequently, the exact same region of interest (ROI) was sequentially studied by confocal fluorescence 
microscopy and by AFM-IR. The IR map at 1770 cm-1, corresponding to the PLA ester, clearly indicated the 
presence of PLA NPs into the cell and the results were in excellent agreement with the confocal images. Thus, 
it was proved that the objects detected by AFM-IR were indeed NPs. One of the major advantage of this 
technique was to further zoom on a particular ROI in a cell to acquire more accurate information detecting 
even single NPs. Moreover, despite the fact that NPs were embedded in the cell, their chemical composition 
could be still assessed from the local spectra acquisitions. The IR spectra obtained with a resolution of 1 cm−1 
were in complete accordance with those of the PLA NPs. Multiple spectra could be recorded on the same NP 
to assess its chemical homogeneity. Similar results were obtained when Rh-PLA NPs were replaced with 
unlabelled ones. 
In a nutshell, AFM-IR could offer a high level of resolution, together with the possibility of chemical 
identification, that to the best of our knowledge no other technique is able to provide.  
AFM-IR can offer a considerable amount of interesting perspectives. The spectral range of the IR source could 
be extended to enlarge the applications of the technique and to increase the probability to find a fingerprint 
band for a wider range of molecules. A future challenge would also be to couple the AFM-IR with fluorescence 
confocal microscopy allowing identifying the intracellular compartments where the NPs are located. 
Alternatively, a comprehensive study of the specific IR absorption of each type of subcellular compartment 
could be performed with the aim to find a fingerprint band for each one of them, hence enabling to locate NPs 
by using exclusively AFM-IR. Moreover, this technique could be applied not only to NPs localisation but also 
to the study of their degradation and to the tracking of one or more drugs, following their release from the 
carrier and unravelling their intracellular fate. This intriguing tool could be used to design nanocarriers capable 
of releasing their drug cargo at intracellular targets. 
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In this study, the ability of PLA/PLGA and pCD NPs to encapsulate different antibiotics have been 
investigated. The obtained drug-loaded systems have been comprehensively characterised by using 
complementary techniques at the forefront in the field. Moreover, in an attempt to go beyond the state of art, 
a new technique, namely the AFM-IR, has been applied for the first time to unravel the structure of individual 
PLGA NPs and to detect them in eukaryotic cells. 
1. PLA and pCD NPs co-loaded with ETH and Booster were successfully prepared and deeply characterised 
with the purpose of obtaining a combined therapy in the treatment of TB. PLA NPs allowed achieving a 
high drug loading of both drugs, but they were not able to totally avoid ETH crystallisation. On the other 
hand, pCD NPs, despite their lower loading capability, enabled preventing the formation of ETH crystals. 
Noticeably, ETH and Booster maintained their in vitro antimicrobial activity on extracellular and 
intracellular Mtb after encapsulation in both PLA and pCD NPs. 
Drug-loaded pCD NPs were proved to be compatible with the Microsprayer® and could therefore be 
endotracheally aerosolised in mouse lungs. Remarkably, empty pCD NPs showed no major toxicity after 
repeated pulmonary administrations of high doses opening the way for further applications. Impressively, 
a 1000 times decrease in the lung bacterial load of infected animals could be obtained with only 6 doses 
of ETH:Booster loaded pCD NPs in comparison with non-treated animals. 
 
2. A complementary study was performed on ETH loaded pCD NPs to unravel the type and strength of 
interactions occurring in these systems. The ability of pCD NPs to increase ETH apparent solubility of 
about 10 times was confirmed. Moreover, the spectroscopy studies evidenced that ETH in NPs is located 
not only in CD cavities but also in confined domains between CDs, inside the crosslinked NPs. ETH was 
incorporated in a molecular state, thus avoiding its crystallisation even over long storage time. These NPs 
could be highly concentrated in aqueous media (up to more than 200 mg/mL) emphasizing the interest of 
using them for drug encapsulation instead of monomeric βCDs, which otherwise display a very limited 
aqueous solubility (<18 mg/mL). 
 
3. The ability of PLA/PLGA and pCD NPs to achieve the encapsulation of PIP, a poorly soluble first-
generation quinolone with a strong tendency to crystallize, was investigated. PIP was unfortunately poorly 
entrapped in PLA/PLGA NPs formulated by either nanoemulsion or nanoprecipitation. Drug 
crystallisation remained a major issue and PIP burst-release was evidenced upon dilution thus leading to 
the conclusion that PIP was mostly localised on NPs surface. Moreover, PIP did not show any affinity for 
pCD NPs. In light of these results, the drug was directly conjugated to the polymers to obtain stable NPs 
with high PIP payloads. An original drug-initiated and catalyst-free polymerization was developed. The 
PCL-PIP conjugate was thoroughly characterised and it was shown to self- assemble in NPs. PCL-PIP NPs 
displayed a monodisperse size distribution and contained around 27 wt% PIP. 
However, as PIP was conjugated to PCL through a tertiary amide bond, particularly difficult to hydrolyse, 
the complete enzymatic degradation of the conjugate could not be achieved. Further studies are now 
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focused on the synthesis of novel PCL-PIP conjugates able to release PIP. Main applications will include 
the delivery of PIP to infected cells. 
 
4. In an attempt to go beyond the state of art in the NPs characterisation field, an original nanospectrocopic 
technique was adapted to unravel the structure of core-shell PLGA NPs. This method, namely AFM-IR, 
combines the high resolution provided by atomic force microscopy (AFM) with chemical characterisation 
offered by IR spectroscopy. A region of the IR spectrum specific of each NPs component was chosen as 
its specific fingerprint and it was used to detect and image its chemical distribution with the AFM-IR.  
An additional innovation of this study is the first-time use of the recently developed tapping mode of AFM-
IR. The tapping mode allowed the investigation of soft or non-adhesive samples such as PLGA NPs which 
could be well-described without crushing or pushing them as it happened when the contact mode was 
employed. One of the main achievements of this study was the visualisation of the surfactant corona around 
NPs. Moreover, the localisation of a drug of interest, PIP, within the NPs, could be assessed thus 
confirming the surface localisation of this drug and its affinity with the PVA corona which where 
hypothesised in the second chapter of this work. It is remarkable to highlight that PIP was incorporated at 
only 1% with respect to NPs weight but, despite the challenge of such low loading, the location of the drug 
could still be identified. Additionally, tapping AFM-IR was very useful to undoubtedly confirm the 
homogeneous localisation of PIP inside PCL-PIP NPs and to move the first steps towards a particle by 
particle drug quantification. Indeed, a first strategy confirming the PIP/PCL theoretical ratio by means of 
IR cartographies on individual NPs was successfully presented here. With further studies, the current 
approach could be improved and a more precise quantification could be achieved opening the way to a 
revolution in drug delivery domain. Furthermore, the soft exploration by tapping AFM-IR allowed 
detecting NPs as small as 10-20 nm. 
These findings have particular relevance in the NPs field because, to the best of our knowledge, this 
technique is the first one able to provide such precise information about NPs components localisation on 
a particle by particle basis and with such high resolution. 
 
5. In addition to the achievements in the domain of NPs characterisation, here the AFM-IR was proved to be 
a reliable, non-destructive and direct method able to locate PLA NPs of around 170 nm within cells with 
a high lateral resolution, by taking advantage of the specific IR response of their constitutive PLA polymer.  
This response was used as a fingerprint to enable the unambiguous chemical identification of the NPs, 
avoiding the need of labelling. Indeed, the most common techniques usually employed to intracellularly 
detect NPs require the modification of plain NPs with a dye. Such labelling can lead to several 
inconveniences and it is the label, not the object itself, which is detected by the instrument. The AFM-IR 
instead, detect directly the object of interest thus avoiding misinterpretations. 
In this context, with further studies, AFM-IR could become a powerful tool to unravel the fate of individual 
unlabelled NP inside cells. Moreover, the identification of the NPs chemical composition with high-
resolution could enable determining drug release and NP degradation. AFM-IR could find a plethora of 
applications in the field of drug delivery and its use could be extended to other kinds of NPs. 
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In conclusion, during this PhD work, two promising approaches for the treatment of intracellular diseases were 
developed by means polymeric NPs. The potential of such polymeric carriers for the efficient entrapment of 
challenging drugs was illustrated. Moreover, the application of an original IR nanospectroscopic technique to 
NPs characterisation enabled the acquisition of invaluable and unprecedented information about their structure, 
the localisation of drug and its amount on a particle by particle basis. This technique was also proved to be a 
reliable, direct and label-free method for NPs intracellular detection. Moreover, it was sensitive enough to 
detect nanostructures of only 10-20 nm and drug molecules despite loadings of less than 1 wt%. 
In a nutshell, these studies pave the way towards an in deep investigation of NPs and we believe that the AFM-
IR methodology developed here could be an invaluable tool in the near future in the development of complex 
NPs containing one or more synergic drugs. 
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contre des bactéries intracellulaires 
Mots clés : Nanoparticules, Cyclodextrines, Polymères biodégradables, Bactéries intracellulaires, 
encapsulation médicament, AFM-IR 
Résumé : Le traitement des infections 
intracellulaires est compliqué par la capacité des 
bactéries à «se cacher» à l’intérieur des cellules 
de l’hôte, en particulier celles du système 
immunitaire, entravant ainsi l’action de 
nombreux agents antimicrobiens. La diffusion 
croissante de souches résistantes est très 
inquiétante. Dans ce cadre, les nanoparticules 
(NPs) constituent une stratégie prometteuse pour 
administrer de manière optimisée des agents 
antimicrobiens. 
Ce travail de thèse, réalisé dans le cadre du projet 
européen ITN Cyclon Hit, visait à développer et 
caractériser des NPs biodégradables et 
biocompatibles chargées en antibiotiques, 
composés d’acide polylactique (PLA), d’acide 
poly (lactique-co-glycolique) (PLGA) et de 
polycaprolactone (PCL) ou de cyclodextrines 
polymérisées (pCD). 
Les deux premiers chapitres sont consacrés aux 
verrous technologiques liés à l'encapsulation de 
certains médicaments puissants dans les NPs 
polymériques. Tout d'abord, ces vecteurs ont été 
utilisés pour la délivrance simultanée d'une 
combinaison de molécules actives récemment 
découverte, l'éthionamide (ETH) et son Booster, 
pour le traitement de la tuberculose. 
Deuxièmement, ils ont été employés pour relever 
les défis liés à l'incorporation d'une quinolone de 
première génération, l'acide pipémidique (PIP), 
dans le but d'optimiser sa distribution 
intracellulaire dans des infections telles que la 
salmonellose. 
La co-incorporation efficace de l'ETH et du 
booster a dû surmonter de nombreuses difficultés 
liées à des problèmes de solubilité, de 
cristallisation et de biodisponibilité. Nos NPs en 
PLA et en pCD ont montré leur capacité de co-
encapsuler efficacement les deux molécules et 
tout particulièrement celles en pCD. Elles 
incorporent les médicaments à la fois dans les 
cavités des CD et dans des microdomaines 
hydrophobes. Les NPs en pCD, non toxiques 
après administration pulmonaire répétée de 
fortes doses, ont été administrés in vivo par voie 
endotrachéale directement au site d'infection. 
Elles ont permis une diminution de 3-log de la 
charge bactérienne pulmonaire des animaux 
infectés après seulement 6 administrations. De 
même, l'incorporation de PIP a été confrontée à 
des défis liés à la cristallisation de PIP et à sa 
libération incontrôlée. Malheureusement, le PIP 
présentait une faible affinité pour tous les 
matériaux polymériques étudiés et son 
encapsulation physique était infructueuse. Ainsi, 
une approche alternative a été développée en 
couplant le PIP au PCL via une réaction sans 
catalyseur initiée par le médicament. Le 
conjugué PCL-PIP se auto-assemble en forme de 
NPs avec une charge en PIP de 27%. Cependant, 
le PCL-PIP n'a pas pu être dégradé in vitro, mais 
l’approche de synthèse de conjugués est 
séduisante pour obtenir de particules stables et 
avec un contenu important en PIP. 
La compréhension approfondie de la structure et 
de la composition du noyau et de la couronne des 
nanostructures contenant une ou deux molécules 
actives est cruciale pour leur optimisation. Les 
deux derniers chapitres sont donc consacrés à 
l'application innovante de l'AFM-IR, une 
méthode nanospectroscopique originale 
combinant la microscopie à force atomique 
(AFM) avec la spectroscopie infrarouge (IR), à 
l'analyse chimique des NPs en PLGA ou à leur 
détection sans marquage après internalisation 
dans les cellules. 
L’AFM-IR est capable de fournir une 
caractérisation chimique à l'échelle 
nanométrique (résolution ~10 nm). Une avancée 
majeure du travail est l'application du mode 
tapping permettant l'investigation individuelle de 
chaque NP. Le signal IR spécifique des 
composants des NPs a été utilisé pour 
appréhender la composition chimique de leur 
cœur et couronne ainsi que pour localiser 
précisément le médicament. De plus, l'AFM-IR 
en mode contact a permis pour la première fois 
la localisation sans marquage et l'identification 
chimique des NP à l'intérieur des cellules. Ce 
travail ouvre la voie à d'innombrables 
applications de cette technique dans le domaine 
de la nanomedecine. 
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Abstract: The treatment of intracellular 
infections is very challenging given the ability 
of bacteria to “hide” inside the cells of the host, 
especially the ones of the immune system, thus 
hampering the action of many antimicrobial 
agents. The battle against these bacteria has 
been further exacerbated by the increasing 
diffusion of antimicrobial resistant strains. In 
this frame, nanoparticles (NPs) are a very 
promising strategy to overcome the limitations 
of free antimicrobial agents by administering 
them in an optimized manner. 
This PhD work, performed as part of the 
European Project ITN Cyclon Hit, aimed at the 
development and advanced characterisation of 
antibiotic-loaded biodegradable and 
biocompatible NPs made of poly (lactic acid) 
(PLA), poly (lactic-co-glycolic) (PLGA) and 
polycaprolactone (PCL) or of polymerised 
cyclodextrins (pCDs).  
The first two chapters are dedicated to the 
encapsulation of powerful but challenging drugs 
in polymeric NPs. Firstly, these carriers were 
employed for the simultaneous delivery of a 
potent drug combination recently discovered, 
ethionamide (ETH) and its booster, for 
tuberculosis therapy. Secondly, they were used 
to address the challenges related to the 
incorporation of a first-generation quinolone, 
pipemidic acid (PIP), with the aim of optimising 
its intracellular delivery in infections such as 
salmonellosis.  
The efficient co-incorporation of ETH and 
booster had to overcome several technological 
barriers. These drugs presented solubility, 
crystallisation and bioavailability-related 
problems which were overcome thanks to the 
developed NPs. Our engineered PLA and pCD 
NPs were both able to efficiently co-encapsulate 
the two molecules. Among the in depth-
characterised formulations, pCDs NPs 
displayed the best physico-chemical properties 
and were shown to host the drugs both in the CD 
cavities and in confined spaces inside NPs 
crosslinked polymer. The pCD NPs were 
administered in vivo by endotracheal route 
directly to the infection site. 
 
Empty NPs were shown non-toxic after repeated 
pulmonary administration of high doses. 
Moreover, loaded pCD NPs led to a 3-log 
decrease in the pulmonary bacterial load of 
infected animals after only 6 administrations. 
Similarly, the incorporation of PIP faced 
challenges mainly related to PIP crystallization 
and burst release. Unfortunately, PIP displayed 
poor affinity for all the studied polymeric 
materials and its physical encapsulation was 
unsuccessful. Thus, an alternative approach was 
developed by coupling PIP to PCL by using an 
original catalyst-free drug-initiated reaction. 
The PCL-PIP conjugate self-assembled in NPs 
with up to 27 wt% PIP which were thoroughly 
characterised. However, the conjugate couldn’t 
be enzymatically degraded. With the design of 
novel PCL-PIP conjugates, this self-assembly 
approach could represent a promising strategy. 
The deep understanding of the structure and 
composition of complex core-corona 
nanocarriers containing one or two active 
molecules is crucial for their optimisation. The 
last two chapters are devoted to the innovative 
application of AFM-IR, an original 
nanospectroscopic method combining atomic 
force microscopy (AFM) with infrared (IR) 
spectroscopy, to the chemical analysis of PLGA 
NPs or to their label-free detection after cell 
internalisation. 
AFM-IR is able to provide chemical 
characterisation at the nanometer scale 
(resolution ~10nm). One main breakthrough 
here is the application of the recently developed 
tapping mode allowing the investigation of 
single polymeric NPs. The specific IR signal of 
NPs constituents was used to unravel the 
chemical composition of their core and corona 
as well as to precisely locate the drug. Moreover, 
the AFM-IR in contact mode enabled for the 
first time the label-free localisation and 
unambiguous chemical identification of NPs 
inside cells   using the polymer IR specific 
response as a fingerprint. This work paves the 
way for countless application of this technique 
in the field of drug delivery. 
 
 
